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Abstract 
The drugs use in human medicine covers the whole range of chemical structure types, but the majority are 
heterocyclic small molecules or have heterocyclic structural components. In particular, anticancer drugs 
include rings in their structures. IUPAc gives the following definition of heterocyclic compounds : “cyclic 
compounds having as ring members atoms of at least two different elements” [1]. Heterocycles ring 
structures are in essence composed of elements other than carbon, where the most frequent substituents 
are oxygen, nitrogen and sulfur [2]. The discovery of novel multicomponent reactions enables new 
methodologies to synthesize known medicinally active compounds. Among all the multicomponent 
reactions presently known, the MCRs (multicomponent reactions) mediated by isocyanides are the most 
popular. The peculiar ability of the divalent carbon of isocyanides to react first with electrophiles and 
subsequently with nucleophiles, is key to the success of the multicomponent process. For this reason, the 
discovery of new electrophilic partners is a starting point for the development of novel multicomponent 
transformations. In this context, it is reported the usage of α-isocyanoacetamides along with (Z)-Aryl 
chlorides to give substituted 1,3-oxazol-2-oxime. However, since the final product is not stable, it can be 
hydrolized to give α-ketoamide amides. These molecules constitute useful scaffolds and intermediates for a 
variety of transformations in organic chemistry. As a continuation of this study, this work demonstrates 
that an electron deficient phenol could be a good nucleophiles third component in a reaction with (Z)- aryl 
chlorides and isocyanide to form a library of 41 aryloxyiminoamide derivates. The final product, namely 
aryloxyiminoamide, is an interesting compound because it can be used as intermediate for further 
synthetic transformations. 
The modern treatment of cancer involves surgery, radiotherapy and chemotherapy. However, the 
development of chemo-resistance, namely the lack of drugs response, is a persistent problem for the 
treatment of local and disseminated cancers. In fact, one of the hallmarks of human cancers is the ability to 
escape cell death, which is a major cause of treatment failures. In particular, the cancer cells block the 
apoptotic process by increasing the expression of anti-apoptotic BCL-2 members at the mitochondria and 
inactivate the effector arm of apoptosis, e.g. BAX, through mutations or inhibition.  The recent discovery of 
the first small heterocyclic molecule BAM7 as BAX direct activator represents the starting point for a 
structure-based lead optimization program aimed at the discovery of new potent BAX activators. My work 
resulted in the discovery of BTC-8 which resulted 10 fold more potent than the lead BAM7. In vivo 
experiments have suggested that BAX direct activators may be considered as novel, effective anticancer 
drugs in a near future. 
Furthemore, some compounds ,which were synthesized as BAX direct activators, were included in the 
library of small molecules selected for acting as pharmacological chaperones  on a misfolded mutant of the 
Frizzled4 (Fz4) receptor [3]. Fz4 is a key component of Wnt-β-catenin signalling and misregulation of Fz4 
activity is involved in tumor proliferation and cencer stem cell genesis in many typer of malignancies, such 
as glioblastoma, colorectal and breast cancer.  My work reported ,what are to our knowledge, the first 
small molecules that address the until-now-undruggable Fz4 receptor and inhibit Wnt signalling. This goal is 
achieved by using the potency of candidate molecules to rescue  the misfolding mutant of the Fz4, as a 
readout in screening campaigns toward the identification of new ligands. 
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Another key aspect of cancer cells is an increase of aerobic glycolysis and an altered energy metabolism 
supporting continuous cell growth and proliferation. The epigenetic mechanisms involving covalent 
modifications of both DNA and histones have recently emerged as important players in the regulation of 
glucose metabolism. In particular, the sirtuin family of histone deacetylases are important regulators of 
diverse physiological and pathological events, including cancer metabolism. The most representative 
example is SIRT6, which is considered a promising pharmaceutical target for chemo-resistance cancers 
treatment. In this thesis, the identification of one heterocyclic compound which binds and inhibits the 
function of SIRT6 is reported. The result of this work, although very preliminary, may represent a starting 
point for the development of SIRT6 inhibitors. 
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Chapter 1 – Multicomponent reactions 
 
The expectation in terms of the number and quality of compounds for drug discovery has increased 
enormously with the introduction of molecular biology and high-throughput biological screening. 
Multicomponent reactions have naturally become a rapidly evolving field of research due to their inherent 
convergence and high productivity, together with their exploratory and complexity-generating power and 
they have attracted the attention of both academic and industrial scientists. Multicomponent reactions 
(MCRs) are defined as a one-pot process that involves the reaction of at least three components to form a 
single product that incorporates essentially all the atoms of the starting materials. These reactions are 
atom economic, step efficient, and have high exploratory power with regard to chemical space and are 
therefore ideally suited for the generation of libraries of compounds [4]. MCRs constitute an especially 
attractive synthetic strategy since they provide easy and rapid access to large libraries of organic 
compounds with diverse substitution patterns. Very large libraries can be built up from a small set of 
starting materials within a short time, which can be used then for research on medicinal substances. 
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1.1 History of MCRs 
The first modern contribution to the development of multicomponent chemistry was made in 1850 by 
Strecker. In this reaction an aldehyde is condensed with ammonium chloride in the presence of potassium 
cyanide to form an α-aminonitrile, which is subsequently hydrolyzed to give the desired α- amino acid 
(Scheme 1) [5]. 
 
Scheme 1 Strecker synthesis of α-amino acids. 
 
Many important heterocycle synthesis are MCRs. 1,4-Dihydropyridines were first synthesized in a four 
component reaction by Hantzsch in 1882 from ammonia, aldehydes and 2 equivalent of β-
ketoesters.(Scheme 2) [6] 
 
Scheme 2 Hantzsch multicomponent synthesis of dihydropyridines 
 
Another contribution made by Hantzsch in 1890 to MCRs was the synthesis of pyrroles by reacting primary 
amines, β-ketoesters and α- halogenated β-ketoesters.(Scheme 3). [7] 
 
Scheme 3 Hantzsch multicomponent synthesis of pyrroles 
 
The Biginelli reaction, discovered in 1891,involves the synthesis of 3,4-dihydropyrimidin-2(1H)-ones from 
aldehydes, (thio)ureas and β-ketoesters  (Scheme 4). [8] 
 
 
Scheme 4 Biginelli multicomponent synthesis of dihydropyrimidines 
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The Mannich reaction (1912) consists of an amino alkylation of an acidic proton placed next to a carbonyl 
functional group with formaldehyde and  ammonia or any primary or secondary amine; the final product is 
a β-aminocarbonyl compound also known as a Mannich base.(Scheme 5) 
 
Scheme 5 Mannich reaction 
 
The first famous isocyanide-based MCRs ,was described in 1921, was the Passerini reaction. This is a 
reaction between isocyanides, carboxylic acids, and aldehydes or ketones to afford a-acyl carboxamides in a 
single step [9](Scheme 6) . 
 
Scheme 6 The Passerini three component reaction (P-3CR). 
 
The second and arguably the most important isocyanide-based MCR is the Ugi four component reaction 
(Scheme 7). This elegant four-component reaction, discovered in 1959, is a reaction between isocyanides, 
carboxylic acids, ketones or (usually) aldehydes and primary amines to afford dipeptide-like structures. [10] 
 
Scheme 7 The Ugi four component reaction (U-4CR). 
 
Owing to their flexibility, MCRs have found application in many fields of chemistry and in medicinal 
chemistry in particular. 
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1.2 Chemistry of Isocyanides 
A large and important class of MCRs are the Isocyanide Multicomponent reactions. Isocyanides, formerly 
known as isonitriles, represented for a long time the only class of stable organic compounds with a formally 
divalent carbon. Moreover, in exothermic reactions CII is oxidized to CIV.  The isocyanides are also well-
known for their strange odour. Almost all commercially available isocyanides are volatile and carry this 
repulsive odour “ which is reminiscent of artichokes and phosphorus at the same time” [11]. Prolonged 
inhalation of isocyanides is believed to increase the intensity of dreams at night. Isocyanides were first 
synthesized in 1859 by Lieke, who did not recognize them and believed them to be nitriles [12]. It was 
Gautier the first to understand the isomeric relationship between isocyanides and nitriles in 1869 [13]. At 
the same time Hofmann [14] found a new approach to isocyanides with the reaction of primary amines 
with potash and chloroform (Scheme 8). Anyway, all methods known at that time were complicated, poorly 
generalizable and low yields affected, with difficult separation of isocyanides from their isomeric 
accompanying nitriles. The method of choice regarding cost, yield and execution remains however the 
dehydration of the corresponding N-formamides with inorganic dehydratants and organic matching bases, 
such as POCl3 or Phosgene, and Triethylamine [15]. 
 
 
Scheme 8 The Hofman reaction 
 
 
The chemistry of isocyanides is characterized by three properties: the α-acidity, the α- addition, an intrinsic 
high affinity toward metallorganic reagents and their subsequent reactions, and the easy formation of 
radicals. Especially phenyl-isocyanides are substrates for radical-induced cyclizations. The α-acidity  is 
increased by further electron-withdrawing substituents in the α-position such as carboxylic esters, nitriles, 
phosphonic esters, or sulfonyl groups. Isocyanides polymerize under Lewis acid catalysis to 
polyiminomethylenes. The most important property of isocyanides is the reaction with nucleophiles and 
electrophiles at the isocyanide carbon atom. The α-addition of nucleophiles and electrophiles leads to the 
α-adduct. Only carbenes and carbon monoxide share this property with the isocyanides [16]. The great 
potential of isocyanides for the development of MCRs lies in the diversity of bond forming processes 
available, their functional group tolerance, and the high level of chemo- and regio-selectivity often 
observed. 
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1.3 Passerini and Ugi reactions 
The Passerini reaction, described in 1921, involves an oxo-component (an aldehyde or ketone), an 
isocyanide and a nucleophile (tipically carboxylic acids) to afford α-acyloxycarboxamides in one step. A 
plausible mechanism provides the formation of a loosely hydrogen-bonded adduct 4 from a carbonyl 
compound 1 and a carboxylic acid 2, followed by the α-addition of the electrophilic carbonyl carbon and the 
nucleophilic oxygen atom of the carboxylic acid to the isocyanide carbon of 3 (Scheme 9) under formation 
of a cyclic transition state with all three parent compounds. The α-adduct 5, which cannot be isolated, 
rearranges in an intramolecular trans-acylation to the stable α- acyloxycarboxyamide 6. 
 
 
Scheme 9 Suggested mechanism of P-3CR 
 
The Passerini reaction is carried out at high concentrations of the starting materials and in inert solvents at 
or below room temperature. On the other hand, Ugi reaction (Scheme 10) could be seen as the aza-version 
of the Passerini 3-CR, as it involves an amine as additional fourth component: it is indeed the reaction of a 
Schiff base or an enamine with a nucleophile and an isocyanide affording α-acylaminoamides. The Ugi 4-CR 
is much more versatile than the Passerini in terms of library size and scaffold. First of all the U-4CR is 
favoured in a polar solvent (MeOH being the most common) in contrast the P-3CR,which is accelerated by 
aprotic solvents. In the first step the oxo component and the amine condense to the imine, the Schiff base, 
via a hydroxyl aminal. It is also possible that the hydroxyl aminal can be transformed directly in the course 
of the reaction without formation of a Schiff base under certain circumstances. Imines can be seen as 
carbonyl analogues. Like most imine reactions, the U-4CR runs better upon activation of the Schiff base. For 
this, the acid component protonates the nitrogen atom of the Schiff base, thus increasing the 
electrophilicity of the C=N bond. Depending on the solvent, the ions can be present as a salt pair or 
separately. The electrophilic iminium ion and the nucleophilic acid anion add to the isocyanide carbon 
atom. The α-adduct thus formed can be seen as a hetero analogue of an acid anhydride in which an exo-
oxygen atom has been substituted by an NR group. After an intramolecular acylation, the stable Ugi linear, 
peptide-like adduct is obtained. This type of intramolecular acylation was first described in 1910 by Mumm 
and was subsequently called the Mumm rearrangement [17]. All elementary steps of this reaction are 
equilibria; however, the last step, the rearrangement to the stable α-acylaminoamide, lied exclusively on  
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the product side. The driving force of the total reaction sequence is the oxidation of the isocyanide CII atom 
to the amide CIV atom. 
 
 
 
Scheme 10 Simplified mechanism of the U-4CR 
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1.4 Novel MCRs:  A procedure for the synthesis of Aryl α-
ketoamide Amides 
 
The discovery of novel multicomponent reactions can afford the development of innovative ways to 
synthesize know or unknow molecular scaffolds. The most of MCRs are mediated by isocyanides , which are 
the only class of stable organic compounds with a divalent carbon. This property is very important because 
the divalent carbon reacts first with electrophiles and subsequently with nucleophiles. The identification of 
novel electrophilic partners constitutes a starting point for the discovery of new MCRs. The recent 
discovery that nitrile N-oxide species 2 , which generated by base dehydrochlorination of (Z)-chlorooximes 
1 [18], are good electrophilic partners for isocyanides 3 to give a nitrilium ion 4 ,that can be intercepted by 
a third nucleophile [19] , has led to the development of novel multicomponent reactions.(Scheme 11)  
 
 
Scheme 11 Proposed scheme for the formation of Novel MCRs via Nitrile N-oxide species 
 
 
A possible explanation of this missed opportunity might be found in a 1965 paper [20] where it was 
documented that nitrile N-oxides 6 and isocyanides 7 react to give isocyanates 8 and nitriles 9 according to 
the reaction reported in Scheme 12. 
 
 
Scheme 12 The reported reaction between nitrile-N-oxides and isocyanides 
 
 
It was proposed the following meccanism: the isocyanide 11 attacks, in a stereospecific way [21], the 
electrophilic carbon of the nitrile N-oxide 10 to give the intermediate a. This intermediate is then 
intramolecularly intercepted by the oxygen of the nitrile N-oxide, to give the highly unstable 4H-1,2-oxazet-
4-imine deriviative b [22], which, by a retro [2+2] cycloaddition, provides the corresponding cyanide 12 and 
isocyanate 13 (Scheme 13).  
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Scheme 13 Proposed mechanism for the formation of isocyanates and cyanides starting from nitrile N-oxides and isocyanides. 
 
The presence of a third nucleophile in the reaction mixture can prelude the formation of the high energy 
content 4H-1,2-oxazet-4-imine deriviative b driving the reaction toward another synthethic pathway as 
reported in this work. On the other hand, an isocyanide containing an internal nucleophile can 
intramoleculary intercept the nitrilium ion species generating a novel molecular framework.(Figure 1) 
 
  
Figure 1 Intramolecular trapping of the nascent nitrilum ion 
 
As a starting point for this study , it was inspired by pioneering work by Professor Jeping Zhu reported in a 
paper 2001 [23].  He demostrated a three-component reaction of aldehydes, primary or secondary amines 
and α-isocyanoacetamides to provide 5-aminooxazoles through interception of the nitrilium ion by the 
oxygen atom of the amide. For this reason the α-isocyanoacetamides could react with the nitrile N-oxides 
and then intermoleculary intercept the nascent nitrilium species. In this work [24] it was explored the 
reaction between (Z)-arylchlorooximes 5 and α-isocyanoacetamides 2 to produce 1,3-oxazol-2-oxime 
derivates 18 in good yields.(Figure 2) 
                     
Figure 2 Comparison between Zhu's work and the reaction described in this work 
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The reaction was carried out without TEA and with 1 equiv of TEA in dichlorometane at room temperature. 
The results were that the reaction with TEA was complete after 2h giving the desired product in good yields 
after column chromatography. On the other hand, the reaction without TEA didn’t formed the desired 
product and starting material, syn-chlorooxime was recovered after column chromatography. The reaction 
was explored using these already optimized conditions ( 1 equiv of TEA, room temperature , DCM) and (Z)-
phenylchloroximes bearing electron-withdrawing (22,26,27,28,29) or electron-donating (methyl 23 or 
methoxy 24) substituents on the para position, as well as one (Z)-heteroarylchloroxime with thiophene 
ring(25). α-Isocyanoacetamides contain two points of diversity: the amide function derived from cyclic 
secondary amines (20,30-32,36,37) or noncyclic secondary amines (35) and α-substitution (methyl 30 or 
benzyl 31,32). (Figure 3) 
 
 
 
Figure 3 Structure of (Z)-chlorooximes and α- isocyanoacetamides. 
 
Arylchloroximes were synthesized by chlorination of the corresponding oximes with N-chlorosuccinimide 
[25], while α-isocyanoacetamides were accesible by amidation of the corresponding α-isocyanomethyl 
ester using The Dömling procedure [26](α-Isocyanoacetic acid methyl ester was added to amine and stirred 
overnight at room temperature); to obtain the α-substituted α-isocyanoacetamides the alkylation was 
carried out in the presence of cesium hydroxide in acetonitrile at 0°C. [27]  The different (Z)-
arylchloroximes reacted with the isocyanoacetamides giving the corresponding 1,3-oxazol-2-oxime 
derivates in a range of yields from 32% to 88%.  Moreover, when isocyanoacetamide 36 was used , the base 
TEA was not necessary because the basic nitrogen of piperazine was able to trigger the formation of the 
nitrile N-oxide species. The reaction failed when a secondary amide was present such as in the 
isocyanoacetamides (33 e 34). 
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1,3-Oxazol-2-oximes were not stable molecules with isomerization of the oxime, especially when the 
oxazole ring was substituted at the 4-position, and formation of decomposition products. Although we have 
fully characterized them, they cannot be stored for long time (even at 0 °C). At the beginning, we 
attempted a one-pot procedure for the conversion of 1,3-oxazol-2-oximes into aryl-α-ketoamides. 
Hydrolysis of these intermediates in the presence of HCl, at room temperature, afforded the oxime-
dipeptide analogue 55, favoring, at the same time, the partial isomerization of the oxime. When the 
reaction was heated, we did observe the hydrolysis of the oxime and also the formation of several 
byproducts, which decrease the yield and make difficult the chromatographic purification. For these 
reasons, we opted to use milder catalysts as a Lewis acid, and we identified the copper(II) chloride [28] as 
the reagent of choice. After the aminooxazole ring was opened with HCl, the deoximation reaction in the 
presence of copper(II) chloride was carried out. Both reactions proceeded well and only a purification step 
was required (Scheme 14).  
 
 
Scheme 14 Acid Hydrolysis and Deoximation of 1,3-Oxazol-2-oximino Derivates. 
 
By using this protocol, we prepared different aryl-α- ketoamide amides (57−73) in good yields (Figure 4) 
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Figure 4 Synthesized aryl-α-ketoamides   
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1.5 Novel MCRs: Solution-Phase Parallel Synthesis of 
Aryloxyimino Amides 
 
As a continuation of previous studies, an electron deficient phenol could be a good nucleophiles third 
component to intercept the nitrilium ion giving aryloxyiminoamides. The mechanism of this reaction 
remember the Passerini-Smiles reaction developed by Prof El Kaim [29] [30].  The Passerini coupling 
involves an aldehyde, an acid carboxylic and an isocyanide and the mechanism consists in the activation of 
the aldehyde by the carboxilic acid followed the addition of the nucleophilic isocyanide and trapping of the 
resulting nitrilium by the carboxylate. All of these reversible reactions are finally displaced by a Mumm type 
rearrangment to form α-hydroxyamide derivates.  
An interesting strategy for discovery the new reactions and reactivity is to use surrogates of the carboxylic 
or the carbonyl partners. The o-nitrophenol is a good group because it is acidic (pKa=7.2) enough to activate 
carbonyl compound and induce isocyanide addition. The phenoxide is a good nucleophilic to trap the 
resulting nitrilium, forming imidate 2. The latter undergoes a Smiles rearrangement(consisting of the 
transfer of an aromatic ring from one heteroatom to another located in the same chain) to give the more 
stable α-aryloxi amide 3 [31].(Figure 5) 
 
 
 
Figure 5 Passerini-Smiles Mechanism 
 
 
  
- 24 - 
 
1.5.1 Results and method 
In this work a library of 41 aryloxyimino amides was prepared via solution phase parallel synthesis using (Z)-
chlorooximes, isocyanides and electron-deficient phenols. This is a simil Passerini-Smiles reaction when is 
changed the carbonyl species with syn-chlorooximes; an phenol could be attack the nitrilium ion and after 
the formation of the imidate , the hydroxyl group of the oxime, which is properly positioned, thanks to the 
stereoselective addition of isocyanide to the nitrile N-oxide, should trigger a Smiles rearrangement. In this 
case, a six membered transition state should occur [32], contrary to the typical Smiles rearrangement which 
forms a five-membered transition state. 
 
 
Scheme 15 Three-Component Synthesis of Aryloxyimino Amide 
 
To analyse this reaction, it is used (Z)-phenylchlorooxime (1), pentylisocyanide(2), and p-nitrophenol(3). 
(Scheme 15). The last component has been shown to be less reactive in Ugi-Smiles [33] and completely non 
reactive in the Passerini-Smiles rearrangement [29]. Moreover it is more problematic than o-nitrophenol in 
favouring the Smiles rearrangement, and so presented a good challenge for reaction development and 
optimization. The reaction was carried out in the presence of 2 equiv of TEA , in dichlorometane at room 
temperature (2h), it was obtained a mixture of the desired product 5 and the imidate 4 , with yields of 14% 
and 20%, respectively. The result did not change when the reaction was heated at reflux in toluene (6h). 
The difficulty in triggering the Smile rearrangement could be due to the inability of TEA (pKa=10.65) to fully 
deprotonate the oxime (pKa=10.78). The use of 2 equiv of potassium tert-butoxide (pKa=18) did not 
improve the result. Under such conditions the reaction was not clean and the desired compound (5) {1,1,1} 
was isolated only in very low yield (less than 10%). For this reason , it is possible to search for a base 
stronger than TEA but weaker than t-BuOK, such as using 2 equiv of DBU (pKa=12) which the desired 
product 5 was obtained in 20% yield and the imidate 4 was not observed. In this case, as with TEA, heating 
the reaction at 80°C in toluene(6h) did not change the yield. To put it simply, the formation of the nitrile N-
oxide species required an equimolar amount of base, while the Smiles rearrangement ,occuring after the 
addition of p-nitrophenol to the nitrilium ion, could proceed in the presence of a catalytic amount of base. 
In this way, reducing amount of DBU to 1.2 equiv in dichlorometane at room temperature overnight, the 
product was be isolated in 37% yield without the imidate. 
The aryloxyimino amide is stable in particular with respect to a potential Beckmann rearrangement due to 
the presence of a nitrophenol leaving group. After refluxing in toluene for several hours no signal of 
Beckmann product could be detected.  In this work three aryl-(Z)- chlorooximes 1 {1-3} bearing electron 
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donor substitutents, three isocyanides 2 {1-3} and five electron-deficient arenes 3 {1-5} were involved in 
the combinatorial parallel synthesis of a library of 45 compounds (Figure 6).  
 
 
 
Figure 6 Building blocks used 
 
To optimize the management of such a large number of reactions and minimize the chances of trival 
operator errors (such as miscalculations which could compromise the outcome of some of the reactions), 
the computer program MCRcombiS was used, able to manage large amounts of data and quickly output the 
correct quantities/concentrations of reagents (mmol, mg/mL, etc.)  to be used in each reaction. This 
program is now freely available for non-commercial use [34]. The results obtained are shown in Figure 7. 
 
 
 
Figure 7 General scheme of the aryloxyiminoamides synthesized 
 
The reactions proceeded efficiently and only in four cases the desired aryloxyimino amide was not isolate . 
The reaction does not seem to be very sensitive to steric or electronic factors. The purity of the final 
compounds were analyzed by HPLC-UV-MS after a simple silica gel filtration. Four compound 5 {1,3,5}, 5 
{2,3,5}, 5 {2,3,1}, 5 {3,3,5} were found to be mixture of Z and E isomers of the oxime, detected by both 1H 
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NMR and HPLC,  while six compounds [5 {1,1,1}, 5 {1,2,1}, 5 {1,1,2}, 5 {2,2,1}, 5 {2,1,2}, and 5 {2,2,2}] 
showed the presence of less than 5% of the E isomer visible only by HPLC. In this case, the E-isomer was 
easily removed by crystallization. Aryloxyimino amides are interesting compounds per se, but it was also 
intrigued by their potential use as intermediates for further synthetic transformations. As an example, the 
synthesis of benzo[d]isoxazole-3-carboxamides was explored, a well-known scaffold in medicinal chemistry, 
which usually requires a long and tedious synthesis (8 steps) [35]. As it has been demonstrated that SN2 
reactions can occur at the sp2 nitrogen of oximes [36], so the aryloxyimino amide 7, derived from the (Z)-
chlorooxime of salicylaldeyde (6) may, after hydroxyl deprotection, trigger an intramolecular SN2 type 
reaction affording benzo[d]isoxazole-3-carboxamides (8) (Scheme 16). It was pleased to find that, when 
TBAF was used to cleave the silyl protecting group, the desired transformation occurred in quantitative 
yield.  
 
 
 
Scheme 16 Synthesis of Benzo[d]isoxazole-3-carboxamides 
 
The discovery of these multicomponent reactions lead to development of new synthetic methodologies, 
which can be apply in medicinal chemistry. 
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Chapter 2 – Structure-Based Lead Optimization and 
Biological Evaluation of BAX Direct Activators as Novel 
Potential Anticancer Agents 
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2.1 Programmed Cell Death -Apoptosis 
Apoptosis is a genetically programme leading to cell death that is involved in normal development and 
homeostasis to maintain cell populations in tissues. Apoptosis also occurs as a defence mechanism such as 
in immune reactions or when cells are damaged by disease or noxious agents. In vertebrate cells, the 
process of apoptosis can occur in two different pathways , namely the extrinsic and the mitochondria-
mediated pathway. 
 
 
Figure 8 Intrinsic and extrinsic pathways 
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In the extrinsic signalling pathways (Figure 8) that initiate apoptosis, involve transmembrane death 
receptors, that are members of the tumor necrosis factor (TNF) receptor gene superfamily . Members of 
the TNF receptor family share similar cysteine-rich extracellular domains and have a cytoplasmic domain of 
about 80 amino acids called the “death domain” . This death domain plays a critical role in transmitting the 
death signal from the cell surface to the intracellular signalling pathways. To date, the best-characterized 
ligands and corresponding death receptors include FasL/FasR, TNF-α/TNFR1, Apo3L/DR3, Apo2L/DR4 and 
Apo2L/DR5. The sequence of events that define the extrinsic phase of apoptosis are best characterized with 
the FasL (Fatty acid synthetase ligand )/FasR (Fatty acid synthetase receptor) and TNF-α (Tumor necrosis 
factor alpha )/TNFR1 (Tumor necrosis factor receptor 1) models. In these models, there are clustering of 
receptors and binding with the homologous trimeric ligand. Upon ligand binding, cytoplasmic adapter 
proteins are recruited which exhibit corresponding death domains that bind with the receptors. The 
binding of Fas ligand to Fas receptor results in the binding of the adapter protein FADD (Fas-associated 
death domain) and the binding of TNF ligand to TNF receptor results in the binding of the adapter protein 
TRADD (TNF receptor-associated death domain) with recruitment of FADD and RIP (Receptor-interacting 
protein). FADD then associates with procaspase-8 via dimerization of the death effector domain. At this 
point, a death-inducing signaling complex (DISC) is formed, resulting in the auto-catalytic activation of 
procaspase-8. Once caspase-8 is activated, the execution phase of apoptosis is triggered. Death receptor-
mediated apoptosis can be inhibited by a protein called c-FLIP (FLICE-inhibitory protein) which will bind to 
FADD and caspase-8, rendering them ineffective. Another point of potential apoptosis regulation involves a 
protein called Toso, which has been shown to block Fas-induced apoptosis in T cells via inhibition of 
caspase-8 processing [37] . 
The mitochondria pathway of cell death (Figure 8) can be activated by a variety of receptor-independent 
stimuli such as radiation, toxins, hypoxia, hyperthermia, viral infections, and free radicals. All of these 
stimuli cause changes in the inner mitochondrial membrane that results in an opening of the mitochondrial 
permeability transition (MPT) pore. The major consequences of this change of permeability are the loss of 
the mitochondrial transmembrane potential (ΔΨm), the release of pro-apoptotic proteins and the arrest of 
the bioenergetics function of the organelle. The proteins that are released can be broadly classified into 
two categories. The first group consists of cytochrome c (cyt c) , Smac/DIABLO(second mitochondria-
derived activator of caspases), and the serine protease HtrA2/Omi. These proteins activate the caspase-
dependent mitochondrial pathway. Cytochrome c binds and activates Apaf-1 as well as procaspase-9, 
forming an “apoptosome” . The clustering of procaspase-9 in this manner leads to caspase-9 activation and 
then activates the executioner caspases 3 and 7 resulting in the dismantling of the cell through nuclear 
fragmentation [38]. Smac/DIABLO and HtrA2/Omi are reported to promote apoptosis by inhibiting IAP 
(inhibitors of apoptosis proteins) activity [39].  The second group of pro-apoptotic proteins, AIF, 
endonuclease G and CAD, are released from the mitochondria during apoptosis, but this is a late event that 
occurs after the cell has committed to die. AIF translocates to the nucleus and causes DNA fragmentation 
into ~ 50–300 kb pieces and condensation of peripheral nuclear chromatin [40] . This early form of nuclear 
condensation is referred to as “stage I” condensation [41] . Endonuclease G also translocates to the nucleus 
where it cleaves nuclear chromatin to produce oligonucleosomal DNA fragments [42] . AIF and 
endonuclease G both function in a caspase-independent manner. CAD is subsequently released from the 
mitochondria and translocates to the nucleus where, after cleavage by caspase-3, it leads to 
oligonucleosomal DNA fragmentation and a more pronounced and advanced chromatin condensation [43] . 
This later and more pronounced chromatin condensation is referred to as “stage II” condensation [41]. The 
control and regulation of these apoptotic mitochondrial events occurs through members of the BCL-2 
family of proteins. The founding member of BCL-2 family of proteins, bcl-2, was first cloned in neoplastic B 
cells with the t (14; 18) chromosome translocation [44] . Apoptotic events are highly regulated by this 
family of proteins, which shares homology in any of the four conserved “ Bcl-2 homology (BH) domains”, all  
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of which include α-helical segments. The BCL-2 family of proteins has been divided into three main groups 
based on sequence homology and function [45]. The anti-apoptotic proteins, BCL-2, BCL-XL, MCL-1, BCL-w 
and BFL-1 possess all the four domains (BH1-4). These proteins also contain a hydrophobic carboxy-
terminal domain that enables them to dock onto the outer mitochondria membrane (OM), the nucleus and 
ER. It has been shown that BCL-2 and Bcl-XL can protect the cells by interacting with mitochondrial proteins 
such as the adenine nucleotide translocase (ANT) or the voltage dependent anion channel (VDAC), thus 
preventing them from forming mitochondrial pores, protecting membrane integrity, and inhibiting the 
release of apoptogenic factors such as cyt c [46]. More recent evidence has highlighted novel functional 
biology of the anti-apoptotic protein BCL-2 [47]. Overexpression of BCL-2 was associated with a slight 
increase in steady state intracellular superoxide (O2
-) production, which was linked to increases in 
mitochondrial oxygen consumption and the activity of the rate limiting enzyme in the electron transport 
chain, cytochrome c oxidase (COX). Interestingly, pharmacological or molecular inhibition of the NADPH 
oxidase restored apoptosis sensitivity of BCL-2 overexpressing cells, thus implicating the pro-oxidant 
activity of BCL-2 in its anti-apoptotic function [48]. The second category of BCL-2 family, also known as 
multidomain pro-apoptotic proteins or “effectors”,  share homology in the BH domains 1, 2 and 3. These 
proteins would include BAX and BAK. BAX is a pro-apoptotic protein that resides in the cytosol under 
physiological conditions. An apoptotic trigger,however, can lead to its translocation to the mitochondria 
and its subsequent insertion into the OMM. At the mitochondria, BAX can homodimerize or heterodimerize 
with other pro-apoptotic members such as BAK or truncated BID, thus disrupting the integrity of the OMM 
by forming mitochondrial pores and increasing its permeability. These pores can then lead to the release of 
apoptogenic factors such as cyt c [49] . Some reports have also suggested that BAX engages in a close 
molecular cooperation with proteins from the PTPC, such as ANT and/or VDAC, to induce mitochondria 
membrane permeabilization (MMP) [50]. BCL-2 and BCL-XL have been shown to antagonize the apoptotic 
cascade by a direct interaction and sequestration of these pro-apoptotic proteins [51]. Similarly BAK, which 
is normally inhibited by its interaction with VDAC, can also homodimerize and result in pore formation at 
the mitochondria when freed. The third group of BCL-2 family of proteins is the BH3-only proteins. They are 
so named because they share homology only in the BH3 domain, which is essential for pro-death function. 
Certain of the BH3- only proteins, including BIM and BID, are called “activators” and induce activation by 
causing an allosteric change in BAX and BAK. A second class of propoptotic BH3-only proteins, called 
“sensitizer”, include BAD, BIK, NOXA, HRX, BMF and PUMA, are unable to induce activation of BAX and BAK 
directly. They act by neutralizing the anti-apoptotic proteins, binding the anti-apoptotic BCL-2 proteins 
causing a release of pro-apoptotic proteins. Sensitizers may be considered inhibitors of the inhibitors of 
apoptosis. [52]. Interactions between members of the sensitizer BH3-only class and the antiapoptotic class 
are selective. For istance, while BCL-2 is bound and antagonized by the BAD BH3 domain, NOXA BH3 binds 
BCL-2 very poorly. (Figure 9) 
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Figure 9 Model of BCL-2 family control over mitochondrial apoptosis. 
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2.2 Apoptosis in Cancer Cells 
Cancer cells block the apoptotic process by increasing the expression of anti-apoptotic BCL-2 members at 
the mitochondria. There are many mechanisms known by which BCL-2 is expressed at high levels in cancer 
cells. BCL-2 was originally cloned from the breakpoint of the chromosomal translocation t (14; 18) in 
patients with follicular lymphoma [44]. The translocation placed BCL-2 next to enhancer elements of the 
immunoglobulin promoter causing an increased expression of BCL-2. The BCL-2 translocation occurs in 
approximately 90% of follicular lymphomas and in about one-third of diffuse large B cell lymphomas [53]. 
On the other hand, BCL-2 overexpression has also been linked to gene amplification [54], hypermethylation 
of the BCL-2 gene [55], or chromosomal deletions causing the loss of micro-RNAs involved in the silencing 
of BCL-2 [56].  Reciprocally, cancer cells can evade death through mutations that inactivate the effector arm 
of apoptosis, such as the mutations of BAX observed in some solid tumors and hematopoietic malignancies 
[57]. For example, single nucleotide substitution or frameshift mutations of the BAX gene can occur in 
mismatch repair-deficient colon cancer or hematopoetic malignancies [58]. An especially common defect of 
cancers is  a mutation in the tumor suppressor gene p53 [59], which in turn has a negative effect on the 
activation of apoptosis, as the BH3-only proteins NOXA and PUMA are transcriptional targets of p53.  
A recent paper [60] segregated each of these blocks in apoptosis into three classes. In a Class A block, there 
is a loss of activator BH3-only proteins. A Class B block is caused by a failure to activate the effector arm of 
apoptosis through loss or inactivation of BAX or BAK. Finally, increased expression of an inhibitor protein 
such as BCL-2/MCL-1 causes a class C block  (Figure 10). 
 
 
Figure 10 The apoptotic blocks used by cancer cells .  
A new technique called BH3 profiling can detect the class of apoptotic block a cancer cell has evolved to 
evade apoptosis. BH3 profiling exploits the binding pattern of sensitizer BH3 proteins to the anti-apoptotic 
proteins BH3 profiling has been used to categorize diffuse large cell lymphoma cell lines into each of the 
three classes of apoptotic blocks, and it has shown that membership in the class C block correlates with 
increased drug sensitivity. From  the results generated by overexpression studies in cell lines, it is easy to 
envision that increased expression of BCL-2 would provide additional opposition against chemotherapy 
[61]. 
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2.3 Design Strategy 
The three-dimensional superimposition of BAX, alone (inactive state) [62] and with BIM−BH3 helix (active 
state) bound in the “rear site” [63] clearly revealed that, upon BIM binding, significant changes took place 
in the α1−α2 loop, which moves from a closed to an open conformation. Similar changes were observed 
upon 1 (BAM7) binding [64]. As the first step of this  lead optimization protocol, docking experiments were 
performed, by means of Glide, [65] [66] in order to reproduce the 1 binding mode, [64] which was then 
overlapped onto that of BIM peptide. As shown in Figure 11a, the strongest interaction was observed 
between the carbonyl group of 1 pyrazolone core and the BAX K21, a key residue which interacts with BIM 
as well (see Figure 11a, charge−charge interaction with BIM E158). Notably, the ethoxyphenyl group of 1 
lays adjacent to a presumed hinge site for loop opening upon initiation of BAX activation and well overlaps 
onto BIM F159. However, as shown in Figure 11a, the BIM−BH3 helix is much longer if, compared to 1, 
holding five further amino acids next to F159, (e.g., Y162 and Y163). On the opposite side, the 
phenylthiazole portion of 1 well fitted on BIM L152 and I155, although lacking the terminal amino group, 
that as in the case of BIM, engages charge reinforced hydrogen bonds with BAX D142 and E146, 
respectively. On the basis of these premises, it was planned lead optimization studies of 1 aimed at 
understanding the BAX requirements and hopefully at improving the binding affinity. Given the importance 
of the pyrazolone core, it was retained while a rebranching approach was accomplished in the attempt to 
better mimic the essential features of the physiological activator (BIM BH3 only protein). Thus, as shown in 
Figure 11b, a number of different moieties were considered. Basically, in the replacement of the 2-
ethoxyphenyl-hydrazono group, two considerations were taken into account: (i) substitution of hydrazone 
bridge with other spacer groups, for synthetic reasons, and (ii) substitution of the ethoxyphenyl with 
bulkier aromatic moieties (see compounds 2−7, and 15−16), in the attempt to approach the region 
occupied by BIM Tyr residues, which abut the hinge site for α1−α2 loop opening. Analogously, for the 
replacement of the phenylthiazole group, the substitutions were planned based on the following 
considerations: (i) neither the N nor the S of the thiazole ring engaged interactions with BAX, so that the 
thiazole ring could, in principle, be replaceable by other aromatic systems such as phenyl ring, which can be 
easily substituted with the aim to establish further interactions with other BAX residues (e.g., E17), (ii) the 
para position of the biphenyl moiety is in proximity of D142 that together with E146 seizes the BIM amino 
terminal group (Figure 11a). Thus, it was inserted an exocyclic or endocyclic basic group at the terminal 
phenyl ring (8, 12, and 10, respectively). Compounds 9 and 13 were synthesized as negative control to test 
the importance of the N,N-dimethylamino group. Compound 14 was synthesized as negative control to test 
the importance of the hydroxyl group on the biphenyl moiety. Finally, 11 was conceived as a replacement 
of the 5−6 thiazole-phenyl system with a 6−5-phenyl-thiazole one. 
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Figure 11 Design strategy. a) Docked structure of BAM-7 (pink) at the BAX rear site (green surface). BIM BH3 helix is colored in 
transparent blueb) Representation of  the re-branching approach. c) Binding mode of 8 (BTC-8) within BAX rear site. 
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2.4 Chemistry 
Synthesis of compounds 2−16 are depicted in Scheme 17-Scheme 19. Compounds 2−5 and 16 were 
prepared by reacting the 5- methyl-2-(4-phenylthiazol-2-yl)-2,4-dihydro-3H-pyrazol-3-one (17), obtained by 
treatment of 2-hydrazinyl-4-phenylthiazole with ethyl acetoacetate in acetic acid at reflux temperature for 
3 h, with the appropriate benzaldehyde in the presence of piperidine in boiling ethanol for 4 h (Scheme 17). 
Reaction of compound 17 with 2-(2-ethoxyphenyl)acetyl chloride in the presence of potassium tert-
butoxide in anhydrous tetrahydrofuran at 0 °C for 1 h furnished the derivative 6, which was converted into 
the corresponding dione 7 by oxidation with potassium permanganate in the presence of a catalytic 
amount of sulfuric acid in acetone at reflux temperature for 12 h. Compounds 8, 12, and 15 were 
synthesized starting from the 2- (3-bromo-5-hydroxyphenyl)-5-methyl-2,4-dihydro-3H-pyrazol- 3-one (19), 
which was treated with 2-ethoxybenzenediazonium chloride or naphthalene-2-diazonium chloride in the 
presence of sodium acetate in ethanol at 0 °C for 2 h and then coupled with the appropriate boronic acid in 
the presence of sodium carbonate and Pd catalyst in tetrahydrofuran at reflux temperature for 90 min 
under Ar stream (Scheme 18). Analogously, treatment of compound 19 with the appropriate boronic acid 
and subsequent reaction with 2-ethoxybenzenediazonium chloride gave derivatives 9, 11, and 13. 
Compounds 22−24 were prepared as above-reported, starting from the 3- bromo-5-hydrazinylphenol 
hydrochloride (18), obtained by reaction of 3-bromo-5-nitrophenol with tin(II) chloride dihydrate in boiling 
ethyl acetate for 3 h, treatment with sodium nitrite and 37% HCl at 0 °C for 20 min, and final reduction with 
tin(II) chloride dihydrate at 0 °C for 20 min. Derivatives 10 and 14 were obtained similarly to 8, starting 
from pyrazolones 29 and 30, respectively (Scheme 19). Derivatives 29 and 30 were prepared as above-
reported, by treatment of 3-bromo-5-nitrophenol with the appropriate boronic acid, conversion into the 
corresponding phenylhydrazine derivative, and final cyclization with ethyl acetoacetate. 
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Scheme 17 Synthesis of Compounds 1-7. aReagents and reaction conditions: (a) ethyl acetoacetate, acetic acid, reflux temperature, 
3 h, 62%; (b) appropriate benzaldehyde, piperidine, anhydrous ethanol, reflux temperature, 3 h, 28−61%; (c) (i) potassium tert-
butoxide, anhydrous tetrahydrofuran, −40 °C, 1 h, (ii) 2-(2- ethoxyphenyl)acetyl chloride, 25 °C, 1 h, 74%; (d) potassium 
permanganate, catalytic sulfuric acid, acetone, reflux temperature, 5%. 
 
 
 
 
 
 
Schema 18 Synthesis of Compounds 8, 9, 11-13 and 15a
a
Reagents and reaction conditions: (a) tin(II) chloride dihydrate, ethyl 
acetate, reflux, 3 h; (b) (i) sodium nitrite, 37% hydrogen chloride, 0 °C, 20 min, (ii) tin(II) chloride dihydrate, 0 °C, 20 min, crude 
product; (c) ethyl acetoacetate, acetic acid, 80 °C, 3 h, 13%; (d) 2-ethoxybenzenediazonium chloride or naphthalene-2-diazonium 
chloride, sodium acetate, 96° ethanol, 0 °C, 2 h, 3−48%; (e) appropriate boronic acid, 2 M sodium carbonate, dichloro[1,1′-
bis(diphenylphosphino)ferrocene]-palladium(II) dichloromethane complex (1:1), tetrahydrofuran, reflux temperature, 90 min, Ar 
stream, 13−66%. 
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Schema 19  Synthesis of Compounds 10and 14a 
a
Reagents and reaction conditions: (a) appropriate boronic acid, 2 M sodium 
carbonate, dichloro[1,1 bis(diphenylphosphino)ferrocene]-palladium(II) dichloromethane complex (1:1), reflux temperature, 90 
min, Ar stream, 14−25%; (b) tin(II) chloride dihydrate, ethyl acetate, reflux, 3 h; (c) (i) sodium nitrite, 37% hydrogen chloride, 0 °C, 
20 min, (ii) tin(II) chloride dihydrate, 0 °C, 20 min, crude product; (d) ethyl acetoacetate, acetic acid, 80 °C, 3 h, 12−13%; (e) 2-
ethoxybenzenediazonium chloride, sodium acetate, 96° ethanol, 0 °C, 2 h, 36−47%. 
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2.5 Biological Results 
In Vitro BAX Affinity, Selectivity Profile, and SAR Rationalization. Affinities of candidate compounds for 
recombinant BCl-2 family members were measured in vitro by fluorescence polarization assay (FPA). GST 
tagged full length BAX, untagged BCL-2, and BCL-XL show nanomolar affinity for FITC-BIM (Ki values of 200, 
132, and 794 nM, respectively) ( Figure 12) in line with data previously reported. [63] [64]. 
 
 
 
 
 
Figure 12 Affinity of FITC-BIM for recombinant BCL-2 family targets. FITC-BIM Direct specific binding isotherms are shown for 
engagement of FITC-BIM by GST-BAX (green curve), BCL-2 (red curve) and BCL-XL (blue curve). Total binding (black lines) are shown 
for comparison. Fraction of FITC-BIM bound was measured before and after the addition of Acetylated-BIM (50μM). FITC-BIM 
specific binding was calculated subtracting non specific binding (measured in the presence of Acetylated-BIM) from total binding 
(measured in the absence of Acetylated-BIM). Mean of three experiments and S.D. are indicated. 
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The ability of 1−15 to displace bound FITC-BIM was used to calculate their Ki for each of the three proteins 
(Figure 13 and Table 1). 
 
 
 
Figure 13 8 binds BAX at BIM binding site. Competition between 8 (upper panel) or BAM-7 (lower panel) and FITC-BIM for binding 
to BAX (green curve), BCL-2 (red curve) and BCL-XL (blue curve). Mean of three experiments (SD. are indicated). 
 
 
As previously reported, 1 is selective on BAX over BCL-XL ( Figure 13 and Table 1). It displays, however, 
affinity for BCl-2 despite this being somehow slightly lower than the one for BAX (Ki values of 3.0 and 1.1 
μM, respectively). In the range of concentration tested, the new compounds show either higher affinity for 
BCl-2 over BAX and BCL-XL (compounds 2 and 5), higher affinity for both BCl-2 and BCLXL over BAX 
(compounds 3−5), and similar affinities for the three proteins (compounds 16) or for none of them 
(compounds 6−7) (Table 1).  
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Table 1.Ki (µM) of Compounds 1-15 for BAX, BCL-2, and BCL-XL (FPA, FITC-BIM Displacement). 
 
Compounds 8−10 show higher affinity for BAX over BCL-2 and BCL-XL. Among them, 8 displays higher 
affinity for BAX (Ki = 0.8 μM) than 1 (Ki = 1.1 μM, Figure 13). 9 and 11 are selective for BAX, but they are 
somehow weaker binders than 8. 12 is specific for BAX, but its BAX affinity is lower than 8 and comparable 
to that of 1. 13−15 display high affinity for BAX but less specificity (Table 1)over the other two proteins.  
SAR toward BAX were rationalized on the basis of the complex between 1 and BAX, which was previously 
obtained by a combined approach of docking and NMR experiments [64] and on the basis of docking of its 
analogue 8. Molecular docking of 8 within the BAX rear site resulted in a binding mode highly 
superimposable to that of 1 (Figure 11a,c). However, in line with the lower Ki of 8, compared to that of 1, 8 
reinforces its binding to BAX surface through an H-bond with E17 by the ligand hydroxyl group and through 
a charge reinforced hydrogen bond with D142 coupled with hydrophobic interactions between the methyl 
groups and D142 carbon chain. According to then observed interactions, 9 (unsubstituted on the terminal 
phenyl ring) is less active than 8, 13, and 14. The importance of an amino group on the terminal phenyl ring 
is also proved by the affinity of 12 compared to that of 9 and by the reduced specificity of 13 compared to 8 
and 12. All in all, SAR where the phenylthiazole group is replaced by other moieties clearly demonstrate 
that such a branch is replaceable by other aromatic systems, that if adequately decorated bring an 
improvement of BAX affinity. Regarding the 2-ethoxyphenylhydrazono group of 1, SAR were designed to 
explore: (i) bridges different from the hydrazono one and (ii) possible, fruitful hydrophobic interactions 
established by different aromatic moieties. Among the different bridges synthesized, just the ene one (16) 
seems to be well tolerated. The higher Ki of 6 and 7 seemed to be ascribable to the different geometries of 
ketomethylen- and diketo bridges with respect to hydrazono group, which would bring the 2-ethoxyphenyl 
farther from L25, with which an hydrophobic interaction was observed (Figure 11a). Although no H-bond 
between the ethoxy group of 1 and K21 was observed with a semiflexible docking approach, their proximity 
would suggest a possible interaction, which can be also the reason for the slightly lower Ki of 16 with 
respect to that of 1. Analogues of 1, where the phenyl moiety were replaced by a benzhydryl (2), biphenyl 
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(3), and naphthalene (4) group, were all less active than the lead. Rationalization of the lower Ki of 2−4 is 
somehow difficult, as the benzhydryl, biphenyl, and naphthalene group would occupy the hinge site for 
loop opening, a region that undergoes to profound change upon ligand binding and activation. 
 
Cell Viability and Apoptosis Assays. Affinities and selectivity of 1−15 measured by FPA well correlate with 
their potency on inducing apoptosis in MEF knock out cells. At the EC50 of 1, all the compounds but 6, 7, and 
1 induced apoptosis in MEF wt cells (Table 2 and Table 3), while they were ineffective on MEF BAK−/− BAK−
/− double knockout cells, indicating that they ultimately lead to pro-apoptotic protein activation.  
 
 
Table 2 EC50 (µM) Values of Apoptosis Induction of Compound 8 or 1 Treatment on the Indicated MEF Knockout Clones 
 
1, 8− 10, and 12−15 are the most effective at the concentration of 10 μM. 2−5 potencies are overall lower 
and partially affected by the absence of BCL-2 as well as of BID, BAD, BAK, or BAX, suggesting that, at least 
in MEF cells, BAX direct activation is not their main mechanism of action (Table 3).  
 
 
Table 3 Sensitivity of the indicated MEF clones to 24 hours of treatment with the candidate compounds (15 μM). – (less than 5% of 
apoptotic cells); + (5-30% of apoptotic cells); ++ (30-60% of apoptotic cells); +++ (more than 60% of apoptotic cells). 
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On the contrary, 1, 8−10, and 12−16 induce apoptosis independently by the absence of BCL-2, BID, and 
BAD, pointing to their target being located downstream in the apoptotic pathway (Figure 14, and Table 3).  
 
 
 
Figure 14 8 induces apoptosis in a BAX dependent way. Effect of 8 treatment on MEF cells. Apoptotic rate of the indicated MEF 
clones upon 24 h of treatment with vehicle (0.1% DMSO, gray bars), 1 (15 μM, white bars), or 8 (15 μM, green bars). The 
photographs represent appearance of apoptotic cell membrane blebbing upon MEF treatment with 8 and its absence when 8 
treatment was done in the presence of the caspase inhibitor Ac-DEVD-CHO (10 μM). 
 
12, 13, 14, and 16 affected MEF BAX−/− as well as MEF BAK−/−, indicating that they can trigger apoptosis 
either by BAK or by BAX. 8−10 and 15 similarly to 1 induced apoptosis in BAK−/− but not in BAX−/− 
knockout cells and represent, among the tested ones, the candidate compounds with the best features of 
selective BAX activators (Figure 14, Table 3). MEF cells treated with 8, the most potent compound of our 
series (EC50 of 8 on MEF-wt of 1.1 μM, EC50 of 1 on MEF-wt of 7.7 μM) undergo apoptotic processes, as 
shown by the appearance of fragmented nuclei and cell membrane blebbing. Moreover, its potency is 
reduced by the presence of the caspase inhibitor Ac-DEVD-CHO [67] (Figure 14), indicating that its 
mechanism of action involve apoptotic effectors. Differently from MEF cells, tumor cells overcome pro-
apoptotic stimuli by overexpressing ant-apoptotic proteins or by downregulating pro-apoptotic ones. It was 
thus decided to challenge these compounds in inducing apoptosis in in vitro cultured tumor cells. Apoptosis 
was followed in human hepatoma HuH7 cells, which express wt BAX, a high level of BCL-2 but a low level of 
caspase 3, [68] the final effector of the apoptotic cascade. Under apoptotic stimuli, they survive for longer 
time than other tumor cells and, thus, they represent an ideal platform to look exclusively at the early 
events of the apoptotic process. Apoptosis was followed in HuH7 by measuring MOMP, which inhibits 
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mitochondrial accumulation of the fluorescent probe Mitotracker Red. Among the tested compounds, 8 
was the most potent in affecting probe accumulation (Figure 15 and Figure 16). 
 
 
 
 
Figure 15. 8 affects mitochondria in HuH7 cells. (a) Mitochondrial activity of 8 and 1 treated cells visualized by Mitotracker Red 
fluorescence uptake. Magnification bars are indicated. (b) After lysis of the cells absorbance of the dye was measured at 570 nm 
and plotted versus 8 or 1 concentration. EC50 were calculated by fitting values by non linear regression analysis of dose response 
analysis and reported together with their 95% CI (error bars are indicated, n = 3). 
  
 
Other compounds of the series (e.g., 2 and 3) affected mitochondrial potential only after 72 h of treatment, 
in line with a reduced affinity for BAX but an increased affinity for BCL-2 or BCL-XL or both (Table 1 and 
Figure 16). 
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Figure 16 mitochondrial Effect of 12 (a) and 72 hours (b) of compounds 1-16 treatment on mitochondrial activity of HuH7 cells 
measured by Mitotracker Red accumulation. After lysis of the cells absorbance of the dye was measured at 570 nm and reported as 
percentage of that measured in untreated cells (mean of at least 3 experiments, error bars are indicated (S.D.)). 
 
While 1 and 8 affected the cultures similarly at 10 μM, 8 induced a stronger reduction in probe 
accumulation at 1 μM (Figure 15a) .The higher potency of 8 over 1 was quantified by a dose response curve 
revealing the EC50 of 1 and 8 in cultured HuH7 cells to be 8.2 μM and 700 nM, respectively (Figure 15b and 
Table 3). Similarly to 1, 8 induces a conformational change in BAX that exposes an epitope recognized by 
the anti-BAX 6A7 antibody [64], specific for the activated form of the protein (Figure 17). 
 
Figure 17 8 activates BAX. Lysates of HuH7 cells treated with 8 or with vehicle alone were immunoprecipitated or not with the 6A7 
monoclonal anti-BAX antibody. All samples were equally boiled, run on a SDS-PAGE and decorated with a polyclonal antibody anti-
BAX. 
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As expected from a BAX direct activator, 8 was able to induce the translocation of BAX to mitochondria, the 
cyt-C release from these organelles (Figure 18 and Figure 19), the activation of caspase 3, and the 
formation of apoptotic nuclei (Figure 18 and Figure 20). 
 
 
 
Figure 18 8 induces translocation of BAX to mitochondria. a) HuH7 cells were treated with 1 and 8 to be then fixed and processed 
for immunofluorescence to localize BAX intracellularly. In untreated cells, BAX localizes in the cell cytoplasm with no clear 
indication of association to any intracellular organelle, while after treatment of the cell with 10 μM 1 or 8, BAX localization 
drastically changes moving to punctuate structures. b) As further proof HuH7 cells were cultured with the indicated amount of 8, or 
with vehicle alone for 12 hours. After treatment cell were permeabilized and the mitochondrial and cytosolic fractions were 
isolated as described in the manuscript. Equal amount of proteins were separated by SDS PAGE and processed for Western 
Blotting. BAX was revealed by decorating the filters with the indicated anti-BAX antibody (fullblots are shown). 
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Figure 19 8 induces cyt-C release from mitochondria. HuH7 cells were treated with BAM-7 (1) and 8, then were fixed and processed 
for immunofluorescence to localize cyt-C intracellularly. Before the treatment with 8, the cyt-C is localized in mitochondria, as 
shown by its colocalization with the structures labeled by the Mitotracker Red. After the treatment with 8, its localization changed 
becoming diffuse thus indicating its exit from the organelle. Boxed area are shown at higher magnification at the corner of each 
panel. 
 
 
 
Figure 20a) 8 induces caspase-3 activation and formation of apoptotic nuclei. b) Quantification of caspase-3 positive cells after 
treatment with 8 and 1 as described in the manuscript. Mean of 10 random fields (error bars are indicated S.D.) 
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Similarly to what we have already shown in MEF BAX−/− cells, 8 treatment had no effects on the leukemic 
Jurkat (T-cell lymphoma) cell line. Jurkat cells express a mutated form of BAX and rely only on BAK to induce 
MOMP [69]. Jurkat cells resulted insensitive to 8 treatment, confirming that our compound activates 
selectively BAX (Figure 20). Differently leukemic NB4 cells (promyelocytic), which express wt BAX [70], 
showed hallmarks of apoptosis already after 12 h of treatment with 8. Then, to have indication about the 
toxicity of 8 on healthy cells, we tested the effect of the compound on primary healthy splenocytes. At 
concentration of 10 μM, 8 did not alter the apoptosis rate in primary cells, indicating that could selectively 
affect tumoral cells (Figure 20). This observation could be explained by the fact that, as seen for many 
other cancer drugs, 8 could affect predominantly highly proliferating cells rather than resting ones. 
 
 
 
Figure 21 8 induces apoptosis in tumor cells but it does not alter apoptotic rate in healthy splenocytes. The indicated tumor cell 
lines (a) or primary splenocytes (b) were incubated for 72 h with 8 (10 μM). Apoptosis rates were detected by counting apopototic 
nuclei. Mean values are reported together with their SD (n = 3 in a; n = 4 in b). 
 
 
Compound 8 is able to affect mitochondrial membrane potential in all the tumor cell lines tested (Figure 
22). Like HuH7, Lewis lung carcinoma (LLC1) and human neuroblastoma (SHSY-5Y) cells were reported to be 
highly resistant to conventional pro-apoptotic drugs. Like for HuH7, after treatment with 8, these cells did 
not show sign of death (visible in only the 20% of cell (data not shown)), but they stop duplicating to 
undergo in a process of growth arrest. This effect likely suggests that even in those tumor cell lines that 
have developed strategies to block the initiation of the apoptotic process or its completion, BAX direct 
activation can hamper mitochondrial activity, reduce intracellular energy content, and ultimately affects 
cell growth. 
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Figure 22 8 induces growth arrest and cell death. (a) Cells were incubated for 72 h with the indicated concentration of 1 and 8 and 
then with Mitotracker. Absorbance was measured after lysis of the cell. Values are the mean of at least three experiment. Error 
bars (SD) are indicated. (b) HuH7 cells were incubated for the indicated time with 10 μ 1 or 8 or vehicle alone. After the treatment 
cells were counted. Values are expressed as percentage of control (cells at 0 min of treatment) and are representative of at least 
three experiments. 
 
In Situ BAX Activation and in Vivo Tests. LLC1 cells resulted sensitive to 8 (Figure 22). These cells well 
represent lung carcinoma, the primary cause of adult mortality. To establish whether 8 would be 
efficacious in vivo, it was used them in a murine Lewis lung carcinoma model that reliably recapitulates 
human lung cancer in pathology, disease progression, clinical outcome, and response to therapies [71]. 
LLC1 cells have a high tropism for the lung and are able to form tumor lesions [72] that after 14 days are in 
exponential growth, making the drug treatment clinically relevant. On day 0, tumor cells were injected into 
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mice via the tail vein. From day 14 to day 17, one group of mice were treated once a day with an 
intraperitoneal injection of 8 (1 mg/kg) or of vehicle (1% DMSO). On day 17, animals were euthanized. The 
compound ability to induce an in vivo activation of BAX was confirmed trough immunoprecipitation of lung 
lysates with 6A7 antibody (Figure 23). 
 
 
 
Figure 23 In vivo treatment with 8 induces in situ BAX activation. Homogenates of mouse lungs treated or not with 8 were lysed 
and immunoprecipitated with the 6A7 monoclonal antibody. Samples were boiled, run on a SDS-PAGE, and decorated with a 
polyclonal antibody anti-BAX (only relevant part of the gel is shown). 
 
 A visual inspection of the exposed lung of control mice showed very large tumor lesions covering the lung 
surface, whereas the lungs of mice treated with 8 showed highly size-reduced tumor lesions. Histological 
analysis using hematoxylin and eosin (H&E) staining of lung sections demonstrated that after only 4 days of 
treatment the ratio between tumor burden and lung area in mice treated with 8 compared with control 
was significantly (P < 0.01) decreased by 50% (Figure 24). 
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Figure 24. In vivo activity of 8. (a) Effect of the daily administration of 8 1 mg/kg from day 14 to day 17 on tumor growth (dark 
violet staining). Microphotographs showing the entire lung sections; the boxed areas in the upper-magnification H&E panels are 
shown at a higher magnification in the lower panels. (b) Graph showing the effect of 8 on tumor growth. The results are expressed 
as tumor lesions/lung area ratio. Individual data points represent average value per mouse; horizontal bars denote mean. P < 0.01 
vs control group. 
 
 It is noteworthy that 8 seemed to be well tolerated because no mortalities, evidence of gross toxicity, 
behavioral side effects, or body weight changes were observed in the four days of treatments. A 
microscopic examination of heart, femoral muscle, and healthy lung did not reveal any pathologic change 
(data not shown). The in vivo efficiency of 8 in tumor mass reduction was of relevance especially if a rough 
comparison with marketed anticancer drugs on similar tumor models is done. In fact, cyclophosphamide 
(60 mg/kg) or adriamycin (1.25 mg/kg) gave a reduction of 40% even in the case of prolonged treatments. 
[73] [74]. 
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2.6 Pharmacological folding chaperones act as allosteric 
ligand of Frizzled4 
 
Upon binding, ligands can chaperone their protein targets by preventing them from misfolding and 
aggregating. Thus, an organic molecule that works as folding chaperone for a protein might be its specific 
ligand, and, similarly, the chaperone potential could represent an alternative readout in a molecular 
screening campaign toward the identification of new hits. The aim of this work is to demonstrate that small 
molecules selected for acting as pharmacological chaperones on a misfolded mutant of the Frizzled4 (Fz4) 
receptor bind and modulate wild-type Fz4, representing what are to our knowledge the first organic ligands 
of this until-now-undruggable GPCR. The novelty and the advantages of the screening platform, the 
allosteric binding site addressed by these new ligands and the mechanism they use to modulate Fz4 suggest 
new avenues for development of inhibitors of the Wnt–b-catenin pathway and for drug discovery. The 
compounds 2,3,4,5,16 (Figure 11b), which were synthesized as BAX direct activators, were included in this 
library of small molecules selected for acting as pharmacological chaperones  on a misfolded mutant of the 
Frizzled4 (Fz4) receptor [3]. Fz4 is a member of the Frizzled cell surface receptors, which belong to the 
GPCR class F family [75]. Seven-transmembrane (TM) segments arrange in the canonical GPCR TM bundle 
(TMD) and interconnect via three intracellular loops (ICL) and extracellular loops [75] (Figure 25). A large 
extracellular domain (ECD) binds the receptor’s ligands, the lipoproteins WNTs [75] and Norrin [76]. Finally, 
a short cytosolic C-terminal tail helps the ICLs orchestrate the downstream intracellular signal [77]. Several 
mutations in the coding region of the Fz4 gene have been described in different organisms.  In humans, 
despite being rare, they lead to the development of familial exudative vitreoretinopathy (FEVR), a 
pathology resulting in aberrant vascularization of the retina during embryo development [78]. Among the 
mutations, the frameshift L501fsX533 of Fz4 shows autosomal dominant inheritance and causes a 
conformational defect by generating a different and shorter C-terminal cytosolic tail that hampers signaling 
of the mutant receptor (henceforth referred as Fz4-FEVR) and its correct folding and transport to the cell 
plasma membrane (PM) [78] ( Figure 25).  
 
 
 
Figure 25 Schematic cartoon of Fz4-WT (a) and Fz4-FEVR (b) receptors.  Through improper interactions with the ER membranes, the 
Fz4-FEVR tail causes receptor aggregation. 
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The search for organic modulators of Fz4 was recently intensified owing to evidence of its involvement in 
malignancy. Fz4 is indeed a key component of Wnt–β-catenin signaling that regulates stemness during 
cellular development and in adult life [79]. Misregulation of Fz4 activity is involved in tumor proliferation 
and cancer stem cell genesis in many types of malignancies, such as glioblastoma, colorectal and breast 
cancer [80]. In this work it was attempted a molecular screening campaign toward pharmacological 
chaperones rescuing Fz4-FEVR folding with the ultimate goal to identify small organic wild-type (WT) Fz4 
(Fz4-WT) modulators. It was selected molecules able to work as folding chaperones by measuring their 
potency in restoring Fz4-FEVR folding and localization at the PM. It was identified three pharmacological 
chaperones of Fz4-FEVR that are indeed Fz4-WT ligands and act as Wnt–β-catenin inhibitors, proving the 
validity of the new screening strategy. One of our hits, namely FzM1, exerts its modulatory activity by 
inducing conformational changes in Fz4-WT that ultimately allow it to inhibit β-catenin nuclear transport 
and antagonize the Wnt pathway. The Fz4 modulators here described represent what are to our knowledge 
the first organic molecules addressing this still-undruggable receptor. Here, the novelty of the screening 
approach, the step of the Wnt–β-catenin cascade targeted by our new compounds together with their 
mechanism of action are discussed in terms of future development of Wnt pathway inhibitors. 
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2.6.1 Results 
Among the Fz4 mutations described, the one resulting in Fz4-FEVR shows the most clearly identifiable 
phenotype, trapping the mutant receptor in the endoplasmic reticulum (ER) and hampering its transport to 
the PM of the cells [78]. The mutated C-terminal tail of Fz4-FEVR improperly interacts with the ER lipid 
bilayer, disturbing receptor stability and inducing its aggregation and retention in the ER [81] (Figure 25b). 
Notwithstanding, Fz4-FEVR localization at the PM can be rescued by overexpressing the protein chaperone 
α-B crystallin [82]. Fz4-FEVR can be thus included among the proteins that are responsible for 
conformational diseases whose phenotype can be rescued by strategies aiming to improve folding. The 
marked difference in localization between the WT and mutant receptor makes Fz4-FEVR an ideal platform 
to screen for folding chaperones by offering an unambiguous readout. Two cell lines stably expressing 
hemagglutinin (HA)-tagged WT Fz4 (HA-Fz4-WT) or Fz4-FEVR (HA-Fz4-FEVR) were generated. As previously 
shown [82], HA-Fz4-WT was localized in the Golgi complex and at the PM, whereas HA-Fz4-FEVR appeared 
to be trapped intracellularly, mainly in the ER [78]. HA-Fz4-FEVR HEK293 cells were treated with a library of 
small molecules for 48 h. Chaperone activity was then assayed by measuring the recovery of HA-Fz4-FEVR 
localization at the PM. Among others, the library contained folding chaperones (radicicol, geldanamycin 
and 17AAG) and correctors (acridine derivatives, DMSO and glycerol) with known rescuing activity on the 
cystic fibrosis transmembrane conductance regulator (CFTR) mutant CFTRΔF508 [83]. Those folding 
chaperones that were already known failed in rescuing Fz4-FEVR localization, whereas the compound FzM1 
rescued Fz4-FEVR localization at the PM in 15% of the cell population. FzM1 pharmacological activity was 
confirmed after resynthesis. A further pool of molecules that were structurally similar to FzM1 was added 
to the screen (Figure 11b compounds 2-3-4-5-16). Among the tested candidates, FzM1, 2 and 3  rescued 
HA-Fz4-FEVR PM localization with an efficiency higher than 10% and with a half-maximum effective 
concentration (EC50) in the micromolar range (Figure 26) In untreated cells, Fz4-FEVR forms covalent 
aggregate [81]. 
 
 
 
 
 
 
 
 
 
 
 Figure 26 Chemical structures of compound FzM1, 2 and 3. Their EC50 for PM rescue of Fz4- FEVR are indicated together with 
s.e.m. ( n= 3). 
log EC50 
(PM Rescue) 
= -4,92 ± 0,04 
log EC50 
(PM Rescue) 
= -4,70 ± 0,04 
log EC50 
(PM Rescue) 
= -4,77 ± 0,07 
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2.6.2 FzM1 binding site 
To further confirm that the new screening platform indeed selected molecules addressing our target,  it 
was identified the FzM1 binding site on Fz4-WT. Attempting to transform FzM1 in a molecular probe, it was 
derivatized  with an alkyne moiety (FzM1alk ). Despite being extremely unreactive, alkynes can receive 
nucleophilic attacks from sulfhydryl or hydroxyl group of amino acids to generate covalent adducts. This 
extremely rare event has been shown to happen at catalytic sites of enzymes as well as in ligand binding 
pockets [84]. FzM1alk is still a pharmacological chaperone of Fz4-FEVR, and it is also able to inhibit Wnt-β-
catenin pathway in Fz4-WT–expressing cells (log EC50 as pharmacological chaperones and as Wnt antagonist 
of −4.8 and −4.9, respectively;Figure 27). 
 
 
Figure 27 Chemical structure of FzM1alk. EC50 values for FzM1alk as a folding chaperone for Fz4-FEVR and as a Wnt inhibitor are 
indicated. (n=3, means ± s.e.m.) 
 
HA-Fz4-WT HEK293 cells were cultured in the presence of FzM1alk. Fz4 was immunopurified, digested with 
trypsin and analyzed by LC/MS. HPLC profiles of samples from FzM1alk-treated cells and untreated cells 
were compared. These almost totally overlapped, with the exception of a fraction eluting with a retention 
time of 17.2 min and present only in samples obtained from FzM1alk-treated cells .Among the peptides 
eluting in this fraction, the one with an m/z of 1,386.9 Da corresponded, with a deviation (Δmass) of 1.6 Da 
from the theoretical mass, to amino acids 418–426 of Fz4 ICL3 (theoretical mass of 990 Da) carrying 
FzM1alk (molecular weight 398.5 Da) covalently linked either to S418 or to T425; theoretical mass [M-H-
FzM1alk]+ of 1,388.5 Da). Thus, the spectra indicated that FzM1alk interacted with Fz4 ICL3 by contacting 
at least S418 or T425. Together with the C-terminal tail, this loop forms the binding region for Dsh [85]. 
Binding of FzM1alk or FzM1 to Fz4 ICL3 should cause a change in solvent accessibility in this region of the 
receptor. These changes can be highlighted by measuring the rate of hydrogen-to-deuterium exchange 
(HDX) at this site (Figure 28). In the absence of FzM1, almost the entire receptor exchanged its hydrogen 
atoms with deuterium (with the exception of a helix of the ECD domain, amino acids 154–164). As 
expected, the C-terminal tail and the ECD of the receptor showed the higher rate of exchange compared to 
the TMD. Upon FzM1 binding, solvent accessibility of ICL3, TM5–7 and the C-terminal tail of the receptor 
was reduced, whereas the rest of the protein became more solvent accessible (Figure 28). The buried ICL is 
part of the Dsh binding region [85]. Its burial from solvent upon ligand binding appears compatible with 
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ICL3 being contacted by FzM1 and with a change in the conformation of this loop. A burial of the C-terminal 
tail can be also hypothesized from the HDX data. The latter could be due to a tighter interaction of the tail 
with ICL3 or, more likely, as seen for many other GPCRs41, with the tail interacting with the detergent 
micelles. It was envisaged that the diminished solvent accessibility of ICL3 upon FzM1 binding could have 
been the mechanism behind the folding chaperone effect of the molecule on Fz4-FEVR. 
 
 
 
 
Figure 28 Solvent accesibility of Fz4 region upon binding to FzM1 measured by the rate of HDX. The color scale reflects the level of 
deuterium exchange measured as difference in peptide mass in the presence or in the absence of FzM1. The arrows indicate FzM1 
binding site and the C-terminal tail movement upon FzM1 binding. Numbers indicate TMDhelices (5–7) and the C-terminal tail helix 
(8). ICL3 is indicated. 
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2.6.3 The effect of FzM1 on tumor cells 
FzM1 acts as inhibitor of Wnt–β-catenin signaling by inhibiting transcription of TCF/LEF–regulated genes( T-
cell factor/lymphoid enhancer factor). The prerequisite for TCF/LEF transcription is the nuclear 
accumulation of β-catenin [86]. However, for this to happen, β-catenin must be first dislodged from the 
PM, where it forms a stable complex with E-cadherin. This complex keeps β-catenin in a resting state by 
protecting it both from the APC destruction complex (Axin, APC and GSK3-β) [86], which is responsible for 
its degradation, and from its nuclear transport, which is necessary for TCF/LEF activation. Fz4 controls 
several events leading to β-catenin nuclear accumulation. It recruits Dsh, which is protected by 
proteasomal degradation [87], and, in complex with Fz4, recruits the intracellular kinases [88] responsible 
for β-catenin C-terminal phosphorylation and its dislodgment from the PM [89]. Furthermore, the Dsh–Fz4 
complex destabilizes the APC complex, protecting β-catenin from degradation and ultimately allowing its 
nuclear translocation. By blocking TCF/LEF–dependent gene transcription, FzM1 might have potential as an 
inhibitor of tumor cell growth. Some of the TCF/LEF genes are, indeed, related to tumor cell survival, differ-
entiation and invasiveness [86]. It was thus looked at the effects of FzM1 treatment on growth, 
differentiation and migration of U87MG glioblastoma cells. Fz4 expression in these cells has already been 
shown to relate to invasiveness and the differentiation state of the cells [80]. The treatment with FzM1 
reduced cell viability and affected their morphology, causing them to acquire a more elongated or neuronal 
appearance. 
The Wnt inhibition exerted by FzM1 affects the growth, migration and differentiation of U87MG glio-
blastoma cells, which well represent this frequent and highly malignant type of brain tumor [80] , 
suggesting the future applicability of these Fz4 allosteric modulators as antitumor drugs [90]. FzM1 is to our 
knowledge the first example of a compound able to hit the same protein-protein complex by contacting, in 
contrast, the Dsh binding site on Fz4. Owing to its properties, FzM1 represents what is to our knowledge 
the first template on which Fz4 modulators with improved potency and efficacy can be designed and 
suggests new avenues for developing Wnt-β-catenin pathway modulators [3]. 
 
 
.  
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Chapter 3 – Design and synthesis of  Novel SIRT6 
inhibitors 
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3.1 The Human Sirtuin Family 
The founding member of the sirtuin family, yeast Sir2 (silent information regulator 2), was originally 
isolated in a screen for silencing the mating-type information loci in yeast [91]. Sir 2-4 are also required for 
gene silencing at telomeres [92]. Sir 2 also mediates gene silencing at the rDNA loci, which was shown to be 
independent of other Sir proteins. It was demonstrated that the silencing genetic loci have low histone 
acetylation levels compared to loci that are not silenced. Mutation in Sir2-4 increase histone acetylation 
levels and overexpression of Sir2 but not other Sir proteins led to decreases in histone H4, H2B and H3 
acetylation [93] . 
Sirtuins are evolutionarily conserved in all domains of life. On the basis of sequence similarity, sirtuins from 
different species are classified into at least four classes, classes I−IV [94]. Mammalian SIRT1−3 and all yeast 
sirtuins belong to class I. Mammalian SIRT4 is in class II, SIRT5 is in class III, while SIRT6 and SIRT7 are both 
in class IV. Sirtuins compose the class III family of histone deacetylase enzymes (HDACs) that, unlike the 
class I and II HDACs, require the cofactor NAD+ as a substrate. Sirtuins catalyze the removal of an acetyl 
moiety from the ɛ-amino group of lysine residues within protein targets [95] to yield the deacetylated 
protein product, nicotinamide, and 2’-O-acetyl-ADP-ribose. The enzymatic reaction mechanism for sirtuin-
catalyzed NAD-dependent protein lysine deacetylation is reported in Figure 29. 
 
 
 
Figure 29 Enzymatic function of sirtuins. (A) NAD-dependent protein lysine deacylation activity of different sirtuins. (B) Enzymatic 
reaction mechanism of sirtuins.  
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Figure 30 Structure of a ternary sirtuin-NAD-acetyl peptide complex(PDB ID 2H4F). NAD, acetyl lysine, and the key catalytic His 
residue are shown in stick representation. Bound zinc is shown as a gray sphere. Protein structure picture is generated using PyMol. 
 
The conserved catalytic core of sirtuins consists of a zinc-binding domain and a Rossmann fold domain 
(Figure 30) [96]. The active site lies at the interface of the two domains. It was thought that the acetyl lysine 
peptide binds first, followed by the binding of NAD+. Once the tertiary complex is formed, the carbonyl 
oxygen of the acetyl group attacks the C1-position of the nicotinamide ribose, displacing nicotinamide and 
forming the alkylamidate intermediate (intermediate I, Figure 29B) [97].  A conserved histidine residue then 
serves as a general base to deprotonate the ribose 2-OH, which then attacks intermediate I at the carbonyl 
carbon, generating the 1,2-cyclic intermediate (intermediate II, Figure 29B). Intermediate II is then 
hydrolyzed to produce 2-O-acetyl- ADP-ribose (2-O-Ac-ADPr), which can be non-enzymatically isomerized 
to 3-O-Ac-ADPr. [97]. Sirtuins regulate many aspects of chromatin biology, such as transcription, 
recombination, and genome stability, by modifying histones, transcription factors, and epigenetic enzymes. 
Sirtuins also regulate metabolism by modifying a diverse set of metabolic enzymes, both in the cytosol and 
in the mitochondria. The defatty-acylation activity of SIRT6 on TNF also revealed that sirtuins can regulate 
protein secretion and membrane trafficking. The diverse substrate proteins of sirtuins also dictate that 
sirtuins may be involved in various human diseases, such as cancer, neurodegeneration, diabetes, and 
other metabolic disorders [98]. Humans have seven proteins of the sirtuin family (SIRT1 through 7) that 
share the catalytic domain with Sir2 [99]. 
SIRT1 is by far the most understood mammalian sirtuin and has the greatest homology to yeast SIR2. SIRT1 
is predominantly present in the nucleus, yet it shuttles between the nucleus and the cytoplasm in a context-
dependent manner. SIRT1 deacetylates lysine residues in both histones and non-histone proteins, thereby 
regulating transcription, protein stabilities, and activities. SIRT1 controls various cellular processes, such as 
chromatin organization, metabolism, cell survival, differentiation, and development, as well as stress 
responses. Although the role of SIRT1 is far more expansive , the majority of its functions are intimately 
connected to epigenetic regulation. The role of SIRT1 in epigenetics is achieved via several different 
mechanisms, such as regulating chromatin structure by histone deacetylation, regulating the activity of  
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transcription factors by deacetylation, and regulating the activity of other epigenetic enzymes by 
deacetylation. SIRT2 is connected with multiple cellular processes, including mitosis, cell cycle, cell death, 
metabolism, and aging. SIRT2 was initially reported to be mainly in the cytoplasm, co-localizes with 
microtubules, and deacetylates α-tubulin at Lys40 [100]. It was recently reported to regulate many other 
cytosolic proteins, including LDH-A (lactate dehydrogenase A), PEPCK1 (phosphoenolpyruvate 
carboxykinase 1), ACLY (ATP-citrate lyase), and G6PD (glucose-6-phosphate dehydrogenase). It was later 
found that SIRT2 can translocate to the nucleus and has important epigenetic roles. SIRT3−5 are considered 
to localize mainly in the mitochondria, where they regulate numerous mitochondrial proteins. Therefore, 
the roles of SIRT3−5 are mainly in metabolic regulation. Consistently, SIRT3 regulates substrates involved, 
for example, in ATP production, fatty acid oxidation, and the citric acid cycle but also in mitochondrial 
integrity,  oxidative stress responses, and apoptosis [101]. SIRT4 influences fatty acid metabolism through 
deacetylation of malonyl-CoA decarboxylase [102] , and strong evidence links this isoform to insulin 
secretion [103]. SIRT5 was recently described to more efficiently demalonylate or desuccinylate its 
substrates [104] and it was reported to regulate the urea cycle through its target carbamoyl phosphate 
synthetase 1 [105]. 
Similar to SIRT6, SIRT7 is also a class IV sirtuin that is mainly localized in the nucleus. SIRT7 specifically 
mediates deacetylation of histone H3 at 'Lys-18' (H3K18Ac). In contrast to other histone deacetylases, 
displays selectivity for a single histone mark, H3K18Ac, directly linked to control of gene expression. 
H3K18Ac is mainly present around the transcription start site of genes and has been linked to activation of 
nuclear hormone receptors. SIRT7 thereby acts as a transcription repressor. Moreover, H3K18 
hypoacetylation has been reported as a marker of malignancy in various cancers and seems to maintain the 
transformed phenotype of cancer cells [106]. These data suggest that SIRT7 may play a key role in 
oncogenic transformation by suppresses expression of tumor suppressor genes by locus-specific 
deacetylation of H3K18Ac at promoter regions. Also required to restore the transcription of ribosomal RNA 
(rRNA) at the exit from mitosis: promotes the association of RNA polymerase I with the rDNA promoter 
region and coding region. Stimulates transcription activity of the RNA polymerase I complex. May also 
deacetylate p53/TP53 and promotes cell survival, however such data need additional confirmation. 
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3.2 Biochemical functions of SIRT6 
SIRT6 is a nuclear sirtuin that possess diverse enzymatic activities, including: 1) deacetylation of histone H3 
at lysine 9 (H3K9ac) and 56 (H3K56ac) as well as the acetyltransferase GCN5 and the C-terminal binding 
protein interacting protein (CtlP); 2) mono ADP-ribosylation of itself and poly[adenosine diphosphate 
(ADP)-ribose] polymerase 1 (PARP1); and 3) hydrolysis of long-chain fatty acyl groups (deacetylation) from 
lysine residues in tumor necrosis factor-α(TNF- α) [107] . Figure 31 summarizes all the catalytic functions of 
SIRT6, as mentioned above. 
 
 
 
 
Figure 31 Sirtuin 6 (SIRT6) cellular functions and their impact on organismal biology and disease. 
 
SIRT6 is tightly bound to chromatin [108] and is best characterized as a NAD+-dependent deacetylase of 
histone H3 lysine 9 (H3K9) [109] and H3 lysine 56 (H3K56) [110]. Histone deacetylation is associated with a 
closed chromatin conformation and decreased chromatin accessibility [111]. Thus, the discovery of this 
enzymatic activity instigated a series of studies that demonstrated roles for SIRT6 in regulating telomeric 
chromatin, the dynamic binding of DNA repair factors to chromatin, and gene expression. SIRT6-mediated 
deacetylation of telomeric H3K9 [109]  and  H3K56 residues [112]  during S-phase is required for efficient 
association of the Werner syndrome (WRN) protein with telomeric chromatin [109]. ( Figure 31). 
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The WRN protein is a RecQ-like helicase that plays a major role in genome stability, particularly during DNA 
replication and telomere metabolism [113] . WRN may be required for proper capping of telomeres by the 
telosome/shelterin complex, as well as for replication of lagging telomeric DNA [114] ; therefore, the 
genomic instability observed when SIRT6 is lost could partly be explained by a loss of association between 
WRN and chromatin. Both deacetylation and mono-ADP-ribosylation activities of SIRT6 are required to 
stimulate DSB repair (Double-strand break). More specifically, SIRT6 was found to interact and ADP-
ribosylate PARP1 and stimulate its poly-ADPribosylation activity [115]. The effect of SIRT6 on PARP1 may 
only play a role during DNA damage caused by oxidative stress. Because PARP1 is involved in both BER(base 
excision repair) and DSB repair, the role of SIRT6 as an activator of PARP1 may also explain the BER defects 
observed in SIRT6-deficient cells. Moreover, SIRT6 interacts and deacetylates CtIP [C-terminal binding 
protein (CtBP) interacting protein [116] ( Figure 31) CtIP [117]  and BRCA1 (breast cancer 1) [118] are 
responsible for DSB end resection, which results in single-stranded DNA (ssDNA). This ssDNA is bound by 
replication protein A (RPA), leading to the formation of a ssDNA–RAD51 nucleoprotein filament that 
mediates HR(homologous recombination) [119]. SIRT6 thus promotes end resection and HR, thereby 
improving genome stability . SIRT6 also interacts with the DNA-dependent protein kinase (DNA-PKc) 
holoenzyme macromolecular complex, which comprises repair factors such as DNA-PKc and Ku70/80. This 
complex is known to promote DNA DSB repair in mammalian cells [120] . Finally, recent studies indicate 
that SIRT6 deacetylation of H3K56 and its interaction with the ATP-dependent chromatin remodeler SNF2H 
(SWI/SNF-related matrix-associated actin-dependent regulator of chromatin; also known as SMARCA5) 
accelerate the localization of SNF2H to sites of DSB damage, and both of these events are required for 
efficient DSB repair [121] ( Figure 31). 
Glucose metabolism  
SIRT6 is a central regulator of glucose homeostasis, and SIRT6 function impacts upon both glycolysis and 
gluconeogenesis. SIRT6 was found to suppress directly the expression of multiple glucose-metabolic genes 
[pyruvate dehydrogenase kinase-1 (PDK1), lactate dehydrogenase (LDH), phosphofructokinase-1 (PFK1), 
and GLUT1] by interacting with hypoxia inducible factor-1a (HIF1a) and deacetylating H3K9 at the promoter 
of HIF1a target genes ( Figure 31). HIF1a is known to modulate multiple genes to activate glycolysis and 
repress simultaneously mitochondrial respiration in a coordinated fashion [122]. In addition, SIRT6 controls 
gluconeogenesis through by modulating the activity of peroxisome proliferator-activated receptor-a 
coactivator 1a (PGC-1a), the main regulator of gluconeogenesis that stimulates hepatic gluconeogenesis in 
part by increasing the expression of gluconeogenic enzymes [123] . SIRT6 does this through its interaction 
with GCN5 (general control non-repressed protein 5) ( Figure 31) which enhances its activity. GCN5, in turn, 
is an acetyltransferase that catalyzes acetylation of PGC-1a. Acetylation of PGC-1a coincides with its 
relocalization away from the promoters of its gluconeogenic enzyme target genes, thus SIRT6 suppresses 
hepatic glucose production. 
 
Lipid metabolism 
 
SIRT6 serves as a negative regulator of triglycerides (TG) synthesis [124]. (Figure 31) SIRT6 was also recently 
described as a crucial histone deacetylase in the regulation of expression of the proprotein convertase 
subtilisin/kexin type 9 (PCSK9) gene and low-density lipoprotein (LDL)–cholesterol homeostasis [125] . 
PCSK9 binds to the LDL receptor, the receptor is broken down and can no longer remove LDL cholesterol 
from the blood so to increase LDL-cholesterol levels. FoxO3 works to recruit SIRT6 to the Pcsk9 gene 
promoter to suppress its gene expression through H3K9 and H3K56 deacetylation.   
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SIRT6 was found to repress the sterol-regulatory element binding protein (SREBP), a key regulator of 
cholesterol biosynthesis, by three mechanisms. First, SIRT6 is recruited by FoxO3 to the Srebp gene 
promoter where it represses the transcription levels of Srebp and that of its target genes by deacetylating 
H3K9 and H3K56 [126]  at Srebp promoter regions. Second, SIRT6 inhibits the cleavage of SREBP1/SREBP2 
into their active forms by decreasing the transcription of the SREBP1/SREBP2 pro- tease complex (SCAP, 
S1P, and S2P) [127] . Third, SIRT6 activates AMPK by increasing the AMP/ATP ratio; AMPK phosphorylates 
SREBP1 on Ser372, thus inactivating SREBP1 by suppressing its cleavage and nuclear translocation. In 
addition, SIRT6 was also found to hydrolytically remove long-chain fatty-acyl groups, including myristoyl 
and palmitoyl groups, a process known as lysine deacylation [128] . In fact, long-chain deacylase activity 
was found to be an intrinsic activity of most sirtuins . Acyl lysine modifications such as formylation, 
propionylation, butyrylation, crotonylation, malonylation, succinylation, and myristoylation are post- 
translational modifications that may occur on histones or other cellular proteins for which their removal 
could modify enzyme activity or chromatin regulation.  
 
Inflammation 
SIRT6 can catalyze the hydrolysis of myristoylated lysine 19 and 20 of tumor necrosis factor-α (TNF-α), 
which allows TNF-α secretion from the cell [128] .( Figure 31)TNF-α is a key proinflammatory cytokine that 
is known to play a major part in numerous inflammatory diseases. On the other hand, SIRT6 could also play 
an anti-inflammatory role by inhibiting TNF-α function downstream. TNF-α is known to activate nuclear 
factor kB (NF-kB), a potent proinflammatory cytokine. It was demonstrated that SIRT6 is recruited to 
promoters of a subset of NF-kB target genes through a physical interaction with the NF-kB subunit RELA (v-
rel avian reticuloendotheliosis viral oncogene homolog A) and functions as a corepressor of NF-kB, silencing 
NF-kB target genes through deacetylation of H3K9 at target gene promoters and decreasing NF-kB-
dependent apoptosis and senescence [129] . Mechanistically, SIRT6 interacts with c-JUN and deacetylates 
H3K9 at the promoter of proinflammatory genes including those encoding monocyte chemotactic protein-1 
(MCP-1), interleukin 6 (IL-6), and TNF-α. SIRT6 acts as a negative regulator of cardiac hypertrophy. At the 
cellular level, SIRT6 blocks IGF signaling by interacting with c-JUN and deacetylating H3K9 at IGF 
downstream targets. Inhibition of c-JUN or IGF signaling blocks hypertrophy of SIRT6-deficient hearts [130] . 
Cancer  
 
Proliferating tumor cells have unique metabolic requirements, characterized by enhanced cell-autonomous 
nutrient uptake and reorganization of metabolic pathways supporting the biosynthesis of macromolecules 
needed for cell growth and division [131]. Enhanced glycolysis under aerobic conditions is the best-known 
example of metabolic reprogramming observed in cancer cells, as described dec- ades ago by Otto Warburg 
(the Warburg Effect) [132]. SIRT6 is a critical regulator of glucose homeostasis by controlling the HIF1α-
dependent transcriptional activation of glycolytic gene [133]. (Figure 31) Consequently, the expression of 
glycolytic genes is elevated in SIRT6 depleted cells, which leads to lower levels of oxygen consumption 
along with high production of lactate, a phenotype that is reminiscent of the Warburg effect. In addition, 
SIRT6 also plays a critical role in maintaining genomic stability, another hallmark in transformed cells, since 
accumulation of genomic abnormalities are associated with the tumorigenic capacity of cancer cell [134]. 
Indeed, SIRT6 was recently described to function as a tumor suppressor by regulating the metabolic defects 
associate with cancer [135]. These studies showed that SIRT6 suppresses aerobic glycolysis, in addition to 
repressing MYC-dependent ribosome biosynthesis [135]. MYC-mediated regulation of ribosome biogenesis 
is associated with tumorigenesis . Additionally, the expression of SIRT6 was shown to decrease in human 
colorectal and pancreatic cancers [135] . An additional enzymatic activity of SIRT6 is the hydrolysis of long-
chain fatty acyl modifications (myristoyl groups) from lysine residues in TNF-α [107]. SIRT6-dependent 
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hydrolysis of myristoyl groups triggers the secretion of TNF-𝛼. TNF-α is a pro-inflammatory cytokine having 
a pleiotropic function in cell physiology, whose release can signal either cell survival and proliferation, or 
cell death [136]. Binding of TNF-α to its receptor TNF-R1 was shown to promote apoptosis through the 
caspase-8-activating complex [137]. This pro-apoptotic effect mediated by TNF-α was shown to be 
antagonized upon NF-kB-dependent suppression of reactive oxygen species [138] . More specifically, the 
pro-apoptotic effect induced by TNF-α is dependent on the balance between NF-kB-dependent cell survival 
and the JNK signaling promoting cell death pathway [139] . Since SIRT6 was also shown to attenuate NF-kB 
signaling [112], it is plausible that TNF-α-dependent tumor cell death might be regulated upon SIRT6-
mediated removal of myristoyl groups to trigger the secretion of TNF-α, a hypothesis that remains to be 
tested. This could add to the molecular mechanisms by which SIRT6 functions as a tumor suppressor. The 
expression of SIRT6 has been recently shown to be downregulated by the microRNA-34a (miR-34a) in 
human keratinocytes (HKCs)  In contrast to normal keratinocytes, miR-34a is suppressed in skin cancers 
such as squamous cell carcinomas (SCCs) leading to an increment in SIRT6 expression. Thus, in contrast to 
other cancers such as hepatocellular carcinomas and colon adenocarcinomas, the expression of SIRT6 
seems to be upregulated in SCCs due to a miR-34a downregulation.  
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3.3 Structure of Sirtuins 
The sirtuin proteins  contain an approximately 275 amino acid conserved catalytic core region. Additionally, 
the sirtuin proteins have N- and C-terminal flanking regions that are variable in length and sequence [140]. 
The catalytic core region adopts an elongated shape containing a large and structurally homologous 
Rossmann-fold domain, characteristic of NAD+/NADH binding proteins; a more structurally diverse, smaller, 
zinc-binding domain; and several loops connecting the two domains (Figure 32).  
 
 
 
Figure 32 Three-dimensional structure of sirtuin. The enzyme is shown in cartoon representation without bound ligands. The 
Rossmann-fold domain is indicated in magenta, the small domain in blue, the loops in green, the cofactor binding loop in black, the 
Zn ion in red, the N-terminal region in orange, and the C-terminal region in yellow. Disordered regions are indicated with dashed 
lines. 
These loops form an pronounced, extended cleft between the large and small domains where the NAD+ and 
acetyl-lysine containing peptide substrates enter from opposite sides and bind to the enzyme ( Figure 33). 
The amino acids involved in catalysis and the reactive groups of both bound substrate molecules are buried 
within a protein tunnel in the cleft between the two domains ( Figure 33), the region of the enzyme that 
contains the highest sequence conservation within the sirtuin enzymes. 
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Figure 33 Sirtuin active site binding cleft. . The Hst2 protein is shown in tan surface representation. The catalytic residues H135 and 
N116 are shown in red stick representation in the close-up view. The peptide substrate backbone is shown in green cartoon 
representation, the acetyl-lysine side chain is shown in green cpk stick representation, and the NAD+ substrate molecule is shown 
in cyan cpk stick representation. 
 
The Rossmann-fold domain contains many of the hallmarks of a typical NAD+-binding site such as a 
conserved Gly-X-Gly sequence important for phosphate binding, a pocket to accommodate an NAD+   
molecule, and charged residues responsible for ribose group binding [141]. The small, structural Zn2+  
binding domain results from two insertions in the Rossmann-fold domain and is the most diverse region 
between sirtuins for which structures have been determined in terms of primary sequence, three-
dimensional structure, and position relative to the large domain ( Figure 32). A Zn2+  molecule is bound by 
the sulphydryl groups of two pairs of strictly conserved cysteine residues in the β sheet module in a 
tetrahedral conformation [142]. The small domain contains the conserved sequence motif Cys-X2-4-Cys-X15-40-
Cys-X2-4-Cys, a characteristic Zn-binding motif. The role of the zinc ion seems to be structural, as it is 
postulated to be required for holding together the β strands in the small domain. One of the most 
interesting characteristics of the small domain is a conserved salt bridge (between R/K178 and E186, Hst2 
numbering, unless otherwise indicated) [142], which seems to be important for positioning the small 
domain with respect to the large domain. The position of the small domain relative to the Rossmann-fold 
domain is also dependent on the conformation of bound NAD+  or the presence of acetyl-lysine in the 
enzyme active site . The diversity in the small domain may have a potential role in regulating protein–
protein interactions, which may be important for substrate specificity, enzyme localization, and potentially 
for modulation of enzyme activity. Indeed, structural differences between sirtuin proteins within the small 
domain might be exploited as binding sites for sirtuin-selective small molecule inhibitors. 
 
 
 
Figure 34 . Conformational changes of the cofactor binding loop upon substrate and product binding. The Hst2 protein is shown in 
tan cartoon representation, the C-terminus is shown in yellow, and the cofactor binding loop is shown in magenta. The peptide 
substrate is shown in green cartoon representation, while the acetyl-lysine residue is shown in green cpk stick representation. (A) 
The apo Hst2 enzyme, the cofactor binding loop is disordered (dashed lines). (B) Hst2 with bound peptide substrate and carba-
NAD+, the cofactor binding loop is in an open conformation. (C) Hst2 with bound peptide substrate and 2"-O-acetyl-ADP-ribose, the 
cofactor binding loop is in a closed conformation. 
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The four loops that connect the small and large domains form the cleft that acts as the enzyme active site. 
Both the NAD+ and acetyl lysine substrates bind in this cleft ( Figure 33).This region has the most sequence 
homology among the protein family, and mutation of several residues in this region disrupts histone 
deacetylase activity, underscoring the importance of this region in sirtuin catalysis. Generally the largest of 
these four loops (the β1-α2 loop in Hst2) is one of the most conformationally dynamic regions of the sirtuin 
enzymes (Figure 34). Since this loop forms part of the cofactor NAD+ binding site and its conformation is 
largely dependent on the conformation and identity of the bound NAD+   molecule or intermediate, it was 
called as the cofactor binding loop [142] . The cofactor binding loop appears to be disordered or highly 
flexible when NAD+ is not bound (Figure 34A), and becomes ordered upon NAD+ binding into a relatively 
open conformation with residues of the loop (D43-Y52) about 7 Å away from the NAD+ binding site (Figure 
34B) [143] . Residues (A33, G34, T37, F44, and D43) of the cofactor binding loop form part of the so-called C 
pocket, the region of the enzyme where the nicotinamide moiety of NAD+  binds, and they mediate almost 
half of the enzyme contacts to NAD+ [143], which implies that this cofactor binding loop plays an important 
role in NAD+  binding. When the sirtuin reaction product 2’-O-acetyl-ADP-ribose is bound to the enzyme 
active site, the cofactor binding loop adopts a more closed conformation bringing residues (D43-Y52) of the 
loop ~5.5 Å closer to the nicotinamide-binding pocket, partially occluding the site (Figure 34C) [144] 
,suggesting that the loop may also play a role in nicotinamide release. The switch between the open and 
closed conformations of the cofactor binding loop seems to be dependent upon the presence of the bound 
alkylamidate intermediate directly after nucleophilic attack of acetyl-lysine on an NAD+ -derived 
intermediate and not upon nicotinamide cleavage or complete reaction product formation, as the closed 
conformation of the loop is also seen when an analog of the O-alkylamidate intermediate, S-alkylamidate, is 
bound to the enzyme [145] .When the reaction product nicotinamide is bound in the C pocket either in 
complex with acetyl-lysine, NAD+ , or ADP-ribose, the cofactor binding loop adopts slightly different 
conformations which facilitate slightly different interactions between nicotinamide and the C pocket 
residues, although it is not clear whether the binding of different ligands of the ternary complex or the 
different nicotinamide conformations cause the differences in conformation of the cofactor binding loop 
[146] . 
 
 
Figure 35 Productive NAD+ binding interactions in several sirtuin proteins. 
 
The NAD+  binding site, consisting in the large domain and in the loop region which is mainly represented by 
the cofactor binding loop, can be divided into three regions: site A, the adenine-ribose binding site; site B, 
the nicotinamide ribose binding site; and site C, the nicotinamide moiety binding site [142] (Figure 35).The 
conformation of the nicotinamide ribose is variable depending on the NAD+ analog bound (ADP-ribose, non 
productive NAD+ , productive NAD+ , or carba-NAD+ ), which other substrates are also bound to the enzyme, 
or even the particular sirtuin homologue.  In fact, crystallographic structures available in the Protein Data 
Bank show that the nicotinamide moiety of NAD+ is often bound outside of the C pocket in a conformation 
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that is not compatible with acetyl-lysine binding and deacetylation reaction, the so-called non-productive 
conformation. Vice versa, a productive conformation of NAD+ requires the presence of an acetyl-lysine 
containing peptide. Moreover, the hydrophobic tunnel which acts as the acetyl-lysine binding site and not 
simply the peptide binding site must be occupied to facilitate the productive binding of NAD+ [146]. In this 
productive conformation, the bound NAD+   is compatible with both acetyl-lysine binding and enzyme 
catalysis.   
 
 
Figure 36 Acetyl-lysine peptide binding to the sirtuin active site.(A) A peptide containing an acetyl-lysine residue (green) is shown 
bound to the Sir2-Af2 sirtuin enzyme (tan, cartoon representation) active site forming the β staple with flanking β strands of the 
enzyme (cyan). (B) The acetyl-lysine containing peptide (green) makes main chain β strand hydrogen bonds (red dashes) with main 
chain atoms of the enzyme (cyan). (C) The acetyl-lysine residue (green) binds in a hydrophobic tunnel of the enzyme (tan, surface 
representation), making several van der Waals interactions with enzyme residues (orange) and one hydrogen bond (red dashes) 
with an enzyme residue. 
 
The peptide itself binds to the cleft between the small and large domains with the acetyl-lysine side chain 
inserting into a hydrophobic tunnel located within the cleft. The peptide backbone containing the acetyl-
lysine side chain forms β sheet-like interactions with two flanking strands in the enzyme (Figure 36A) [147]. 
This staggered, antiparallel three-stranded β sheet is referred to as the β staple. Main chain atoms of the 
peptide make several hydrogen bonds with main chain atoms of catalytic residues from the flanking strands 
of the β staple (Figure 36B). A comparison of sirtuin enzymes with and without bound acetyl-lysine 
containing peptide suggests that peptide binding induces a significant shift in the position of the small 
domain relative to the large domain, bringing the two domains together to form the β staple motif and 
resulting in the correct positioning of conserved residues for formation of the acetyl-lysine binding tunnel 
[148]. It has been hypothesized that NAD+ and peptide binding may be cooperative, as the region 
surrounding the peptide binding site adopts the more closed conformation seen in the peptide bound 
structure when NAD+  is bound but not in the absence of NAD+ [147]. The aliphatic region of the acetyl-lysine 
side chain makes several van der Waals interactions with conserved hydrophobic residues (H135, V228, 
F184, and L188). The acetyl group appears to be positioned by a single hydrogen bond between the Nɛ 
atom of the lysine side chain and the main chain of a valine residue (182) and van der Waals interactions 
between the acetyl methyl group and other highly conserved residues (I117 and H135), which position the 
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unliganded carbonyl oxygen toward the NAD+  binding B site (Figure 36C) [147] . When the peptide is bound 
in a ternary complex with the intermediate-like molecule ADP ribose, or the reaction product 2’-O-acetyl-
ADP-ribose, the acetyl-lysine carbonyl oxygen hydrogen bonds to the 1’-OH of the nicotinamide ribose ring 
[143] . The β staple binding motif and the residues involved in peptide binding seem to be conserved 
features of acetyl-lysine peptide binding. 
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3.3 Structure of SIRT6 
 
SIRT6 displays low deacetylase activity (~ 1000-fold lower) compared with other sirtuins. Human SIRT6 has 
355 amino acids and consists of a putative catalytic sirtuin core with N- and C-terminal flanking extensions.  
 
 
 
 
 
 
Figure 37 Structure of human SIRT6 in complex with ADP-ribose. A, overall structural features of SIRT6 monomer. B, 
superimposition of the six molecules in the asymmetric unit. Red, chain A; green, chain B; dark blue, chain C; orange, chain D; cyan, 
chain E; yellow, chain F. C, schematic illustration of the hydrogen bonding network surrounding ADPr; hydrogen bonds are 
indicated as dashed lines, and water molecules are shown as spheres. 
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As mentioned for other solved sirtuin structures, SIRT6 contains two globular domains composed of eight 
α-helices and nine β-strands: a large Rossmann fold for NAD+ binding (residues 25–128 and 191–266) and a 
smaller domain, which contains a zinc-binding motif (residues 129–190) (Figure 37A). The large Rossmann 
fold domain is formed by a six-stranded (β1,β2, β3, β7, β8, and β9) parallel β-sheet sandwiched between 
two helices (α6 and α7) on one side and four helices (α1,α4,α5, and α8) on the other side. The small 
domain is formed by two extending loops ( connecting β3 and α6) from the large domain and consists of a 
three stranded antiparallel β-sheet (β4, β5, and β6). Interestingly, although most sirtuins contain a Cys-XX- 
Cys-X15–20-Cys-X-X-Cys sequence motif for Zn2+ - binding, SIRT6 contains a 10-residue insertion between 
the second set of cysteines, resulting in an extended flexible long loop . The NAD+- binding pocket of 
sirtuins has been divided into three regions: sites A, B, and C [142]. Similar to all other solved sirtuin 
structures, the adenosine moiety of ADPr is bound in the A site of SIRT6, and the nicotinamide ribose 
moiety is bound in the B site. Many of the residues involved in ADPr binding are conserved between SIRT6 
and the other sirtuins . The ADPr interactions in the SIRT6 active site are shown in Figure 37C . For all six 
molecules in the asymmetric unit, the ribose moiety of ADPr assumes the C2’ exo conformation in its α-
form. Although SIRT6 shares the overall domain architecture with SIRT2, SIRT3 , and SIRT5 , there are 
several differences on the surface of the protein. In all previously solved sirtuin structures, a conserved 
“cofactor binding loop” [142] is involved in NAD+ binding; this loop adopts several different conformations 
depending on the ligand(s) bound in the active site . SIRT6 lacks the cofactor-binding loop, which is replaced 
by a single helix (α3) containing several NAD+-binding residues, which appears to be ordered in the 
SIRT6.ADPr and SIRT6.NAADPr structures. This is an indication that the SIRT6 substrate-binding pocket may 
be less flexible and does not significantly vary its conformation when different ligands are bound. In 
addition, helix α1 in SIRT6 is much longer, and the N-terminal unstructured coil folds back toward and may 
structurally stabilize the NAD+ binding site ,although there is no direct interaction between the random coil 
and ADPr. In contrast to class I, II, and III human sirtuins, class IV sirtuins contain a deletion in the sequence 
immediately following the α3 helix .The result is that SIRT6 does not have a helix bundle in its small domain. 
The helix bundle is replaced by a short loop, which interacts with the loop between α2 and α3 and contacts 
a small region on the zinc binding module. The lack of a helix bundle to form extensive interactions with the 
β-sheets in the zinc-binding module provides one explanation for why SIRT6 has a splayed small domain. 
This unique structural feature is likely to be adopted by SIRT7, another class IV sirtuin that also contains a 
deletion in this region but that has not yet been structurally and functionally characterized. This unique 
feature may be responsible for the observed lower activity (1000 times) of SIRT6. To date, there are no 
reports of detectable deacetylase activity for SIRT7. In addition to the missing helical bundle, another 
reason for the splayed small domain in SIRT6 is the loss of a conserved salt bridge, which has been reported 
to contribute to the positioning of the zinc-binding motif with respect to the Rossmann fold domain and 
substrate-binding site [142] . Based on precedent from other sirtuins, a salt bridge should be formed 
between Arg180 and Asp188 in SIRT6. However, this interaction is not observed. The side chain of Arg180 is 
directed toward the surface of the protein rather than toward the Asp188 residue. Instead,  Arg124 on the 
loop connecting α5 and β3 and Gln145 on β5 form a hydrogen bond to tether the zinc-binding motif and the 
large domain together .The loss of the previously described salt bridge removes the constraint on the two 
loops, which would otherwise result in a more closed conformation. The new Arg124–Gln145 hydrogen bond 
in SIRT6 pulls the two domains together on the opposite side, and therefore, the small domain is not 
directly above the Rossmann fold but rather in an open conformation tilted in a 45° angle. It is generally 
observed that peptide substrates interact with sirtuins via nonspecific backbone interactions [149] . There is 
a conserved FGEXL ( Phe, Gly, Glu, Lys, Leu) loop that forms hydrogen bonds with the substrate peptide 
[147]. However, in the case of SIRT6, the sequence is WEDSL ( Trp, Glu, Asp, Ser, Leu) .The amide nitrogen of 
Trp186 appears to be flipped, whereas its analog in other sirtuins is involved in a hydrogen bond with a 
carbonyl group from the peptide substrate backbone.  
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 Sirtuins catalyze deacetylation through a sequential mechanism in which the substrate peptide binds first 
to form an ordered NAD+ -binding pocket for the subsequent co-substrate binding. SIRT1, SIRT2, and SIRT3 
were all found to require a substrate/ligand binding prior to NAD+ binding [149]. The unique SIRT6 
structural features suggest that SIRT6 utilizes a different binding mechanism, which does not require 
peptide substrate binding prior to NAD+ binding. These features include an ordered helix regardless of 
substrate binding, a large open channel in the substrate and NAD+ binding site due to the missing helix 
bundle, and a NAD+  site potentially reinforced by the N-terminal loop. In a paper 2011 [150] it was 
monitored by isothermal titration calorimetry ITC , the binding of NAD+ in the absence of an acetyl lysine 
substrate. , SIRT1 to -3, and SIRT5 did not bind NAD+ in the absence of the acetyl lysine substrate , while 
SIRT6 can bind NAD+ efficiently in the absence of an acetylated substrate. Moreover  there was no binding 
when NADH was titrated into SIRT6 suggesting that SIRT6 cannot accommodate the puckered conformation 
of the nicotinamide ring of NADH. The binding pocket of SIRT6 distinguishes structural differences between 
NAD+  and ADPr. Interestingly, unlike NAD+  and ADPr, 2’-NAADPr bound to SIRT6 with a negative –T𝛥S , 
suggesting that there is more disorder when 2’-NAADPr binds. This result is consistent with the crystal 
structure, which showed a high degree of variability and poor electron density for the 2’-N-acetyl-ribose 
moiety of 2’-NAADPr. 
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3.4 Results and Discussion 
 
To the author’s knowledge, no study has ever been published in the literature concerning SIRT6 inhibition 
by small molecules. Hence, structure-activity relationship (SAR) analyses have never been carried out really. 
This thesis constitutes a starting point for the development and SAR analysis of small molecules inhibitors 
of SIRT6. In the absence of any literature guidance, this work focuses on the potent pan SIRT1/SIRT2/SIRT3 
inhibitor (compound 1) [151] trying to assees its potential capability to bind to SIRT6 (Figure 38). The 
authors in [151] have demonstrated that the compound 1 is a potent pan SIRT1/2/3 inhibitor and exhibits a 
low nanomolar value of IC50. However, compound 1 had never been tested on SIRT6 before this work.     
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38 Chemical structure of the compound 1. 
 
 
 
As the first step, the structure-activity study has been done, yielding compounds 2 and 3 which are 
obtained by introducing modifications in the side chain of compound 1. Specifically, the thiophene in the 
side chain of compound 1 is replaced by the polar sulfonamide group in compound 2, whereas the 
ethylamide substituent on the thiophene of compound 1 is substituted with carboxylic acid in compound 3. 
In addition, the intermediate compounds 4 and 5, are analysed. In particular, compound 4 is the 
intermediate Boc-protected on the amine, and compound 5 is the amine-free derivate.  Compounds 6 and 
7, instead, are truncated analogues in which the linker length is changed, more specifically the ethyl linker 
is replaced by the methyl linker (Figure 39).  
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Figure 39 Compounds synthesized as SIRT6 inhibitors 
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3.5 Synthesis 
Synthesis of compounds 1-5 are showed in Scheme 20 and compounds 6-7 in Scheme 21. Compounds were 
prepared by treatment of  dimethyl-3-aminothiophene-2,5-dicarboxylate a with formamidine acetate salt 
in 2-methoxyethanol dry at 130°C for overnight to obtain the methyl-3H thieno[3,2-d]pirimidin-4-one-6-
carboxylate b.  Then the ester of b was hydrolyzed through the solution of lithium hydroxide monohydrate 
in 2-propanol at 75°C for 1h. Treating b with oxalyl chloride in DMF dry and quenching the intermediate 
acid chloride with ammonia hydroxide solution in EtOAc at rt for 2h afforded the versatile 4-
chlorothieno[3,2-d]pyrimidine-6-carboxamide intermediate d. The chloride on d was subsequently 
displaced with 4-(2-Boc-aminoethyl)piperidine or 4-(Boc-aminomethyl)piperidine in CH3CN in presence of 
DIEA at reflux for 2h to afford Boc-protected precursors 4 and 6 (Scheme 21). The Boc group were removed 
by treatment with trifluoroacetic acid in CH2Cl2 , and the resulting amines 5 and 7 were reacted under 
amide coupling conditions (HATU,DIEA,DMF) with 5-(ethylcarbamoyl)thiophene-2-carboxylic acid e and  5-
(tert-butoxycarbonyl)thiophene-2-carboxylic acid f to afford 1 and 3 after chromatography column. 
Treatment of compound 5 with methansulfonyl chloride in presence of TEA and pyridine at rt overnight 
gave the compound 2. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 20 Synthesis of Compounds 1-5.  Reagents and reaction conditions: I) formamidine acetate salt, 2-methoxyethanol dry , 
130°C,overnight. II) LiOH.H2O, 2-propanol,H2O,75°C ,1h.III) SO2Cl, DMF, 80°C , 2h, crude product. IV) NH4OH 28-30% basis, in EtOAc, 
rt,2h. V) 4-(2-Boc-aminoethyl)piperidine, DIEA, CH3CN,reflux,2h. VI) TFA,CH2Cl2,rt,overnight. VII) 5-(ethylcarbamoyl)thiophene-2-
carboxylic acid e ,HATU, DIEA, DMF,rt,overnight. VIII) TEA, Pyridine, CH3SO2Cl,0°C-rt,overnight. IX) 5-(tert-
butoxycarbonyl)thiophene-2-carboxylic acid f, HATU, DIEA,DMF, rt,overnight.X) TFA, CH2Cl2,rt,overnight. 
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Scheme 21 Synthesis of compounds 6-7. Reagents and reaction conditions: XI) 4-(Boc-aminomethyl)piperidine, DIEA, 
CH3CN,reflux,2h. XII) TFA,CH2Cl2,rt,overnight. 
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3.6 SIRT6 Inhibitor in vitro test: HPLC Assay 
 
The compounds affinity with SIRT6 is measured using a SIRT6 Inhibitor in vitro test, specifically a HPLC 
assay. The HPLC-based Deacetylase Assay relies on the separation of substrates and products of the 
deacetylase reaction by a reversed-phase HPLC. Quenched reaction mixtures are injected onto a C18 
column and, using a gradient of increased levels of organic solvent, substrates, products, and enzyme can 
be resolved. 25 μM of inhibitors and 3μM of SIRT6 are mixed and pre-incubated in a 37°C water bath for 15 
min, then 25μM of Myr-H3K9 is added and the reaction can finally take place. After 1 hour, the reaction is 
quenched by the addition of a quantity of TFA to the final concentration of 1%. Quenched samples are kept 
on ice or stored at the temperature of -20°C  if they are not immediately injected onto the HPLC column. 
Next, samples are injected onto a reversed-phase HPLC column (e.g., a Vydac C18 column) to resolve 
substrates and products. A 100-μl loop is typically used for the injections and the flow rate is set to 1 
ml/min. After injection, the system is run isocratically with solvent A (0.05% TFA/H2O) for 1 minute followed 
by increasing levels of solvent B (0.02% TFA in acetonitrile). The gradient used for each assay may vary 
depending on the type of peptide substrate used. Following each run, the column is washed with 100% B 
for 3–5 column volumes followed by reequilibration with solvent A for 3–5 column volumes. Elution of 
substrates and products is monitored by measuring the absorbance at 214 nm (to monitor all substrates 
and products) or at 260 nm (to specifically monitor nicotinamide, NAD+ , and O-AADPr). The areas of the 
peaks are integrated for quantification. To calculate the percentage of deacetylation, the area of the 
deacetylated peptide peak is compared to the combined areas of the acetylated and deacetylated peptide 
peaks. Because a known amount of acetylated peptide is used, the percentage of the deacetylation is then 
used to determine the amount of deacetylated product formed over the particular time of the assay, to 
obtain an initial rate. The results of this first test are shown in the graphs depicted in Table 4, which report 
the percentage of NAD+, consumed by the SIRT6 defatty-acylation activity, against the synthesized 
compounds. Compound 1 is the only product showing a low percentage of consumed NAD+ and 
consequently able to bind and reduce the SIRT6 activity. On the other hand, nearly all the other compounds 
appear to increase SIRT6 activity, possibly due to the absence of a side chain (in the case of compounds 4-5-
6-7) as can be noticed in Figure 39. Focusing on compound 2, it has the polar sulfonamide group which is 
substantially different from the thiophene of compound 1. Finally, concerning compound 3, it has the 
carboxyl acid as substituent of the thiophene, and as a consequence it generates different interactions. 
Beyond the synthesized compounds, the graphs plot a positive control (Ctrl), chosen ad-hoc to yield 100% 
NAD+ consume, and the Thiomyristoyl peptide (TM3) which reduces SIRT6 activity by a 50% factor [152]. 
The main reason why TM3 has such a positive effect is because it acts using a fundamentally different 
mechanism, in that it forms a stalled covalent intermediate with NAD+ in the sirtuin active sites and inhibits 
SIRT6 as a direct effect [152]. 
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Table 4 Test in vitro HPLC 
 
In the light of the above results, the docking experiments have been performed in order to reproduce the 
binding mode of compound 1 to SIRT6, demonstrating, for the first time, the activity of compound 1 on 
SIRT6. As a result, it has been observed that compound 1 is able to take on many different isoenergetic 
poses in the binding sites of SIRT6, which are the nicotinamide C and substrate binding pockets.  In order to 
identify one “favourite” (in terms of thermodynamics) pose (Figure 40), molecular dynamic studies have 
been carried out. As shown in Figure 40, compound 1 sits in the substrate binding pocket where it is 
involved in the formation of hydrogen bonds with the aminoacid residues left in the pocket. 
 
 
 
Figure 40 Possible conformation of the compound 1 in SIRT6 
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3.7 Future Perspectives 
Based on the lack of small molecule inhibitors of SIRT6 in the literature, the main contribution of this work  
has been to synthesize and test the pan inhibitor 1 on SIRT6 and to identify, for the first time, its ability to 
bind it and reduce its deacetylation activity . The identification of the compound 1 as one of the first small 
molecule SIRT6 inhibitors, may represent the starting point for future structure-activity relationship and 
lead optimization studies. As future developments, more docking experiments may be performed in order 
to explore possible changes in the chemical structure of compound 1. As an example, changing the 
ethylamide substituent on the thiophene present in compound 1 to chains of different lengths, or to 
different groups with similar physicochemical properties could be a meaningful way to proceed. In addition, 
the spacer ethylpiperidine and the core thieno[3,2-d]pyrimidine-6-carboxamide could replaced with other 
groups . In any case molecular studies could be an important tool to identify novel SIRT6 small molecule 
inhibitors which could find significant applications in cancer treatment by targeting several aspects of 
cancer pathophysiology and contributing to enhance the efficacy of currently available therapeutics.  
 
 
Figure 41 Changes in the chemical structure of compound 1  
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Chapter 4 – Experiments 
4.1 Part I : Synthesis of Aryl-α-ketoamide Amides 
General information 
Commercially available reagents and solvents were used without further purification. Dichloromethane was 
dried by distillation from P2O5 and stored over activated molecular sieves (4 Å). When necessary, the 
reactions were performed in oven-dried glassware under a positive pressure of dry nitrogen.Melting points 
were determined in open glass capillaries and are uncorrected. All the compounds were characterized by IR 
, 1H and 13C APT NMR were recorded on a 300 MHz. Mass spectrometry was equipped with an ESI source 
and an ion trap detector. HRMS were recorded on ORBITRAP mass spectrometer equipped with an ESI 
source. Chemical shifts (δ) are reported in part per million (ppm) relative to the residual solvent peak. 
Column chromatography was performed on silica gel (Merck Kieselgel 70–230 mesh ASTM) using the 
reported eluents. Thin layer chromatography (TLC) was carried out on 5 x 20 cm plates with a layer 
thickness of 0.25 mm (Silica gel 60 F254). When necessary, they were developed with KMnO4. Elemental 
analysis (C, H, N) of all the new compounds were within ± 0.4% of the calculated values.  Chloroximes 19 
and 22-29 are not new, and they were prepared following literature procedure [25]. Isocyanoacetamides 20 
and 33-36 were prepared following Domling’s procedure [26], while isocyanoacetamides 30-32 were 
prepared following Zhu’s procedure [27]. 
 
Synthesis of 4-Benzyl-1-(isocyanoacetyl)piperidine (37) Methyl isocyanate (1 equiv) was reacted with 4-
benzylpiperidine (1 equiv) overnight under neat conditions. The solution was evaporated and the crude was 
purified by column chromatography Hex/EtOAc 7:3 to give 37 as amorphous solid ( yield 75%): 1H NMR (400 
MHz, CDCl3) δ 7.26-7.09 (m,5H), 4.45 (br d, 1H), 4.24 (br d,2H), 3.45 (br d, 1H), 2.93 (br t, 1H), 2.51-2.49 (m, 
3H), 1.73-1.64 (m, 3H), 1.17-1.10 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 160.7, 160.4, 139.7, 129.1, 128.3, 
126.1, 45.6, 44.6, 42.8, 42.6, 37.7, 32.0, 31.3; HRMS (ESI) m/z (M+H)+ calcd for C15H18N2O 242.1419, 
found 242.1422 
 
 
General Preparation of 1,3-Oxazol-2-oximes (21, 38−54). The chlorooxime (1 equiv) was dissolved in dry 
dichloromethane, and α-isocyanoacetamide (1 equiv) was added dropwise or portionwise at room 
temperature. Finally, TEA (1 equiv) was added dropwise (the reaction is slightly exothermic and on a large 
scale the addition shouldn be done at 0 °C), and the reaction was stirred at room temperature under a 
nitrogen atmosphere until all the chlorooxime was consumed (typically 2−3 h as judged by TLC). The 
reaction mixture was concentrated under reduced pressure, and the crude material was purified by column 
chromatography. 
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(Z)-(5-Morpholinooxazol-2-yl)phenylmethanone Oxime (21). Starting material: chlorooxime 150 mg (0.96 
mmol), isocyanoacetamide 148 mg (0.96 mmol). The crude material was purified by column 
chromatography (PE/EtOAc 7:3) to give 195 mg of product as yellow solid (yield 74%):  1H NMR (300 MHz, 
CDCl3) δH 7.66−7.62 (m, 2H), 7.44−7.40 (m, 3H), 6.26 (br s, 1H), 3.78 (br t, 4H), 3.16 (br t,4H); 13C NMR (75 
MHz, CDCl3) δC 156.2, 146.9, 141.9, 133.0,129.5, 128.4 (2C), 101.5, 65.8, 47.3; HRMS (ESI) m/z (M + Na)+ 
calcd for C14H15N3NaO3 296.1011, found 296.1012. 
 
 
 
(Z)-(4-Chlorophenyl)(5-morpholinooxazol-2-yl)methanone Oxime (38). Starting material: chlorooxime 150 
mg (0.79 mmol), isocyanoacetamide 122 mg (0.79 mmol). The crude material was purified by column 
chromatography (PE/EtOAc 6:4) to give 187 mg of product as a yellow solid (yield 78%): 1H NMR (300 MHz, 
CDCl3) δH 7.60−7.56 (m, 2 H, AA′XX′), 7.44−7.36 (m, 2 H, AA′XX′), 6.26 (br s, 1H), 3.80−3.77 (m, 4H), 
3.18−3.15 (m, 4H); 13C NMR (75 MHz, CDCl3) δC 156.2, 146.5, 141.0, 135.6, 131.5, 129.7, 128.7, 101.6, 65.7, 
47.2; HRMS (ESI) m/z (M + H)+ calcd for C14H14ClN3O3 307.0724, found 307.0727. 
 
 
 
(Z)-(4-Methyl-5-(pyrrolidin-1-yl)oxazol-2yl)phenylmethanone Oxime (39). Starting material: chlorooxime 150 
mg (0.96 mmol), isocyanoacetamide 147 mg (0.96 mmol). The crude material was purified by column 
chromatography (PE/EtOAc 7:3) to give 180 mg of product as yellow solid (yield 69%): 1H NMR (300 MHz, 
CDCl3) δH 7.69−7.66 (m, 2H), 7.40−7.38 (m, 3H), 3.42−3.38 (m, 4H), 2.27 (s, 3H), 1.95−1.91 (m, 4H); 13C 
NMR (75 MHz, CDCl3) δC 150.2, 143.9, 141.4, 133.3, 129.2, 128.4, 128.3, 108.4, 48.8, 25.4, 11.7; HRMS (ESI) 
m/z (M + H)+ calcd for C15H17N3O2 271.1321, found 271.1321. 
 
 
 
(Z)-(4-Chlorophenyl)(4-methyl-5-(pyrrolidin-1-yl)oxazol-2-yl)- methanone Oxime (40). Starting material: 
chlorooxime 150 mg (0.79 mmol), isocyanoacetamide 120 mg (0.79 mmol). The crude material was purified 
by column chromatography (PE/EtOAc 6:4) to give 190 mg of product as orange solid (yield 79%): 1H NMR 
(300 MHz,bCDCl3) δH 7.65−7.62 (m, 2H, AA′XX′), 7.40−7.37 (m, 2H, AA′XX′), 3.45−3.43 (m, 4H), 2.29 
- 82 - 
 
(s, 3H), 1.98−1.92 (m, 4H); 13C NMR (75 MHz, CDCl3) δC 150.3, 143.7, 140.5, 135.3, 131.9, 129.8, 128.6, 
108.5, 48.9, 25.5, 11.7; HRMS (ESI) m/z (M + H)+ calcd for C15H16ClN3O2 305.0931, found 305.0933. 
 
 
 
(Z)-(4-Methoxyphenyl)(5-morpholinooxazol-2-yl)methanone Oxime (41). Starting material: chlorooxime 150 
mg (0.81 mmol), isocyanoacetamide 125 mg (0.81 mmol). The crude material was purified by column 
chromatography (PE/EtOAc 5:5) to give 196 mg of product as yellow solid (yield 80%): 1H NMR (300 MHz, 
CDCl3) δH 7.60−7.56 (m, 2H, AA′XX′), 6.97−6.91 (m, 2H, AA′XX′), 6.25 (br s, 1H), 3.81−3.78 (m, 7H), 
3.17−3.15 (m, 4H); 13C NMR (75 MHz, CDCl3) δC 160.6, 156.1, 147.1, 141.5, 129.7, 125.5, 113.8, 101.5, 65.8, 
55.4, 47.3; HRMS (ESI) m/z (M + Na)+ calcd for C15H17N3NaO4  326.1117, found 326.1120. 
 
 
 
(E)-(5-Morpholinooxazol-2-yl)(thiophene-2-yl)methanone Oxime (42). Starting material: chlorooxime 150 
mg (0.93 mmol), isocyanoacetamide 143 mg (0.93 mmol). The crude material was purified by column 
chromatography (PE/EtOAc 6:4) to give 108 mg of product as brown solid (yield 42%): 1H NMR (300 MHz, 
CDCl3) δH 7.60−7.58 (m, 1H), 7.36−7.34 (m, 1H), 7.10−7.06 (m, 1H), 6.26 (br s, 1H), 3.87−3.83 (m, 4H), 
3.28−3.26 (m, 4H); 13C NMR (75 MHz, CDCl3) δC 156.2, 146.1, 137.1, 135.6, 127.6, 127.3, 127.2, 101.4, 65.8, 
47.3; HRMS (ESI) m/z (M + H)+ calcd for C12H13N3O3S 279.0678, found 279.0677. 
 
 
 
(Z)-(4-Benzyl-5-morpholinooxazol-2-yl)phenylmethanone Oxime(43). Starting material: chlorooxime 150 mg 
(0.96 mmol), isocyanoacetamide 236 mg (0.96 mmol). The crude material was purified by column 
chromatography (PE/EtOAc 7:3) to give 169 mg of product as yellow oil (yield 55%). Mixture of E/Z isomers; 
signals are referred to the main isomer: 1H NMR (300 MHz, CDCl3) δH 7.69−7.66 (m, 2H), 7.45−7.39 (m, 3H), 
7.35−7.21 (m, 5H), 3.94 (s, 2H), 3.75−3.71 (m, 4H), 3.10−3.06 (m, 4H); 13C NMR (75 MHz, CDCl3) δC 151.2, 
148.3, 141.9, 138.3, 132.8, 129.5, 128.7, 128.4, 128.3, 128.0, 126.7, 121.4, 66.5, 49.9, 31.80; HRMS (ESI) 
m/z (M + H)+ calcd for C21H21N3O3 363.1583, found 363.1583. 
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(Z)-(4-Benzyl-5-morpholinooxazol-2-yl)(4-chlorophenyl)-methanone Oxime (44). Starting material: 
chlorooxime 150 mg (0.79 mmol), isocyanoacetamide 193 mg (0.79 mmol). The crude material was purified 
by column chromatography (PE/EtOAc 7:3) to give 200 mg of product as white solid (yield 64%). Mixture of 
E/Z isomers, signals are referred to the main isomer: 1H NMR (300 MHz, CDCl3) δH 7.65−7.58 (m, 2H), 
7.43−7.36 (m, 2H), 7.32−7.18 (m, 5H), 3.96 (s, 2H), 3.75−3.67 (m, 4H), 3.09−3.06 (m, 4H); 13C NMR (75 MHz, 
CDCl3) δC 151.3, 147.7, 141.2, 138.3, 135.5, 131.4, 129.6, 128.8, 128.59, 128.32, 126.65, 121.3, 66.6, 49.8, 
31.81; HRMS (ESI) m/z (M + H)+calcd for C21H20ClN3O3 397.1193, found 397.1197. 
 
 
 
(Z)-(5-(Benzylmethylamino)oxazol-2-yl)(4-methoxyphenyl)-methanone Oxime (45). Starting material: 
chlorooxime 150 mg (0.81 mmol), isocyanoacetamide 152 mg (0.81 mmol). The crude material was purified 
by column chromatography (PE/EtOAc 7:3) to give 210 mg product as yellow solid (yield 77%): 1H NMR (300 
MHz, CDCl3) δH 7.61−7.56 (m, 2H, AA′XX′), 7.37−7.27 (m, 3H), 7.25−7.19 (m 2H), 6.94−6.90 (m, 2H, 
AA′XX′), 6.15 (br s, 1H), 4.37 (s, 2H), 3.85, (s, 3H); 13C NMR (75 MHz, CDCl3) δC 160.5, 156.1, 145.8, 141.3, 
136.1, 129.7, 128.8, 127.9, 127.7, 125.6, 113.7, 55.5, 55.3, 36.6; HRMS (ESI) m/z (M + H)+ calcd for 
C19H19N3O3 337.1426, found 337.1426. 
 
 
 
(Z)-(5-(4-Methylpiperazin-1-yl)oxazol-2-yl)(p-tolyl)methanone Oxime (46). Starting materials: chlorooxime 
150 mg (0.88 mmol), isocyanoacetamide 147 mg (0.88 mmol). The crude material was purified by column 
chromatography (DCM/MeOH 95:5) to give 232 mg product as yellow solid (88% yield): 1H NMR (400 MHz, 
CDCl3) δH 7.56 (d, J = 7.8 Hz, 2H), 7.23 (m, 2H) partially overlapped to the solvent, 6.23 (s, 1H), 3.22 (br t, 
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4H), 2.50 (br t, 4H), 2.39 (s, 3H), 2.33 (s, 3H); 13C NMR (100 MHz, CDCl3) δC 156.2, 146.7, 142.0, 139.3, 
130.4, 128.9, 128.1, 101.4, 53.6, 46.9, 46.0, 21.3; HRMS (ESI) m/z (M + H)+ calcd for C16H20N4O2 
300.1586, found 300.1590. 
 
 
 
(Z)-(4-Chlorophenyl)-(5-(4-methylpiperazin-1-yl)oxazol-2-yl)- methanone Oxime (47).  Starting materials: 
chlorooxime 150 mg (0.79 mmol), isocyanoacetamide 132 mg (0.79 mmol). The crude material was purified 
by column chromatography (DCM/MeOH 97:3) to give the product as yellow solid (195 mg, 77% yield): 1H 
NMR (400 MHz, CDCl3) δH 7.57−7.55 (m, 2H, AA′XX′), 7.36−7.34(m, 2H, AA′XX′), 6.23 (s, 1H), 3.23 (br t, 4H), 
2.52 (br t, 4H), 2.33 (s, 3H); 13C NMR (100 MHz, CDCl3) δC 156.3, 146.2, 141.2, 135.3, 131.9, 129.5, 128.5, 
101.7, 53.6, 46.9, 46.0; HRMS (ESI) m/z (M + H)+ calcd for C15H17ClN4O2 320.1040, found 320.1042. 
 
 
 
(Z)-(5-Morpholinooxazol-2-yl)-p-tolylmethanone Oxime (48). Starting materials: chlorooxime 150 mg (0.88 
mmol), isocyanoacetamide 136 mg (0.88 mmol). The crude material was purified by column 
chromatography (n-hexane/AcOEt 7:3) to give the product as yellow solid (197 mg, 78% yield): 1H NMR 
(400 MHz, CDCl3) δH 7.54 (m, 2H, AA′XX′), 7.23 (m, 2H, AA′XX′), 6.26 (s, 1H), 3.80 (m, 4H), 3.17 (m, 4H), 2.39 
(s, 3H); 13C NMR (100 MHz, CDCl3) δC 156.0, 147.0, 141.7, 139.4, 130.0, 129.0, 128.2, 101.3, 65.7, 47.2, 
21.3; HRMS (ESI) m/z (M + H)+ calcd for C15H17N3O3 287.1270, found 287.1268. 
 
 
 
(4-Benzyl-5-(pyrrolidin-1-yl)oxazol-2-yl)-p-tolylmethanoneOxime (49). Starting materials: chlorooxime 150 
mg (0.88 mmol), isocyanoacetamide 202 mg (0.88 mmol). The crude material was purified by column 
chromatography (n-hexane/AcOEt 7:3) to give the product as yellow solid (168 mg, 53% yield). Mixture of 
E/Z isomers, signals are referred to the main isomer: 1H NMR (400 MHz, CDCl3) δH 7.61 (m, 2H, AA′XX′), 
7.31−7.22 (m, 7H) partially overlapped to  the solvent, 3.99 (s, 2H), 3.42 (br t, 4H), 2.40 (s, 3H), 1.93 (br t, 
4H); 13C NMR (100 MHz, CDCl3) δC 150.3, 144.3, 141.3, 140.0, 139.1, 130.3, 128.9, 128.6, 128.2, 128.1, 
126.3, 110.7, 48.8, 31.8, 25.3, 21.3; HRMS (ESI) m/z (M + H)+ calcd for C22H23N3O2 361.1790, found 
361.1793. 
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(Z)-(4-Benzyl-5-(pyrrolidin-1-yl)oxazol-2-yl)phenylmethanone Oxime (50). Starting materials: chlorooxime 
150 mg (0.96 mmol), isocyanoacetamide 219 mg (0.96 mmol). The crude material was purified by column 
chromatography (n-hexane/AcOEt 7:3) to give the product as yellow solid (233 mg, 70% yield). Mixture of 
E/Z isomers, signals are referred to the main isomer: 1H NMR (400 MHz, CDCl3) δH 7.71 (br d, 2H), 
7.63−7.57 (m, 1H), 7.43−7.41 (m, 3H), 7.33− 7.20 (m, 4H) partially overlapped to the solvent, 4.00 (s, 2H), 
3.41 (br t, 4H), 1.92 (br t, 4H); 13C NMR (100 MHz, CDCl3) δC 150.3, 144.1, 141.4, 140.0, 133.2, 129.1, 128.6, 
128.3, 128.2, 128.1, 126.3, 110.7, 48.7, 31.8, 25.3; HRMS (ESI) m/z (M + H)+ calcd for C21H21N3O2 
347.1634, found 347.1637. 
 
 
 
(Z)-(5-(4-Benzylpiperidin-1-yl)oxazol-2-yl)(4-nitrophenyl)- methanone Oxime (51). Starting materials: 
chlorooxime 150 mg (0.75 mmol), isocyanoacetamide 182 mg (0.75 mmol). The crude material was purified 
by column chromatography (n-hexane/AcOEt 9:1) to give the product as bright yellow solid (97 mg, 32% 
yield). 1H NMR (400 MHz, CDCl3) δH 8.28 (d, J = 8.7 Hz, 2H), 7.89 (d, J = 8.6 Hz, 2H), 7.29−7.12 (m, 6H), 6.23 
(s, 1H), 3.54 (br d, 2H), 2.83 (br t, 2H), 2.58 (br d, 2H), 1.77−1.73 (m, 3H), 1.39−1.33 (m, 2H); 13C NMR (100 
MHz, CDCl3) δC 156.5, 148.2, 145.2, 139.9, 139.5, 139.2, 129.1, 129.0, 128.3, 126.1, 123.5, 100.7, 47.5, 
42.8, 37.3, 30.7; HRMS (ESI) m/z (M + H)+ calcd for C22H22N4O4 406.1641, found 406.1646. 
 
 
 
(Z)-(5-(4-Benzylpiperidin-1-yl)oxazol-2-yl)(naphthalen-2-yl)- methanone Oxime (52). Starting materials: 
chlorooxime 150 mg (0.73 mmol), isocyanoacetamide 178 mg (0.73 mmol). The crude material was purified 
by column chromatography (n-hexane/AcOEt 9:1) to give the product as yellow solid (177 mg, 59% yield): 
1H NMR (400 MHz, CDCl3) δH 8.18 (s, 1H), 7.89−7.85 (m, 3H), 7.79 (br d, 1H), 7.52−7.50 (m, 2H), 7.30−7.25 
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(m, 3H), 7.21 (br d, 1H), 7.13 (br d, 2H), 6.23 (s, 1H), 3.54 (br d, 2H), 2.79 (br t, 2H), 2.56 (br d, 2H), 
1.72−1.70 (m, 3H), 1.38−1.29 (m, 2H); 13C NMR (100 MHz, CDCl3) δC 156.5, 146.2, 141.7, 139.7, 133.6, 
133.0, 130.5, 129.1, 128.5, 128.3, 128.2, 127.9, 127.6, 126.8, 126.4, 126.1, 125.6, 100.6, 47.5, 42.8, 37.3, 
30.7; HRMS (ESI) m/z (M + H)+ calcd for C26H25N3O2 411.1947, found 411.1950. 
 
 
 
(Z)-[1,1′-Biphenyl]-4-yl(5-(4-benzylpiperidin-1-yl)oxazol-2-yl)-methanone Oxime (53). Starting materials: 
chlorooxime 150 mg(0.65 mmol), isocyanoacetamide 158 mg (0.73 mmol). The crude material was purified 
by column chromatography (n-hexane/AcOEt 9:1) to give the product as yellowish solid (142 mg, 50% 
yield): 1H NMR (400 MHz, CDCl3) δH 7.76 (br d, 2H), 7.67−7.63 (m, 4H), 7.47−7.44 (m, 3H), 7.38 (br d, 1H), 
7.31−7.27 (m, 2H), 7.22 (br d, 1H), 7.14 (br d, 2H), 6.22 (s, 1H), 3.56 (br d, 2H), 2.81 (br t, 2H), 2.58 (br d, 
2H), 1.75−1.72 (m, 3H), 1.41−1.32 (m, 2H); 13C NMR (100 MHz, CDCl3) δC 156.5, 146.2, 142.0, 141.4, 140.3, 
139.7, 132.0, 129.1, 128.8, 128.7, 128.3, 127.6, 127.1, 127.0, 126.1, 100.6, 47.6, 42.9, 37.4, 30.7; HRMS 
(ESI) m/z (M + H)+ calcd for C26H25N3O2 411.1947, found 411.1948. 
 
 
 
(Z)-(5-(Benzylmethylamino)oxazol-2-yl)(4-fluorophenyl)- methanone Oxime (54). Starting material: 
chlorooxime 150 mg (0.87 mmol), isocyanoacetamide 163 mg (0.81 mmol). The crude material was purified 
by column chromatography (PE/EtOAc 7:3) to give 198 mg product as yellow solid (yield 70%). Mixture of 
E/Z isomers, signals are referred to the main isomer: 1H NMR (300 MHz, CDCl3) δH 7.65−7.53 (m, 3H), 
7.37−7.19 (m, 3H), 7.10−7.02 (m, 3H), 6.18 (br s, 1H), 4.38 (s, 2H), 2.90 (s, 3H); 13C NMR (75 MHz, CDCl3) δC 
164.9, 161.7, 156.2, 140.8, 136.0, 131.8, 130.3, 128.7, 128.6, 127.8 115.4, 99.5, 55.3, 36.6; HRMS (ESI) m/z 
(M + H)+ calcd for C18H16FN3O2 325.1227, found 325.1229. 
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General Preparation of Aryl-α-ketoamide Amides 56−73. The 1,3-oxazol-2-oxime was dissolved in THF (0.8 
M), concentrated HCl (1 equiv; 2 equiv for oxazoles 46 and 47) was added, and the reaction was stirred at 
room temperature for 30 min. The reaction mixture was diluted with water and extracted with EtOAc (×3). 
The organic phase was washed with NaHCO3 standard solution (×1) and brine (×1), dried over sodium 
sulfate, filtered, and concentrated under reduced pressure. The crude was dissolved in acetonitrile (0.25 
M),and water (55 equiv) and copper(II) chloride (2 equiv) were added. The solution was stirred for 1 h at 75 
°C. The reaction mixture was diluted with water and extracted with EtOAc (×2). The organic phase was 
washed with brine (×1), dried over sodium sulfate, filtered, and concentrated under reduced pressure, and 
the crude material was purified by column chromatography. 
2-(4-Chlorophenyl)-N-(2-morpholino-2-oxoethyl)-2-oxoacetamide (56). Starting material: 1,3-oxazol-2-oxime 
38 150 mg (0.49 mmol). The crude material was purified by column chromatography (PE/ EtOAc 2:8) to give 
100 mg of product as white solid (yield 66%): 1H NMR (300 MHz, CDCl3) δH 8.21−8.18 (m, 2H, AA′XX′), 
8.03 (br s, NH), 7.41−7.38 (m, 2H, AA′XX′), 4.12 (d, J = 4.6 Hz, 2H), 3.65− 3.59 (m, 6H), 3.44.3.41 (m, 2H); 
13C NMR (75 MHz, CDCl3) δC 185.8, 165.8, 161.9, 141.1, 132.4, 131.6, 128.9, 66.6, 66.3, 44.9, 42.4, 40.9; 
m/z 311 (M + H)+; IR νmax/cm−1 (KBr) 3239, 3096, 1670, 1652, 1533, 1465, 1246, 855; mp 122−123 °C. 
Anal. Calcd for C14H15ClN2O4: C, 54.12; H, 4.87; N, 9.02. Found: C, 53.95; H, 4.80; N, 9.31. 
 
 
 
N-(2-Morpholino-2-oxoethyl)-2-oxo-2-phenylacetamide (57). Starting materials: 1,3-oxazol-2-oxime 21 150 
mg (0.55 mmol). The crude material was purified by column chromatography (n-hexane/ EtOAc 5:5) to give 
the product as yellowish solid (103 mg, 68% yield): 1H NMR (400 MHz, CDCl3) δH 8.28 (br d, 2H), 7.93 (br 
s,NH), 7.62 (br t, 1H), 7.47 (br t, 2H), 4.18 (d, J = 4.0 Hz, 2H), 3.72− 3.66 (m, 6H), 3.47−3.45 (m, 2H); 13C NMR 
(100 MHz, CDCl3) δC 187.1, 165.8, 162.2, 134.4, 133.1, 130.9, 128.5, 66.6, 66.3, 44.9, 42.3, 40.8; MS m/z 
277 (M + H)+; IR νmax/cm−1 (KBr) 3380, 1687, 1667, 1642, 1505, 1474, 1275, 745; mp 164−165 °C. Anal. 
Calcd for C14H16N2O4: C, 60.86; H, 5.84; N, 10.14. Found: C, 60.95; H, 5.97; N, 10.01. 
 
 
 
N-(1-Morpholino-1-oxopropan-2-yl)-2-oxo-2-phenylacetamide (58). Starting material: 1,3-oxazol-2-oxime 39 
150 mg (0.55 mmol). The crude material was purified by column chromatography (PE/EtOAc3:7) to give 92 
mg of product as yellow oil (yield 60%). Mixture of rotamers, signals are referred to the main rotamer: 1H 
NMR (300 MHz, CDCl3) δH 8.20−8.17 (m, 2H), 8.03 (br d, NH), 7.56−7.38 (m, 3H), 4.80−4.72 (m, 1H), 
3.64−3.35 (m, 4H), 1.98−1.78 (m, 4H), 1.39 (d, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δC 187.5, 169.9, 
161.6, 134.2, 133.23, 130.9, 128.4, 46.9, 46.4, 46.2, 26.0, 24.1, 17.9; MS m/z 275 (M + H)+; IR νmax/cm−1 
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(KBr) 3253, 3062, 1638, 1667, 1510, 1449, 1264, 715. Anal. Calcd for C15H18N2O3: C, 65.68; H, 6.61; N, 
10.21. Found: C, 65.66; H, 6.65; N, 10.25. 
 
 
 
2-(4-Chlorophenyl)-N-(1-morpholino-1-oxopropan-2-yl)-2-oxoacetamide (59).  Starting material: 1,3-oxazol-
2-oxime 40 150 mg (0.49 mmol). The crude material was purified by column chromatography (PE/EtOAc 
4:6) to give 80 mg of product as colorless oil (yield 53%): 1H NMR (300 MHz, CDCl3) δH 8.25−8.23 (m, 2H, 
AA′XX′), 7.97 (br d, NH), 7.43−7.40 (m, 2H, AA′XX′), 4.77−4.72 (m, 1H), 3.66− 3.39 (m, 4H), 2.03−1.83 
(m, 4H), 1.42 (d, J = 7.0 Hz, 3H);13C NMR (75 MHz, CDCl3) δC 186.1, 169.9, 161.0, 141.1, 132.6, 131.8, 129.0, 
47.1, 46.5, 46.3, 26.2, 24.2, 18.1; MS m/z 309 (M + H)+; IR νmax/cm−1 (KBr) 3239, 3062, 1670, 1668, 1586, 
1455, 856. Anal. Calcd for C15H17ClN2O3: C, 58.35; H, 5.55; N, 9.07. Found: C, 58.23; H, 5.21; N, 9.2. 
 
 
 
2-(4-Methoxyphenyl)-N-(2-morpholino-2-oxoethyl)-2-oxoacetamide (60).Starting material: 1,3-oxazol-2-
oxime 41 150 mg (0.49 mmol). The crude material was purified by column chromatography (PE/EtOAc 2:8) 
to give 70 mg of product as white solid (yield 46%). 1H NMR (300 MHz, CDCl3) δH 8.33−8.8.30 (m, 2H, AA′
XX′), 7.97 (br s, NH), 6.94−6.91 (m, 2H, AA′XX′), 4.16 (br d, 2H), 3.87 (s, 3H),3.71−3.65 (m, 6H), 3.46−43 
(m, 2H); 13C NMR (75 MHz, CDCl3) δC 185.3, 165.9, 164.8, 162.8, 133.8, 126.3, 114.0, 66.8, 66.4, 55.7, 45.0, 
42.4, 41.0; MS m/z 307 (M + H)+; IR νmax/cm−1 (KBr) 3349, 3078, 1682, 1647, 1594, 1474, 1257, 861; mp 
169−169.5 °C. Anal. Calcd for C15H18N2O5: C, 58.82; H, 5.92; N, 9.15. Found: C, 58.93; H, 6.24; N, 9.36. 
 
 
 
N-(2-Morpholino-2-oxoethyl)-2-oxo-2-(thiophene-2-yl)- acetamide (61). Starting material: 1,3-oxazol-2-
oxime 42 150 mg (0.54 mmol). The crude material was purified by column chromatography (PE/EtOAc 2:8) 
to give 85 mg of product as white solid (yield 56%): 1H NMR (300 MHz, CDCl3) δH 8.36 (d, J = 4.0 Hz, 1H), 
8.19 (br s, NH), 7.80 (d, J = 4.8 Hz, 1H), 7.18−7.15 (m, 1H), 4.15 (d, J = 4.5 Hz, 2H), 3.71−3.66 (m, 6H), 
3.53−3.42 (m, 2H); 13C NMR (75 MHz, CDCl3) δC 177.6, 165.7, 161.0, 138.5, 138.0, 136.9, 128.4, 66.6, 66.40, 
42.5, 41.1, 40.7; MS m/z 283 (M + H)+; IR νmax/cm−1 (KBr) 3371, 3071, 1691, 1658, 1495, 1359, 1275, 737; 
mp 193−194 °C. Anal. Calcd for C12H14N2O4S: C, 51.05; H, 5.00; N, 9.92. Found: C, 51.34; H, 5.36; N, 10.10. 
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N-(1-Morpholino-1-oxo-3-phenylpropan-2-yl)-2-oxo-2-phenylacetamide (62). Starting material: 1,3-oxazol-2-
oxime 43 150 mg (0.41 mmol). The crude material was purified by column chromatography (PE/EtOAc 4:6) 
to give 76 mg of product as white solid (yield 50%). Mixture of rotamers, signals are referred to the main 
rotamer: 1H NMR (300 MHz, CDCl3) δH 8.21 (d, J = 8.2 Hz, 2H), 7.87 (br d, NH), 7.64−7.59 (br t, 1H), 
7.52−7.38 (br t, 2H), 7.34−7.23 (m, 5H), 5.18 (br q, 1H), 3.62−3.44 (m, 6H), 3.16−2.94 (m, 4H); 13C NMR (75 
MHz, CDCl3) δC 187.4, 169.0, 161.6, 135.8, 134.5, 131.0, 129.7, 129.6, 128.8, 128.6, 127.4, 66.4, 66.0, 49.7, 
46.1, 42.4, 39.8; MS m/z 367 (M + H)+; IR νmax/cm−1 (KBr) 3277, 3027, 1665, 1642, 1524, 1486, 1211; mp 
151.5−152 °C. Anal. Calcd for C21H22N2O4: C, 68.84; H, 6.05; N, 7.65. Found: C, 68.95; H, 6.40; N, 7.34. 
 
 
 
2-(3-Chlorophenyl)-N-(1-morpholino-1-oxo-3-phenylpropan-2-yl)-2-oxoacetamide (63). Starting material: 
1,3-oxazol-2-oxime 44 150 mg (0.38 mmol). The crude material was purified by column chromatography 
(PE/EtOAc 5:5) to give 78 mg of product as white solid (yield 52%): 1H NMR (300 MHz, CDCl3) δH 8.19 (d, J = 
8.1 Hz, 2H), 7.93 (br d, NH), 7.42 (br d, 2H), 7.34−7.22 (m, 5H), 5.16 (br q, 1H), 3.64−3.58 (m, 2H), 3.55−3.25 
(m, 4H), 3.14−2.87 (m, 4H); 13C NMR (75 MHz,CDCl3) δC 185.8, 169.0, 160.9, 141.3, 135.7, 132.6, 131.6, 
129.7, 129.0, 128.9, 127.5, 66.5, 66.1, 49.8, 46.1, 42.4, 39.9; MS m/z 401 (M + H)+; IR νmax/cm−1 (KBr) 
3246, 3064, 1665, 1617, 1586, 1476, 1218, 858; mp 128−129 °C. Anal. Cacld for C21H21ClN2O4: C, 62.92; H, 
5.28; N, 6.99. Found: C, 63.04; H, 5.46; N, 6.74. 
 
 
 
N-Benzyl-2-(2-(4-methoxyphenyl)-2-oxoacetamido)-N-methylacetamide (64). Starting material: 1,3-oxazol-
2-oxime 45 150 mg (0.44 mmol). The crude material was purified by column chromatography (PE/EtOAc 
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5:5) to give 133 mg of product as colorless oil (yield 88%). Mixture of rotamers, signals are referred to the 
main rotamer: 1H NMR (300 MHz, CDCl3) δH 8.35−8.31 (m, 2H), 8.05 (br s, NH), 7.38−7.14 (m, 5H), 
6.94−6.89 (m, 2H), 4.61 (s, 2H), 4.24−4.20 (br t, 2H), 3.85 (s, 3H), 2.92 (s, 3H); 13C NMR (75 MHz, CDCl3) δC 
185.4, 167.4, 164.7, 162.8, 136.4, 133.7, 129.2, 128.8, 127.8, 126.3, 113.9, 55.6, 51.3, 41.3, 33.7; MS m/z 
341 (M + H)+; IR νmax/cm−1 (KBr) 3387, 3300, 1646, 1653, 1511, 1453, 1263, 1028. Anal. Calcd for 
C19H20N2O4: C, 67.05; H, 5.92; N, 8.23. Found: C, 67.14; H, 6.12; N, 8.46. 
 
 
 
N-(2-(4-Methylpiperazin-1-yl)-2-oxoethyl)-2-oxo-2-p-tolylacetamide(65). Starting material: 1,3-oxazol-2-
oxime 46 150 mg (0.50 mmol). The crude material was purified by column chromatography (DCM/ MeOH 
97:3) to give the product as yellow solid (75 mg, 50% yield): 1H NMR (400 MHz, CDCl3) δH 8.19 (br d, 2H, AA
′XX′), 7.92 (br s, NH), 7.27−7.25 (m, 2H, AA′XX′) partially overlapped to the solvent, 4.17 (d, J = 4.2 
Hz, 2H), 3.68 (br t, 2H), 3.47 (br t, 2H), 2.44 (br s, 7H), 2.32 (s, 3H); 13C NMR (100 MHz, CDCl3) δC 186.8, 
165.5, 162.5, 145.5, 131.0, 130.7, 129.2, 54.6, 54.3, 45.8, 44.3, 41.9, 40.9, 21.8; MS m/z 304 (M + H)+; IR 
νmax/cm−1 (KBr) 3351, 3000, 1669, 1642, 1504, 1475, 1276, 789; mp 97−98°C. Anal. Calcd for 
C16H21N3O3: C, 63.35; H, 6.98; N, 13.85. Found: C, 63.67; H, 7.12; N, 14.12. 
 
 
 
2-(4-Chlorophenyl)-N-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-2- oxoacetamide (66). Starting material: 1,3-
oxazol-2-oxime 47 150 mg (0.47 mmol). The crude material was purified by column chromatography 
(DCM/MeOH 97:3) to give the product as yellowish solid (64 mg, 42% yield): 1H NMR (400 MHz, CDCl3) δH 
8.23 (d, J = 8.4 Hz, 2H, AA′XX′), 7.98 (br s, NH), 7.41 (d, J = 8.4 Hz, 2H, AA′XX′), 4.12 (d,, J = 4.0 Hz 
2H), 3.63 (br t, 2H), 3.43 (br t, 2H), 2.40−2.37 (m, 4H), 2.28 (s, 3H); 13C NMR (100 MHz, CDCl3) δC 185.7, 
165.3, 161.7, 141.0, 132.4, 131.5, 128.8, 54.7, 54.4, 46.0, 44.4, 42.0, 40.9; MS m/z 324 (M + H)+; IR 
νmax/cm−1 (KBr) 3344, 1673, 1645, 1586, 1443, 1273, 857; mp 127−128 °C. Anal. Calcd for C15H18ClN3O3: 
C, 55.64; H, 5.60; N, 12.98. Found: C, 55.54; H, 5.42; N, 12.78. 
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N-(2-Morpholino-2-oxoethyl)-2-oxo-2-p-tolylacetamide (67). Starting material: 1,3-oxazol-2-oxime 48 150 
mg (0.52 mmol). The crude material was purified by column chromatography (DCM/MeOH 97:3) to give the 
product as yellow solid (98 mg, 65% yield): 1H NMR (400 MHz, CDCl3) δH 8.20 (d, J = 8.2 Hz, 2H), 7.92 (br s, 
NH), 7.28−7.25 (m, 2H) partially overlapped to the solvent, 4.17 (d, J= 4.0 Hz, 2H), 3.71−3.67 (m, 6H), 
3.47−3.46 (m, 2H), 2.42 (s, 3H); 13C NMR (100 MHz, CDCl3) δC 186.6, 165.8, 162.4, 145.6, 131.1, 130.7, 
129.2, 66.6, 66.3, 44.9, 42.3, 40.8, 21.8; MS m/z 291 (M + H)+; IR νmax/cm−1 (KBr) 3430, 3423, 1695, 1660, 
1494, 1276, 785; mp 83− 84 °C. Anal. Calcd for C15H18N2O4: C, 62.06; H, 6.25; N, 9.65. Found: C, 62.34; H, 
6.43; N, 9.78. 
 
 
 
2-Oxo-N-(1-oxo-3-phenyl-1-(pyrrolidin-1-yl)propan-2-yl)-2-p-tolylacetamide(68). Starting material: 1,3-
oxazol-2-oxime 49 150 mg (0.41 mmol). The crude material was purified by column chromatography (n-
hexane/AcOEt 7:3) to give the product as a light yellow solid (78 mg, 52% yield): 1H NMR (400 MHz, CDCl3) 
δH 8.12 (d, J = 8.0 Hz, 2H), 7.79 (br d, NH), 7.28−7.23 (m, 7H), 4.95 (br q, 1H), 3.47−3.30 (m, 3H), 3.09 (d, J = 
7.4 Hz, 2H), 2.69−2.63 (m, 1H), 2.40 (s, 3H), 1.80−1.55 (m, 4H); 13C NMR (100 MHz, CDCl3) mixture of 
rotamers: δC 186.8, 168.6, 161.7, 145.5, 136.1, 132.0, 131.1, 130.7, 129.5, 128.5, 127.1, 52.4, 46.3, 45.8, 
39.5, 25.8, 23.9, 21.8; MS m/z 365 (M + H)+; IR νmax/cm−1 (KBr) 3239, 3062, 1680, 1662, 1624, 1454, 1228, 
763; mp 88−89 °C. Anal. Calcd for C22H24N2O3: C, 72.51; H,6.64; N, 7.69. Found: C, 72.52; H, 6.65; N, 7.65. 
 
 
 
2-Oxo-N-(1-oxo-3-phenyl-1-(pyrrolidin-1-yl)propan-2-yl)-2-phenylacetamide(69). Starting material: 1,3-
oxazol-2-oxime 50 150 mg (0.43 mmol). The crude material was purified by column chromatography (n-
hexane/AcOEt 7:3) to give the product as ayellowish solid (110 mg, 73% yield): 1H NMR (400 MHz, CDCl3) δ 
8.21 (d, J = 7.8 Hz, 2H), 7.76 (br d, NH), 7.60 (t, J = 7.4 Hz, 1H), 7.45 (t, J = 7.7 Hz, 2H), 7.31−7.25 (m, 6H), 
4.96 (br q, 1H), 3.49−3.36 (m, 3H), 3.10 (d, J = 7.4 Hz, 2H), 2.70−2.64 (m, 1H), 1.81−1.56(m, 4H); 13C NMR 
(100 MHz, CDCl3) mixture of rotamers δC 187.4,168.6, 161.6, 136.0, 134.2, 133.2, 130.8, 129.4, 128.8, 
128.5, 128.4, 128.4, 127.0, 52.4, 46.3, 45.8, 39.4, 25.7, 23.9; MS m/z 351 (M + H)+; IR νmax/cm−1 (KBr) 
3240, 3062, 1682, 1664, 1621, 1555, 1454, 1222; mp 118−119 °C. Anal. Calcd for C21H22N2O3: C, 71.98; H, 
6.33; N, 7.99. Found: C, 72.21; H, 6.12; N, 8.21. 
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N-(2-(4-Benzylpiperidin-1-yl)-2-oxoethyl)-2-(4-nitrophenyl)-2-oxoacetamide(70). Starting material: 1,3-
oxazol-2-oxime 51 150 mg (0.37 mmol). The crude material was purified by column chromatography (n-
hexane/AcOEt 5:5)  give the product as a yellowish solid (100mg, 66% yield): 1H NMR (400 MHz, CDCl3) δH 
8.48 (d, J = 8.6 Hz, 2H), 8.31 (d, J = 8.8 Hz, 2H), 8.08 (br s, NH), 7.31−7.12 (m, 5H),4.59 (br d, 1H), 4.17−4.14 
(m, 2H), 3.72 (br d, 1H), 3.02 (br t, 1H),2.58−2.55 (m, 2H), 1.83−1.76 (m, 3H), 1.21−1.15 (m, 3H); 13C NMR 
(100 MHz, CDCl3) δC 185.5, 164.8,160.8,150.8,139.6,137.9, 132.1, 129.0, 128.4, 126.2, 123.4, 44.8, 42.8, 
42.6, 41.0, 38.0, 32.2, 31.5; MS m/z 410 (M + H)+; IR νmax/cm−1 (KBr) 3280, 1665, 1651, 1602,1519; mp 
78−79 °C. Anal. Calcd for C22H23N3O5: C, 64.54; H, 5.66;N, 10.26. Found: C, 64.78; H, 5.84; N, 10.02. 
 
 
 
N-(2-(4-Benzylpiperidin-1-yl)-2-oxoethyl)-2-(naphthalen-2-yl)-2-oxoacetamide (71).Starting material: 1,3-
oxazol-2-oxime 52 150 mg(0.36 mmol). The crude material was purified by column chromatography (n-
hexane/AcOEt 5:5) to give the product as a sticky solid (81 mg, 54% yield): 1H NMR (400 MHz, CDCl3) δH 
9.06 (s, 1H), 8.18 (br d, AA′XX′, 1H), 8.06 (br s, NH), 7.98 (d, J = 8.1 Hz,1H), 7.90−7.85 (m, 2H), 7.64−7.60 
(m, 1H), 7.56−7.53 (m, 1H),7.31−7.19 (m, 3H), 7.13 (br d, 2H), 4.60 (br d, 1H), 4.22−4.19 (m,2H), 3.75 (br d, 
1H), 3.01 (br t, 1H), 2.61−2.55 (m, 2H), 1.82−1.72(m, 3H), 1.25−1.14 (m, 3H); 13C NMR (100 MHz, CDCl3) δC 
186.9,165.1, 162.3, 139.6, 136.1, 134.5, 132.3, 130.5, 130.2, 129.2, 129.0, 128.3, 128.3, 127.7, 126.7, 126.1, 
125.1, 44.8, 42.8, 42.6, 41.0, 38.0, 32.2, 31.5; MS m/z 415 (M + H)+; IR νmax/cm−1 (KBr) 3280, 1665,1651, 
1602, 1519. Anal. Calcd for C26H26N2O3: C, 75.34; H, 6.32; N, 6.76. Found: C, 75.36; H, 6.46; N, 6.73. 
 
 
 
2-([1,1′-Biphenyl]-4-yl)-N-(2-(4-benzylpiperidin-1-yl)-2-oxoethyl)-2-oxoacetamide (72). Starting material: 
1,3-oxazol-2-oxime 53 150 mg (0.34 mmol). The crude material was purified by column chromatography (n-
hexane/AcOEt 5:5) to give the product as a white solid (112 mg, 75% yield): 1H NMR (400 MHz, CDCl3) δH 
8.38 (br d, AA′XX′, 2H), 8.01 (br s, NH), 7.70 (br d, AA′XX′, 2H), 7.64 (br d, AA′XX′, 2H), 7.49−7.38 
(m, 3H), 7.31−7.19 (m, 3H), 7.13 (br d, AA′XX′, 2H), 4.60 (br d, 1H), 4.24−4.12 (m, 2H), 3.74 (br d, 1H), 
3.01 (br t, 1H), 2.64−2.55 (m, 3H), 1.82−1.75 (m, 3H), 1.25−1.14 (m, 2H); 13C NMR (100 MHz, CDCl3) δC 
186.7, 165.16,162.3, 146.9, 139.7, 139.6, 132.0, 131.6, 129.0, 128.9, 128.4, 128.3,127.3, 127.1, 126.1, 44.8, 
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42.8, 42.6, 41.0, 38.0, 32.2, 31.5; MS m/z 441 (M + H)+; IR νmax/cm−1 (KBr) 3364, 2919, 1682, 1628, 1475; 
mp140−141 °C. Anal. Calcd for C28H28N2O3: C, 76.34; H, 6.41; N, 6.36. Found: C, 76.29; H, 6.42; N, 6.78. 
 
 
 
N-Benzyl-2-(2-(4-fluorophenyl)-2-oxoacetamido)-N-methylacetamide (73). Starting material: 1,3-oxazol-2-
oxime 54 150 mg (0.46 mmol). The crude material was purified by column chromatography (PE/EtOAc 5:5) 
to give 106 mg of product as yellow oil (yield 70%). Mixture of rotamers, signals are referred to the main 
rotamer: 1H NMR (300 MHz, CDCl3) δH 8.37−8.29 (m, 2H), 8.11 (br s, NH), 7.34−7.21 (m, 4H), 7.19−7.05 (m, 
3H), 4.59 (s, 2H), 4.20 (d, J = 4 Hz, 2H), 2.91 (s, 3H); 13C NMR (75 MHz, CDCl3) δC 185.4, 167.2, 164.8, 162.1, 
136.4, 134.1, 129.7, 128.7, 128.1, 127.7, 115.9, 51.3, 41.2, 33.6; MS m/z 329 (M + H)+; IR νmax/cm−1 (KBr) 
3377, 2926, 1647, 1595, 1230, 1089. Anal. Calcd for C18H17FN2O3: C, 65.84; H, 5.22; N,8.53. Found C, 
65.52; H, 4.98; N, 8.76. 
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4.2 Part II: Synthesis of Aryloxyimino Amides 
Solvents and Reagents. Commercially available solvents and reagents were used without further 
purification. Dichloromethane was dried by distillation over P2O5 and stored over activated molecular 
sieves (4 Å). When needed, the reactions were performed in oven-dried glassware under a positive 
pressure of dry nitrogen. Chromatography. Column chromatography was performed on silica gel 60 
(Kieselgel 230−400 mesh ASTM) using the indicated eluents. Thin layer chromatography (TLC) was carried 
out on 5 × 20 cm plates with a layer thickness of 0.25 mm (Silica gel 60 F254). When needed they were 
visualized using KMnO4 reagent. Spectra. Infrared spectra were recorded on a FT-IR with absorption 
maxima (νmax) recorded in wavenumbers (cm−1). NMR spectra were recorded using a 300 or 400 MHz 
spectrometer. Chemical shifts (δ) are quoted in parts per million and referenced to the residual solvent 
peak. The multiplicity of each signal is designated using the following abbreviations: s, singlet; d, doublet; t, 
triplet; q, quartet; quint, quintet; sext, sextet; hept, heptet; m, multiplet; br, broad singlet. Coupling 
constants (J) are reported in Hertz (Hz). HRMS were recorded on ORBITRAP mass spectrometer equipped 
with an ESI source. Melting points were determined and remain uncorrected. Chloroximes 1{1}, 1{2}, and 
1{3} are not new, and they were prepared following literature procedure [153]. 
 
General Preparation of Aryloxyimino Amides. The chlorooxime (1 equiv) was dissolved in dry 
dichloromethane and isocyanide (1 equiv), phenol (1.1 equiv), and DBU (1.2 equiv) were added. The 
reaction was stirred at room temperature under a nitrogen atmosphere until all the chlorooxime was 
consumed (typically overnight as judged by TLC). The reaction mixture was concentrated under reduced 
pressure, and the crude material was purified by column chromatography. 
 
(2Z)-4-nitrophenyl 2-(hydroxyimino)-N-pentyl-2-phenylacetimidate 4{1,3,1}.The crude material was purified 
by column chromatography (PE/EtOAc 95:5, 9:1) to give the product as white solid. 1H-NMR (300 MHz, 
CDCl3, CD3OD) δ 8. 16 (d, J = 7.35 Hz, 2H), 7.58 (d, 2H), 7.37 (m, 5H), 7.08 (br s, NH), 3,12 (br s, 2H), 1.45-
1.33 (m, 2H), 1.15 (m, 4H), 0.57 (m, 3H);13C-NMR (75 MHz, CDCl3) δ 158.3, 153.4, 148.9, 144.4, 131.2, 
130.2, 129.0, 128.6, 125.9, 125.1, 122.4, 50.1, 30.2, 29.5, 22.3, 13.9. 
 
(Z)-N-benzyl-2-((4-nitrophenoxy)imino)-2-phenylacetamide.5{1,1,1} The crude material was purified by 
column chromatography (PE/EtOAc 9:1, 8:2) to give the product as yellow solid (yield 33%). 1H-NMR (300 
MHz, CDCl3) δ 8.23-8.13 (m, 2H), 7.81-7.69 (m, 2H), 7.55-7.18 (m, 10H), 6.52 (br t, NH), 4.67 (d, J = 5.8 Hz, 
2H);13C-NMR (75 MHz, CDCl3) δ 163.4, 162.2, 157.6, 142.9, 137.4, 131.8, 129.6, 129.1 (2C), 128.9, 128.0, 
127.4, 125.8, 114.5, 43.6; νmax/cm-1 (KBr) 3412, 3258, 1646, 1591, 1342, 919; mp 151-152 °C; HRMS (EI+): 
m/z: calcd for C21H17N3O4: 375.1219, Found: 375.1220. 
(Z)-N-(tert-butyl)-2-((4-nitrophenoxy)imino)-2-phenylacetamide.5{1,2,1} The crude material was purified by 
column chromatography (PE/EtOAc 9:1, 8:2) to give the product as white solid (yield 41%). 1H-NMR (300 
MHz, CDCl3) δ 8.13-8.09 (m, 2H), 7.70-7.67 (m, 2H), 7.44-7.34 (m, 3H), 7.23-7.20 (m, 2H), 6.21 (br s, NH), 
1.45 (s, 9H); 13C-NMR (75 MHz, CDCl3) δ 136.5, 161.5, 157.7, 142.5, 131.5, 129.7, 128.9, 127.3, 125.7, 114.3, 
52.9, 28.7; νmax/cm-1 (KBr) 3280, 2969, 1646, 1589, 1519, 1341, 918; mp 154.3-155 °C; HRMS (EI+): m/z: 
calcd for C18H19N3O4: 341.1376, Found: 341.1376. 
- 95 - 
 
(Z)-2-((4-nitrophenoxy)imino)-N-pentyl-2-phenylacetamide.5{1,3,1} The crude material was purified by 
column chromatography (PE/EtOAc 9:1, 8:2) to give the product as yellow solid (yield 37%). 1H-NMR (300 
MHz, CDCl3) δ 8.26-8.19 (m, 2H), 7.81-7.76 (m, 2H), 7.53-7.26 (m, 5H), 5.97 (br s, NH), 3.56-3.49 (m, 2H), 
1.69-1.64 (m, 2H), 1.42-1.38 (m, 4H), 0.95-0.90 (m, 3H); 13C-NMR (75 MHz, CDCl3) δ 163.5, 162.1, 157.9, 
142.9, 131.7, 129.8, 129.1, 127.4, 125.8, 114.5, 39.7, 29.2, 29.1, 22.4, 14.1; νmax/cm-1 (KBr) 3233, 2932, 
1650, 1589, 1517, 1338, 921; mp 124-129.9 °C; HRMS (EI+): m/z: calcd for C19H21N3O4: 355.1532, Found: 
355.1539. 
(Z)-N-benzyl-2-((2-nitrophenoxy)imino)-2-phenylacetamide.5{1,1,2} The crude material was purified by 
column chromatography (PE/EtOAc 9:1, 8:2) to give the product as brown solid (yield 25%). 1H-NMR (300 
MHz, CDCl3) δ 8.01-7.98 (m, 1H), 7.80-7.77 (m, 3H), 7.64-7.15 (m, 10H), 6.70 (br t, NH), 4.75 (d, J = 5.5 Hz, 
2H); 13C-NMR (75 MHz, CDCl3)δ 161.6, 157.9, 152.5, 138.0, 137.3, 135.0, 131.6, 129.3, 129.0, 128.9, 128.4, 
127.9, 127.8, 125.9, 123.1, 118.1, 44.1; νmax/cm-1 (KBr) 3418, 3235, 1636, 1616, 1523, 918; mp 137.2-138 
°C; HRMS (EI+): m/z: calcd for C21H17N3O4: 375.1219, Found: 375.1221. 
(Z)-N-(tert-butyl)-2-((2-nitrophenoxy)imino)-2-phenylacetamide.5{1,2,2} The crude material was purified by 
column chromatography (PE/EtOAc 9:1, 8:2) to give the product as yellow solid (yield 42%). 1H-NMR (300 
MHz, CDCl3) δ 7.92 (dd, J = 8.26, 1.5 Hz, 1H), 7.78-7.72 (m, 3H), 7.58 (td, J = 7.8, 1.5 Hz, 1H), 7.46-7.37 (m, 
3H), 7.14 (td, J = 7.8, 1.23 Hz, 1H), 6.12 (br s, NH), 1.52 (s, 9H); 13C-NMR (75 MHz, CDCl3) δ 160.9, 157.7, 
152.5, 137.9, 134.7, 131.4, 130.2, 128.9, 127.5, 125.5, 122.8, 118.2, 53.2, 28.7; νmax/cm-1 (KBr) 3270, 2964, 
1647, 1519, 1563, 1354, 923; mp 139.5-139.9 °C; HRMS (EI+): m/z: calcd for C18H19N3O4: 341.1376, Found: 
341.1379. 
(Z)-2-((2-nitrophenoxy)imino)-N-pentyl-2-phenylacetamide.5{1,3,2} The crude material was purified by 
column chromatography (PE/EtOAc 9:1, 8:2) to give the product as yellow amorphous solid (yield 51%). 1H-
NMR (300 MHz, CDCl3) δ 7.96 (dd, J = 8.25, 1.8 Hz, 1H), 7.81-7.74 (m, 3H), 7.59 (td, J = 7.9, 1.5 Hz, 1H), 7.49-
7.35 (m, 3H), 7.16 (td, J = 7.16, 1.23 Hz, 1H) 6.50 (br s, NH) 3.56-3.49 (m, 2H), 1.69-1.65 (m, 2H), 1.37-1.35 
(m, 4H), 0.92-0.88 (m, 3H); 13C-NMR (75 MHz, CDCl3) δ 161.6, 157.9, 152.4, 137.6, 134.8, 131.3, 130.0, 
128.8, 127.6, 125.6, 122.7, 117.8, 39.8, 29.1, 28.8, 22.3, 14.0; νmax/cm-1 (KBr) 3266, 2953, 1668, 1523, 
1344, 915; HRMS (EI+): m/z: calcd for C19H21N3O4: 355.1532, Found: 355.1532. 
(Z)-N-benzyl-2-((2,4-dinitrophenoxy)imino)-2-phenylacetamide.5{1,1,3} The crude material was purified by 
column chromatography (PE/EtOAc 9:1, 8:2) to give the product as white solid (yield 30%). 1H-NMR (300 
MHz, CDCl3 + 1 gtt CD3OD) δ 8.85 (d, J = 2.7 Hz, 1H), 8.44 (dd, J = 9.18, 2.7 Hz, 1H), 8.01 (d, J = 9.18 Hz, 
1H),7.79-7.72 (m, 2H), 7.50-7.24 (m. 9H), 4.64 (s, 2H); 13C-NMR (75 MHz, CDCl3 + 1 gtt CD3OD) δ 161.8, 
160.4, 156.6, 141.3, 137.0, 136.3, 132.2, 129.8, 129.3, 129.0, 128.6, 128.0, 127.6, 127.5, 121.9, 117.4, 43.5; 
νmax/cm-1 (KBr) 3332, 3116, 1660, 1527, 1345, 927, 902; mp155-156 °C; HRMS (EI+): m/z: calcd for 
C21H16N4O6: 420.1070, Found: 420.1075. 
(Z)-N-(tert-butyl)-2-((2,4-dinitrophenoxy)imino)-2-phenylacetamide.5{1,2,3} The crude material was purified 
by column chromatography (PE/EtOAc 9:1, 8:2) to give the product as yellow solid (yield 38%). 1H-NMR 
(300 MHz, CDCl3) δ 8.83 (d, J = 2.7 Hz, 1H),8.43 (dd, J = 9.18, 2.7 Hz, 1H), 7.98 (d, J = 9.18 Hz, 1H), 7.76 (dd, J 
= 8.5, 1.5 Hz, 2H), 7.52-7.41 (m, 3H), 5.98 (br s, NH) 1.55 (s, 9H); 13C-NMR (75 MHz, CDCl3) δ 160.3, 159.6, 
156.6, 141.3, 136.3, 132.1, 129.3, 129.2, 129.1, 127.7, 121.8, 117.7, 53.4, 28.6; νmax/cm-1 (KBr) 3398, 2975, 
1685, 1519, 1344, 929, 901; mp 156.5-157 °C; HRMS (EI+): m/z: calcd for C18H18N4O6: 386.1226, Found: 
386.1228. 
(Z)-2-((2,4-dinitrophenoxy)imino)-N-pentyl-2-phenylacetamide.5{1,3,3} The crude material was purified by 
column chromatography (PE/EtOAc 9:1, 8:2) to give the product as yellow solid (yield 32%). 1H-NMR (300 
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MHz, CDCl3) δ 8.72-8.70 (m, 1H), 8.36-8.31 (m, 1H), 7.90-7.85 (m, 1H), 7.64-7.63 (m, 2H), 7.45-7.27 (m, 3H), 
6.67 (br d, NH), 3.46-3.38 (m, 2H), 1.58 (br s, 2H), 1.31-1.29 (m, 4H), 0.88-0.74 (m, 3H); 13C-NMR (75 MHz, 
CDCl3) δ 161.2, 160.1, 156.5, 141.3, 136.1, 132.2, 129.4, 129.1, 128.9, 127.8, 122.0, 117.4, 40.0, 29.1, 28.8, 
22.3, 14.0; νmax/cm-1 (KBr) 3267, 2952, 1648, 1526, 1344, 929, 904; mp 139.7-141.3 °C; HRMS (EI+): m/z: 
calcd for C19H20N4O64: 400.1383, Found: 400.1389. 
(Z)-N-benzyl-2-((2-chloro-4-nitrophenoxy)imino)-2-phenylacetamide.5{1,1,4} The crude material was 
purified by column chromatography (PE/EtOAc 9:1, 8:2) to give the product as white solid (yield 43%). 1H-
NMR (300 MHz, CDCl3) δ 8.17 (d, J = 2.8 Hz, 1H), 8.06 (dd, J = 9.18, 2.1 Hz, 1H), 7.77-7.61 (m, 3H), 7.45-7.26 
(m, 9H), 4.59 (br s, 2H); 13C-NMR (75 MHz, CDCl3) δ 161.8, 159.1, 158.8, 142.5, 137.0, 131.9, 129.4, 129.0, 
128.8, 128.2, 127.8, 127.5, 125.9, 123.7, 120.8, 115.0, 43.6; νmax/cm-1 (KBr) 3249, 3084, 1653, 1584, 1351, 
919, 743; mp 152.8-153 °C; HRMS (EI+): m/z: calcd for C21H16ClN3O4: 409.0829, Found: 409.0832. 
(Z)-N-(tert-butyl)-2-((2-chloro-4-nitrophenoxy)imino)-2-phenylacetamide.5{1,2,4} The crude material was 
purified by column chromatography (PE/EtOAc 9:1, 8:2) to give the product as white solid (yield 45%). 1H-
NMR (300 MHz, CDCl3) δ 8.26 (br d, 1H), 8.13 (dd, J = 9.2, 1.2 Hz, 1H), 7.78-7.70 (m, 3H), 7.52-7.41 (m, 3H), 
5.98 (br s,NH), 1.52 (s, 9H); 13C-NMR (75 MHz, CDCl3) δ 161.4, 159.3, 158.7, 142.2, 131.6, 129.6, 128.8, 
127.2, 125.8, 123.7, 120.5, 114.8, 52.7, 28.4; νmax/cm-1 (KBr) 3263, 3085, 1654, 1583, 1365, 922, 742; mp 
143-144 °C; HRMS (EI+): m/z: calcd for C18H18ClN3O4: 375.0986, Found: 375.0983. 
(Z)-2-((2-chloro-4-nitrophenoxy)imino)-N-pentyl-2-phenylacetamide.5{1,3,4} The crude material was 
purified by column chromatography (PE/EtOAc 9:1, 8:2) to give the product as white solid (yield 53%). 1H-
NMR (300 MHz, CDCl3) δ 8.15 (d, J = 2.8 Hz, 1H), 8.05 (dd, J = 9.1, 2.4 Hz, 1H), 7.71-7.68 (m, 2H), 7.61 (dd, J 
= 9.1, 1H), 7.48-7.35 (m, 3H), 6.54 (br t, NH), 3.42 (br q, 2H), 1.62 (br quintetto, 2H), 1.38-1.31 (m, 4H), 0.90-
0.86 (m, 3H); 13C-NMR (75 MHz, CDCl3) δ 161.7, 159.1, 158.9, 142.4, 131.8, 129.5, 129.0, 127.6, 125.9, 
123.8, 120.7, 114.9, 39.9, 29.2 (2 ), 22.4, 14.0; νmax/cm-1 (KBr) 3261, 2963, 1653, 1589, 1352, 927, 742; mp 
121-122 °C; HRMS (EI+): m/z: calcd for C19H20ClN3O4: 389.1142, Found: 389.1144. 
(Z)-N-(tert-butyl)-2-(((5-nitropyridin-2-yl)oxy)imino)-2-phenylacetamide.5{1,2,5} The crude material was 
purified by column chromatography (PE/EtOAc 9:1, 8:2) to give the product as white solid (yield 20%). 1H-
NMR (300 MHz, CDCl3) δ 9.13 (d, J = 2.46 Hz, 1H), 8.49 (dd, J = 9.18, 2.7 Hz, 1H), 7.79 (dd, J = 8.28, 1.26 Hz, 
2H), 7.56-7.36 (m, 4H), 5.88 (br s, NH), 1.53 (s, 9H); 13C-NMR (75 MHz, CDCl3) δ 167.7, 161.4, 159.6, 145.0, 
140.7, 135.1, 131.9, 130.1, 129.1, 127.5, 109.2, 52.9, 28.7; νmax/cm-1 (KBr) 3290, 2970, 1674, 1516, 1347, 
929; mp 169-171.2 °C; HRMS (EI+): m/z: calcd for C17H18N4O4: 342.1328, Found: 342.1327. 
(Z)-2-(((5-nitropyridin-2-yl)oxy)imino)-N-pentyl-2-phenylacetamide.5{1,3,5} The crude material was purified 
by column chromatography (PE/EtOAc 9:1, 8:2) to give the product as brown amorphous solid (yield 33%). 
Mixture of E/Z isomers, signals are referred to the main isomer: 1H-NMR (300 MHz, CDCl3) δ 8.96 (d, J = 2.8 
Hz, 1H), 8.45 (dd, J = 9.1, 2.8 Hz, 1H), 7.73-7.70 (m, 3H), 7.55-7.47 (m, 4H), 6.69 (br t, NH), 3.51 (br q, 2H), 
1.69-1.59 (m, 2H), 1.43-1.33 (m, 4H), 0.92-0.82 (m, 3H); 13C-NMR (75 MHz, CDCl3) δ 167.7, 161.7, 159.4, 
148.2, 144.9, 135.2, 133.8, 130.1, 129.3, 127.6, 109.0, 39.8, 29.5, 29.1, 22.4, 14.1; νmax/cm-1 (KBr) 3549, 
3417, 1636, 1579, 1345, 937; HRMS (EI+): m/z: calcd for C18H20N4O4: 356.1485, Found: 356.1485. 
(Z)-N-(tert-butyl)-2-(4-methoxyphenyl)-2-((4-nitrophenoxy)imino)acetamide.5{2,2,1} The crude material was 
purified by column chromatography (PE/EtOAc 95:5, 9:1) to give the product as yellow solid (yield 33%). 1H-
NMR (300 MHz, CDCl3) δ 8.06 (d, J = 9.18 Hz, 2H), 7.57 (d, J = 8.7 Hz, 2H), 7.16 (d, J = 9.18 Hz, 2H), 6.81 (d, J 
= 8.7 Hz, 2H), 6.32 (br s, NH), 3.76 (s, 3H), 1.42 (s, 9H); 13C-NMR (75 MHz, CDCl3) δ 163.6, 162.0, 161.7, 
157.3, 142.2, 128.8, 125.5, 121.9, 114.2, 114.0, 55.3, 52.7, 28.6; νmax/cm-1 (KBr) 3277, 2968, 1646, 1511, 
1335, 1239, 914; mp 133.2-134 °C; HRMS (EI+): m/z: calcd for C19H21N3O5: 371.1481, Found: 371.1483. 
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(Z)-2-(4-methoxyphenyl)-2-((4-nitrophenoxy)imino)-N-pentylacetamide.5{2,3,1} The crude material was 
purified by column chromatography (PE/EtOAc 9:1, 8:2) to give the product as yellow solid (yield 39%). 
Mixture of E/Z isomers, signals are referred to the main isomer: 1H-NMR (300 MHz, CDCl3) δ 8.13-8.09 (m, 
2H), 7.63-7.59 (m, 2H), 7.22-7.19 (m, 2H), 6.87-6.82 (m, 2H), 6.53 (br t, NH), 3.80 (s, 3H), 3.47-3.42 (m, 2H), 
1.60-1.57 (m, 2H), 1.34-1.32 (m, 4H), 0.90-0.87 (m, 3H); 13C-NMR (75 MHz, CDCl3) δ 163.6, 162.6, 162.4, 
157.5, 142.6, 129.0, 125.7, 121.9, 114.4, 114.3, 55.5, 39.7, 29.1, 29.0, 22.3, 14.0; νmax/cm-1 (KBr) 3266, 
2930, 1650, 1515, 1337, 1180, 931; mp 116.8-117 °C; HRMS (EI+): m/z: calcd for C20H23N3O5: 385.1638, 
Found: 385.1640. 
(Z)-N-benzyl-2-(4-methoxyphenyl)-2-((2-nitrophenoxy)imino)acetamide.5{2,1,2} The crude material was 
purified by column chromatography (PE/EtOAc 9:1, 8:2) to give the product as yellow solid (yield 26%). 1H-
NMR (300 MHz, CDCl3) δ 7.98 (dd, J = 7.9, 1.5 Hz, 1H), 7.79-7.71 (m, 3H), 7.60 (td, J = 7.8, 1.5 Hz, 1H), 7.43-
7.27 (m, 5H), 7.16 (td, J = 7.9, 1.2 Hz, 1H), 6.97-6.91 (m, 2H), 6.60 (br t, NH), 4.75 (d, J = 5.8 Hz, 2H), 3.85 (s, 
3H); 13C-NMR (75 MHz, CDCl3) δ 162.4, 162.0, 157.6, 152.6, 137.3, 134.9, 129.5, 129.2, 128.9, 128.3, 127.9, 
125.8, 122.7, 122.2, 117.9, 114.5, 55.6, 44.0; νmax/cm-1 (KBr) 3411, 3285, 1646, 1522, 1352, 1176, 924; mp 
130.8-131.6 °C; HRMS (EI+): m/z: calcd for C22H19N3O: 405.1325, Found: 405.1326. 
(Z)-N-(tert-butyl)-2-(4-methoxyphenyl)-2-((2-nitrophenoxy)imino)acetamide.5{2,2,2} The crude material was 
purified by column chromatography (PE/EtOAc 9:1, 8:2) to give the product as yellow solid (yield 49%). 1H-
NMR (300 MHz, CDCl3) δ 7.89 (dd, J = 8.3, 1.5 Hz, 1H), 7.73-7.68 (m, 3H), 7.58-7.53 (m, 1H), 7.14-7.09 (m, 
1H), 6.90 (dd, J = 8.8, 1.8 Hz, 2H), 6.07 (br s, NH), 3.82 (s, 3H), 1.51 (s, 9H); 13C-NMR (75 MHz, CDCl3) δ 
162.2, 161.2, 157.6, 152.7, 138.0, 134.6, 129.2, 125.4 (2C), 122.5, 118.2, 114.4, 55.5, 53.1, 28.7; νmax/cm-1 
(KBr) 3262, 2968, 1646, 1522, 1473, 1230, 918; mp 115.8-116.3 °C; HRMS (EI+): m/z: calcd for 
C19H21N3O5: 371.1481, Found: 371.1478. 
(Z)-2-(4-methoxyphenyl)-2-((2-nitrophenoxy)imino)-N-pentylacetamide.5{2,3,2} The crude material was 
purified by column chromatography (PE/EtOAc 9:1, 8:2) to give the product as brown solid (yield 45%). 1H-
NMR (300 MHz, CDCl3) δ 7.96-7.89 (m, 1H), 7.77-7.65 (m, 3H), 7.57-7.51 (m, 1H), 7.12-7.06 (m, 1H), 6.89-
6.86 (m, 2H), 6.51 (br s, NH), 3.81 (s, 3H), 3.48-3.44 (m, 2H), 1.65-1.61 (m, 2H), 1.34-1.32 (m, 4H), 0.90-0.85 
(m, 3H); 13C-NMR (75 MHz, CDCl3) δ 162.2, 161.9, 157.7, 152.6, 137.7, 134.7, 129.3, 125.6, 122.5, 122.3, 
117.8, 114.3, 55.4, 39.9, 29.1, 28.9, 22.3, 14.0; νmax/cm-1 (KBr) 3244, 2936, 1645, 1558, 1344, 1179, 916; 
mp 105-106 °C; HRMS (EI+): m/z: calcd for C20H23N3O5: 385.1638 Found: 385.1641. 
(Z)-N-benzyl-2-((2,4-dinitrophenoxy)imino)-2-(4-methoxyphenyl)acetamide.5{2,1,3} The crude material was 
purified by column chromatography (PE/EtOAc 8:2, 7:3) to give the product as white solid (yield 40%). 1H-
NMR (300 MHz, CDCl3 1 gtt DMSO-d6) δ 8.74 (d, J = 2.46 Hz, 1H), 8.33 (dd, J = 9.5, 2.76 Hz, 1H), 7.88 (dd, J = 
9.5, 3.96 Hz, 1H), 7.59 (d, J = 8.6 Hz, 2H), 7.27-7.18 (m, 5H), 6.83 (d, J = 8.6 Hz, 2H), 4.56 (s, 2H), 3.77 (s, 3H); 
13C-NMR (75 MHz, CDCl3 + 1 gtt DMSO-d6) δ 163.0, 160.3, 156.9 (2C), 141.5, 137.1, 136.4, 129.7, 129.5, 
128.9, 128.3, 128.0, 122.2, 121.1, 117.6, 114.8, 55.6, 43.9; νmax/cm-1 (KBr) 3269, 1643, 1535, 1340, 1255, 
927; mp 163.3-164 °C; HRMS (EI+): m/z: calcd for C22H18N4O7: 450.1175, Found: 450.1177. 
(Z)-N-(tert-butyl)-2-((2,4-dinitrophenoxy)imino)-2-(4-methoxyphenyl)acetamide.5{2,2,3} The crude material 
was purified by column chromatography (n-hexane/EtOAc 9:1) to give the product as yellow solid (yield 
33%). 1H-NMR (400 MHz, CDCl3) δ 8.86 (s, 1H), 8.45 (d, J = 9.00 Hz, 1H), 7.99 (d, J = 9.28 Hz, 1H), 7.75 (d, J = 
7.56 Hz, 2H), 6.97 (d, J = 7.64 Hz, 2H), 5.80 (br s, NH), 3.87 (s, 3H), 1.54 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ 
162.6, 160.5, 159.2, 156.7, 141.1, 136.2, 129.4, 129.1, 121.7, 121.3, 117.6, 114.5, 55.4, 53.3, 28.5; νmax/cm-
1 (KBr) 3295, 2971, 1666, 1526, 1340, 833; mp 148-149 °C; HRMS (EI+): m/z: calcd for C19H20N4O7: 416.1332, 
Found: 416.1332. 
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(Z)-2-((2,4-dinitrophenoxy)imino)-2-(4-methoxyphenyl)-N-pentylacetamide. 5{2,3,3} The crude material was 
purified by column chromatography (n-hexane/EtOAc 9:1) to give the product as pale yellow solid (yield 
40%). 1H-NMR (400 MHz, CDCl3) δ 8.82 (br s, 1H), 8.40 (br d, AA’XX’, 1H), 7.95 (d, J = 9.32 Hz, 1H), 7.68 (d, J 
= 8.56 Hz, 2H), 6.91 (d, J = 8.56 Hz, 2H), 6.24 (br t, NH), 3.84 (s, 3H), 3.53-3.48 (m, 2H), 1.67-1.63 (m, 2H), 
1.37-1.35 (m, 4H), 0.92-0.89 (m, 3H); 13C-NMR (100 MHz, CDCl3) δ 162.8, 161.4, 159.8, 156.6, 141.1, 136.1, 
129.5, 129.2, 121.9, 121.0, 117.4, 114.4, 55.4, 39.9, 29.1, 28.8, 22.2, 13.9; νmax/cm-1 (KBr) 3283, 2929, 
1654, 1521, 1343, 1260, 833; mp 139-140 °C; HRMS (EI+): m/z: calcd for C20H22N4O7: 430.1488, Found: 
430.1489. 
(Z)-N-benzyl-2-((2-chloro-4-nitrophenoxy)imino)-2-(4-methoxyphenyl)acetamide.5{2,1,4} The crude material 
was purified by column chromatography (n-hexane/EtOAc 8:2) to give the product as light yellow solid 
(yield 63%). 1H-NMR (400 MHz, CDCl3) δ 8.28 (s, 1H), 8.16 (br d, 1H), 7.76-7.71 (m, 3H), 7.42-7.30 (m, 5H), 
6.96 (d, J=7.72, 2H), 6.23 (br s, NH), 4.72 (d, J=5.52, 2H), 3.87 (s, 3H); 13C-NMR (100 MHz, DMSO-d6) δ 
162.6, 161.8, 159.8, 159.2, 142.4, 138.7, 129.5 128.7, 128.2, 127.5, 126.1, 124.9, 121.9, 119.8, 115.8, 115.1, 
55.9, 42.7; νmax/cm-1 (KBr) 3263, 1650, 1512, 1254, 926; mp 149-150 °C; HRMS (EI+): m/z: calcd for 
C22H18ClN3O5: 439.0935 Found: 439.0939. 
(Z)-N-(tert-butyl)-2-(2-chloro-4-nitrophenoxy)imino)-2-(4-methoxyphenyl)acetamide.5{2,2,4} The crude 
material was purified by column chromatography (n-hexane/EtOAc 9:1) to give the product as amorphous 
dark-red solid (yield 38%). 1H-NMR (400 MHz, CDCl3) δ 8.29 (br s, 1H), 8.16 (br d, 1H), 7.75-7.72 (m, 3H), 
6.95 (d, J = 8.76 Hz, 2H), 5.79 (br s, NH), 3.86 (s, 3H), 1.53 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ 162.3, 161.0, 
159.3, 158.1, 142.0, 129.1, 125.8, 123.6, 121.7, 120.5, 114.7, 114.4, 55.4, 52.9, 28.7; νmax/cm-1 (KBr) 3566, 
1652, 1516, 1338, 1255, 920; HRMS (EI+): m/z: calcd for C19H20ClN3O5: 405.1091, Found: 405.1093. 
(Z)-2-((2-chloro-4-nitrophenoxy)imino)-2-(4-methoxyphenyl)-N-pentylacetamide, 5{2,3,4} The crude 
material was purified by column chromatography (n-hexane/EtOAc 8:2) to give the product as yellowish 
solid (yield 50%). 1H-NMR (400 MHz, CDCl3) δ 8.28 (s, 1H), 8.15 (br d, 1H), 7.75-7.71 (m, 3H), 6.95 (d, J = 
8.76 Hz, 2H), 5.99 (br s, NH), 3.86 (s, 3H), 3.55-3.50 (m, 2H), 1.69-1.66 (m, 2H), 1.40-1.36 (m, 4H), 0.93-0.90 
(m, 3H); 13C-NMR (100 MHz, CDCl3) δ 162.5, 161.8, 159.1, 158.5, 142.3, 129.2, 125.8, 123.7, 121.5,120.6, 
114.8, 114.3, 55.4, 39.8, 29.1, 29.0, 22.3, 13.9; νmax/cm-1 (KBr) 3261, 2958, 1646, 1582, 1335, 1255, 921; 
mp 124-125 °C; HRMS (EI+): m/z: calcd for C20H22ClN3O5: 419.1248, Found: 419.1248. 
(Z)-N-(tert-butyl)-2-(4-methoxyphenyl)-2-(((5-nitropyridin-2-yl)oxy)imino)acetamide, 5{2,2,5} The crude 
material was purified by column chromatography (n-hexane/EtOAc 9:1) to give the product as white solid 
(yield 22%). 1H-NMR (400 MHz, CDCl3) δ 9.16 (br s, 1H), 8.50 (br d, AA’XX’, 1H), 7.76 (d, J = 7.76 Hz, 2H), 
7.40 (d, J = 9.16 Hz, 1H), 6.96 (d, J = 7.96 Hz, 2H), 5.65 (br s, NH), 3.86 (s, 3H), 1.53 (s, 9H); 13C-NMR (100 
MHz, DMSO-d6) δ 168.1, 162.4, 161.3, 159.3, 145.4, 140.8, 136.2, 129.4, 122.3, 115.1, 108.8, 55.9, 51.9, 
28.9; νmax/cm-1 (KBr) 3419, 1613, 1515, 1347, 1258, 927; mp 174-175 °C; HRMS (EI+): m/z: calcd for 
C18H20N4O5: 372.1434, Found: 372.1439. 
(Z)-2-(4-methoxyphenyl)-2-(((5-nitropyridin-2-yl)oxy)imino)-N-pentylacetamide, 5{2,3,5} The crude material 
was purified by column chromatography (n-hexane/EtOAc 9:1) to give the product as sticky dark-red solid 
(yield 39%). Mixture of E/Z isomers, signals are referred to the main isomer: 1H-NMR (400 MHz, CDCl3) δ 
9.16 (br s, 1H), 8.80 (br s, NH), 8.02 (br d, AA’XX’, 1H), 7.68 (d, J = 8.72 Hz, 1H), 7.51 (d, J = 8.64 Hz, 2H), 6.88 
(d, J = 8.76 Hz, 2H), 3.81 (s, 3H), 3.37-3.34 (m, 2H), 1.65-1.60 (m, 2H), 1.29-1.25 (m, 4H), 0.90-0.84 (m, 3H); 
13C-NMR (100 MHz, CDCl3) δ 167.6, 162.6, 161.0, 149.1, 136.9, 133.7, 131.9, 128.0, 123.8, 120.8, 114.1, 
55.3, 52.0, 29.7, 28.9, 22.2, 13.9; νmax/cm-1 (KBr) 3473, 3414, 1682, 1616, 1255, 933; HRMS (EI+): m/z: calcd 
for C19H22N4O5: 386.1590, Found: 386.1587. 
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(Z)-N-benzyl-2-(4-chlorophenyl)-2((4-nitrophenoxy)imino)acetamide, 5{3,1,1} The crude material was 
purified by column chromatography (n-hexane/EtOAc 8:2) to give the product as pale yellow solid (yield 
55%). 1H-NMR (400 MHz, CDCl3) δ 8.23 (d, J = 9.20 Hz, 2H), 7.73 (d, J = 8.52 Hz, 2H), 7.44-7.35 (m, 7H), 7.27-
7.25 (m , 2H), 6.22 (br t, NH), 4.72 (br d, 2H); 13C-NMR (100 MHz, CDCl3) δ 163.0, 161.6, 156.4, 143.0, 138.0, 
137.1, 129.3, 128.9, 128.5, 128.0, 127.9, 127.9, 125.7, 114.3, 43.6; νmax/cm-1 (KBr) 3411, 1654, 1515, 1345, 
1220, 929, 850; mp 159-160 °C; HRMS (EI+): m/z: calcd for C21H16ClN3O4: 409.0829, Found: 409.0831. 
(Z)-N-(tert-butyl)-2-(4-chlorophenyl)-2((4-nitrophenoxy)imino)acetamide, 5{3,2,1} The crude material was 
purified by column chromatography (n-hexane/EtOAc 9:1) to give the product as yellow solid (yield 53%). 
1H-NMR (400 MHz, CDCl3) δ 8.25 (d, J = 9.12 Hz, 2H), 7.73 (d, J = 8.48 Hz, 2H), 7.44 (d, J = 8.44 Hz, 2H), 7.34 
(d, J = 9.16 Hz, 2H), 5.61 (br s, NH), 1.53 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ 163.2, 161.0, 156.6, 142.7, 
137.7, 129.2, 128.4, 128.1, 125.6, 114.2, 53.0, 28.7; νmax/cm-1 (KBr) 3272, 2965, 1651, 1517, 1342, 1237, 
917, 841; mp 160-161 °C; HRMS (EI+): m/z: calcd for C18H18ClN3O4: 375.0986, Found: 375.0989. 
(Z)- 2-(4-chlorophenyl)-2((4-nitrophenoxy)imino)-N-pentylacetamide, 5{3,3,1} The crude material was 
purified by column chromatography (n-hexane/EtOAc 9:1) to give the product as yellow solid (yield 43%). 
1H-NMR (400 MHz, CDCl3) δ 8.23 (br d, AA’XX’, 2H), 7.72 (d, J = 8.64 Hz, 2H), 7.42 (d, J = 8.60 Hz, 2H), 7.33 
(br d, J = 9.24 Hz, 2H), 5.94 (br t, NH), 3.55-3.50 (m, 2H), 1.68-1.63 (m, 2H), 1.42-1.38 (m, 4H), 0.94-0.91 (m, 
3H); 13C-NMR (100 MHz, CDCl3) δ 163.1, 161.6, 156.6, 142.7, 137.7, 129.2, 128.5, 128.1, 125.6, 114.3, 39.6, 
29.0, 28.9, 22.2, 13.9; νmax/cm-1 (KBr) 3301, 2953, 1660, 1508, 1339, 927, 854; mp 106-107 °C; HRMS (EI+): 
m/z: calcd for C19H20ClN3O4: 389.1142, Found: 389.1141. 
(Z)-N-benzyl-2-(4-chlorophenyl)-2((2-nitrophenoxy)imino)acetamide, 5{3,1,2} The crude material was 
purified by column chromatography (n-hexane/EtOAc 9:1) to give the product as pale yellow solid (yield 
42%). 1H-NMR (400 MHz, CDCl3) δ 8.00 (d, J = 8.16 Hz, 2H), 7.77-7.72 (m, 3H), 7.63 (br t, 1H), 7.42-7.29 (m, 
7H), 7.22-7.18 (m, 1H), 6.80 (br s, NH), 4.74 (br d, 2H); 13C-NMR (100 MHz, CDCl3) δ 161.0, 156.5, 152.1, 
137.6, 137.0, 134.8, 129.1, 129.0, 128.8, 128.4, 128.1, 127.7, 125.7, 123.1, 117.9, 43.9; νmax/cm-1 (KBr) 
3412, 3248, 1638, 1525, 1337, 1225, 926, 832; mp 145-146 °C; HRMS (EI+): m/z: calcd for C21H16ClN3O4: 
409.0829, Found: 409.0832. 
(Z)-N-(tert-butyl)-2-(4-chlorophenyl)-2((2-nitrophenoxy)imino)acetamide, 5{3,2,2} The crude material was 
purified by column chromatography (n-hexane/EtOAc 9:1) to give the product as yellow solid (yield 48%). 
1H-NMR (400 MHz, CDCl3) δ 7.96 (br d, AA’XX’, 1H), 7.74-7.71 (m, 3H), 7.63-7.59 (m, 1H), 7.41-7.39 (m, 2H), 
7.21-7.17 (m, 1H), 6.07 (br s, NH), 1.53 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ 160.4, 156.5, 152.2, 137.8, 
137.4, 134.5, 129.0, 128.7, 128.6, 125.4, 122.8, 118.0, 53.1, 28.5; νmax/cm-1 (KBr) 3249, 2972, 1634, 1515, 
1347, 1228, 915, 739; mp 125-126 °C; HRMS (EI+): m/z: calcd for C18H18ClN3O4: 375.0986, Found: 375.0983. 
(Z)- 2-(4-chlorophenyl)-2((2-nitrophenoxy)imino)-N-pentylacetamide, 5{3,3,2}The crude material was 
purified by column chromatography (n-hexane/EtOAc 9:1) to give the product as brown solid (yield 41%). 
1H-NMR (400 MHz, CDCl3) δ 7.99 (d, J = 8.20 Hz, 1H), 7.75-7.71 (m, 3H), 7.62 (br t, 1H), 7.40 (d, J = 8.20 Hz, 
2H), 7.20 (br t, 1H), 6.52 (br s, NH), 3.56-3.51 (m, 2H), 1.70-1.67 (m, 2H), 1.37-1.32 (m, 4H), 0.92-0.89 (m, 
3H); 13C-NMR (100 MHz, CDCl3) δ 161.0, 156.7, 152.1, 137.7, 137.4, 134.7, 129.0, 128.9, 128.6, 125.6, 123.0, 
117.8, 39.9, 29.0, 28.8, 22.2, 13.9; νmax/cm-1 (KBr) 3255, 2929, 1652, 1521, 1347, 1226, 921, 833; mp 60-61 
°C; HRMS (EI+): m/z: calcd for C19H20ClN3O4: 389.1142, Found: 389.1141. 
(Z)-N-benzyl-2-(4-chlorophenyl)-2((2,4-dinitrophenoxy)imino)acetamide, 5{3,1,3} The crude material was 
purified by column chromatography (n-hexane/EtOAc 9:1) to give the product as yellow solid (yield 34%). 
1H-NMR (400 MHz, CDCl3) δ 8.92 (br s, 1H), 8.48 (br d, AA’XX’, 1H), 8.00 (d, J = 9.40 Hz, 1H), 7.75 (d, J = 8.52 
Hz, 2H), 7.46-7.37 (m, 7H), 6.42 (br s, NH), 4.75 (br d, 2H); 13C-NMR (100 MHz, DMSO-d6) δ 161.0, 159.8, 
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155.7, 141.8, 138.2, 137.4, 136.7, 130.2, 129.9, 129.6, 128.9, 128.4, 128.0, 127.6, 122.2, 118.0, 42.9; 
νmax/cm-1 (KBr) 3236, 1604, 1533, 1342, 835; mp 142-143 °C; HRMS (EI+): m/z: calcd for C21H15ClN4O6: 
454.0680, Found: 454.0683. 
(Z)-N-(tert-butyl)-2-(4-chlorophenyl)-2((2,4-dinitrophenoxy)imino)acetamide, 5{3,2,3} The crude material 
was purified by column chromatography (n-hexane/EtOAc 9:1) to give the product as yellow solid (yield 
46%). 1H-NMR (400 MHz, CDCl3) δ 8.86 (s, 1H), 8.46 (d, J = 9.28 Hz, 1H), 7.96 (d, J = 9.32 Hz, 1H), 7.73 (d, J = 
8.12 Hz, 2H), 7.43 (d, J = 8.04 Hz, 2H), 5.93 (br s, NH), 1.53 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ 159.7, 158.5, 
156.3, 141.5, 138.4, 136.4, 129.3, 129.1, 128.9, 127.7, 121.7, 117.7, 53.5, 28.5; νmax/cm-1 (KBr) 3275, 2972, 
1660, 1540, 1344, 1283, 833, 740; mp 118-119 °C; HRMS (EI+): m/z: calcd for C18H17ClN4O6: 420.0837, 
Found: 420.0840. 
(Z)- 2-(4-chlorophenyl)-2((2,4-dinitrophenoxy)imino)-N-pentylacetamide, 5{3,3,3} The crude material was 
purified by column chromatography (n-hexane/EtOAc 9:1) to give the product as yellow solid (yield 32%). 
1H-NMR (400 MHz, CDCl3) δ 8.90 (br s, 1H), 8.47 (br d, AA’XX’, 1H), 7.98 (d, J = 9.28 Hz, 1H), 7.74 (d, J = 8.56 
Hz, 2H), 7.44 (d, J = 8.52 Hz, 2H), 6.18 (br s, NH), 3.57-3.52 (m, 2H), 1.70-1.67 (m, 2H), 1.39-1.37 (m, 4H), 
0.93-0.90 (m, 3H); 13C-NMR (100 MHz, CDCl3) δ 160.6, 158.9, 156.2, 141.5, 138.5, 136.2, 129.3, 129.3, 
129.0, 127.4, 121.9, 117.4, 40.0, 29.0, 28.7, 22.2, 13.9; νmax/cm-1 (KBr) 3284, 1652, 1558, 1472, 1344, 834, 
739; mp 156-157 °C; HRMS (EI+): m/z: calcd for C19H19ClN4O6: 434.0993, Found: 434.0995. 
(Z)-N-benzyl-2-((2-chloro-4-nitrophenoxy)imino)-2-(4-chlorophenyl)acetamide, 5{3,1,4} The crude material 
was purified by column chromatography (n-hexane/EtOAc 8:2) to give the product as light yellow solid 
(yield 63%). 1H-NMR (400 MHz, CDCl3) δ 8.22 (br s, 1H), 8.11 (br d, AA’XX’, 1H), 7.69-7.65 (m, 3H), 7.38-7.25 
(m, 8H), 4.61 (s, 2H); 13C-NMR (100 MHz, DMSO-d6) δ 161.2, 158.9, 158.9, 142.7, 138.4, 137.1, 129.8, 129.4, 
128.8, 128.7, 128.2, 127.6, 126.1, 124.9, 119.9, 115.9, 42.8; νmax/cm-1 (KBr) 3353, 3104, 1676, 1523, 1344, 
933, 741; mp 165-166 °C; HRMS (EI+): m/z: calcd for C21H15Cl2N3O4: 443.0440, Found: 443.0441. 
 
(Z)-N-(tert-butyl)-2-((2-chloro-4-nitrophenoxy)imino)-2-(4-chlorophenyl)acetamide, 5{3,2,4} The crude 
material was purified by column chromatography (n-hexane/EtOAc 9:1) to give the product as yellow solid 
(yield 47%). 1H-NMR (400 MHz, CDCl3) δ 8.30 (s, 1H), 8.18 (d, J = 9.04, 1H), 7.75-7.72 (m, 3H), 7.43 (d, J = 
8.20 Hz, 2H), 5.84 (br s, NH), 1.53 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ 160.3, 158.9, 157.3, 142.3, 137.8, 
129.1, 128.6, 128.0, 125.8, 123.6, 120.5, 114.7, 53.0, 28.7; νmax/cm-1 (KBr) 3300, 2972, 1652, 1555, 1344, 
1233, 930; mp 144-145 °C; HRMS (EI+): m/z: calcd for C18H17Cl2N3O4: 409.0596, Found: 409.0595. 
(Z)-2-((2-chloro-4-nitrophenoxy)imino)-2-(4-chlorophenyl)-N-pentylacetamide, 5{3,3,4} The crude material 
was purified by column chromatography (n-hexane/EtOAc 9:1) to give the product as yellow solid (yield 
56%). 1H-NMR (400 MHz, CDCl3) δ 8.29 (br s, 1H), 8.16 (br d, AA’XX’, 1H), 7.74-7.69 (m, 3H), 7.42 (d, J = 8.56 
Hz, 2H), 6.12 (br s, NH), 3.54-3.49 (m, 2H), 1.69-1.66 (m, 2H), 1.38-1.36 (m, 4H), 0.93-0.90 (m, 3H); 13C-NMR 
(100 MHz, CDCl3) δ 161.1, 158.8, 157.7, 142.4, 138.0, 129.1, 128.6, 127.8, 125.8, 123.6, 120.6, 114.6, 39.8, 
31.5, 29.0, 22.2, 13.9; νmax/cm-1 (KBr) 3246, 2929, 1646, 1582, 1343, 928, 834; mp 136-137 °C; HRMS (EI+): 
m/z: calcd for C19H19Cl2N3O4: 423.0753, Found: 423.0757. 
(Z)-N-(tert-butyl)-2-(4-chlorophenyl)-2(((4-nitropyridin-2-yl)oxy)imino)acetamide, 5{3,2,5} The crude 
material was purified by column chromatography (n-hexane/EtOAc 7:3) to give the product as white solid 
(yield 42%). 1H-NMR (400 MHz, CDCl3) δ 9.18 (br s, 1H), 8.52 (br d, AA’XX’, 1H), 7.76 (d, J = 8.56 Hz, 2H), 
7.45-7.39 (m, 3H), 5.70 (br s, NH), 1.53 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ 167.8, 160.8, 158.6, 145.4, 
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141.1, 136.9, 136.3, 129.7, 129.4, 129.1, 109.0, 52.1, 28.8; νmax/cm-1 (KBr) 3414, 3293, 1675, 1577, 1349, 
935, 833; mp 193-194 °C; HRMS (EI+): m/z: calcd for C17H17ClN4O4: 376.0938, Found: 376.0939. 
(Z)-2-(4-chlorophenyl)-2-(((5-nitropyridin-2-yl)oxy)imino)-N-pentylacetamide, 5{3,3,5} The crude material 
was purified by column chromatography (n-hexane/EtOAc 9:1) to give the product as sticky dark-red solid 
(yield 35%). Mixture of E/Z isomers, signals are referred to the main isomer: 1H-NMR (400 MHz, CDCl3) δ 
9.15 (s, 1H), 9.03 (br s, NH), 8.05 (br d, AA’XX’, 1H), 7.70 (d, J = 8.52 Hz, 1H), 7.52 (d, J = 8.56 Hz, 2H), 7.34 
(d, J = 8.60 Hz, 2H), 3.34-3.30 (m, 2H), 1.65-1.62 (m, 2H), 1.27-1.25 (m, 4H), 0.92-0.85 (m, 3H); 13C-NMR 
(100 MHz, CDCl3) δ 167.2, 160.9, 148.8, 148.0, 144.9, 136.6, 135.1, 133.9, 130.0, 129.0, 127.7, 52.1, 29.7, 
28.9, 22.2, 13.9; νmax/cm-1 (KBr) 2932, 1691, 1564, 1345, 1273, 935, 834; HRMS (EI+): m/z: calcd for 
C18H19ClN4O4: 390.1095, Found: 390.1098. 
 
(Z)-2-(2-((tert-butyldimethylsilyl)oxy)phenyl)-2-((2,4-dinitrophenoxy)imino)-N-pentylacetamide, 7 
The crude material was purified by column chromatography (PE/EtOAc 9:1) to give the product as yellow 
solid (yield 48%). 1H-NMR (300 MHz, CDCl3) 8.86 (d, J=2.7 Hz, 1H), 8.42 (dd, J = 6.7, 2.4 Hz, 1H), 7.99 (d, J 
= 9.5 Hz, 1H), 7.46 (dd, J = 7.65, 1.5 Hz , 1H), 6.99-6.85 (m, 3H), 3.42-3.38 (m, 2H), 1.67-1.62 (m, 2H), 1.33-
1.31 (m, 4H), 0.90 (s, 12H), 0,19 (s, 6H); 13C-NMR (75 MHz, CDCl3)  159.7, 159.4, 156.5, 154.3, 141.6, 
136.1, 132.1, 131.0, 129.5, 122.5, 122.1, 121.3, 119.6, 117.9, 40.3, 29.2, 28.7, 25.8, 22.3, 18.4, 14.0, -4.0; 
m/z 532 (M+H)+; νmax/cm-1 (KBr) 3292, 1607, 1537, 1486, 1260, 914; mp 110.8-111.2°C; HRMS (EI+): m/z: 
calcd for C25H34N4O7Si: 530.2197, Found: 530.2201. 
 
N-pentylbenzo[d]isoxazole-3-carboxamide, 8 
The crude material was purified by column chromatography (PE/EtOAc 9:1) to give the product as yellow 
amorphous solid (yield quantitative). 1H-NMR (300 MHz, CDCl3) 8. 26 (d, J = 9.30 Hz, 1H), 7.56 (br d, 2H), 
7.36 (m, 1H), 7.08 (br s, NH), 3.49 (m, 2H), 1.65-1.61 (m, 2H), 1.36-1.33 (m, 4H), 0.89-0.87 (m, 3H); 13C-NMR 
(75 MHz, CDCl3)  164.15, 159.3, 152.0, 130.4, 124.9, 124.0, 120.0, 109.7, 39.5, 29.2, 29.1, 22.4, 14.0; m/z 
233 (M+H)+; νmax/ cm-1 (KBr) 3271, 1672, 1548, 1254, 913; HRMS (EI+): m/z: calcd for C13H16N2O2232.1212, 
Found: 232.1212. 
 
 
- 102 - 
 
 
 
 
- 103 - 
 
 
 
- 104 - 
 
 
 
- 105 - 
 
 
 
- 106 - 
 
 
 
- 107 - 
 
 
 
- 108 - 
 
 
 
- 109 - 
 
 
 
- 110 - 
 
 
- 111 - 
 
4.3 Part III:  Synthesis of BAX Direct Activators as Novel 
Potential Anticancer Agents 
Chemistry. All reagents and solvents were handled according to material safety data sheet of the supplier 
and were used as purchased without further purification. Organic solutions were dried over anhydrous 
sodium sulfate. Evaporation of the solvents was carried out on Büchi Rotavapor R-210 equipped with Büchi 
V-855 vacuum controller and Büchi V-700 (~5 mbar) and V-710 (~2 mbar) vacuum pumps and on Heidolph 
Hei-Vap G3B equipped with Vacuubrand PC 3001 vacuum pump (~2 mbar). Column chromatography was 
performed on glass columns packed with silica gel from Fluka and from Aldrich (70−230 mesh). Silica gel 
thin layer chromatography (TLC) cards from Fluka and Macherey-Nagel (silica gel precoated aluminum 
cards with fluorescent indicator visualizable at 254 nm were used for TLC. Developed plates were visualized 
by a Spectroline ENF 260C/FE UV apparatus. Melting points (mp) were determined on a Stuart Scientific 
SMP1 apparatus and on a Stuart Scientific SMP30 apparatus and are uncorrected. Infrared spectra (IR) 
were run on PerkinElmer SpectrumOne FT-ATR spectrophotometer. Band position and absorption ranges 
are given in cm−1. Mass spectral (MS) and high resolution mass spectral (HRMS) analyses were recorded on 
AB Sciex API-2000 (MS) and Thermo Fisher Scientific Inc. Orbitrap Exactive (HRMS) spectrometers equipped 
with an ESI source. Proton ( 1H, 400.13 MHz) and carbon ( 13C, 100.6 MHz) nuclear magnetic resonance 
spectra were recorded on a Bruker Avance 400 and a Varian Inova 400 spectrometers in the indicated 
solvent and corresponding fid files processed by MestreLab Research SL MestreReNova 6.2.1− 769 and 
Bruker Topspin 3.2 software. Chemical shifts are expressed in δ units (ppm) from tetramethylsilane. 
Elemental analyses of the compounds were found within ±0.4% of the theoretical values. The purity of 
tested compounds was found to be >95% by high pressure liquid chromatography (HPLC) analysis. The 
HPLC system used (Thermo Fisher Scientific Inc. Dionex UltiMate 3000) consisted of a SR-3000 solvent rack, 
a LPG-3400SD quaternary analytical pump, a TCC-3000SD column compartment, a DAD-3000 diode array 
detector, and an analytical manual injection valve with a 20 μL loop. Samples were dissolved in acetonitrile 
at 10 mg/mL. HPLC analysis was performed by using a Thermo Fisher Scientific Inc. Acclaim 120 C18 
reversed-phase column (5 μm, 4.6 mm × 250 mm) at 30 ± 1 °C with an isocratic gradient (acetonitrile:water 
= 90:10), flow rate of 1.0 mL/min, and signal detector at 254 and 365 nm. Chromatographic data were 
acquired and processed by Thermo Fisher Scientific Inc. Chromeleon 6.80 software. 
General Procedure for the Preparation of Compounds 2−5 and 16. Example: 4-(2,2-Diphenylethylidene)-3-
methyl-1-(4-phenylthiazol- 2-yl)-1H-1H-pyrazol-5(4H)-one (2). A mixture of 17 (0.21 g, 0.00084 mol), 2,2-
diphenylacetaldehyde (0.16 g, 0.15 mL, 0.84 mmol), and piperidine (0.071 g, 0.08 mL, 0.84 mmol) in 
ethanol (0.5 M) were heated to reflux for 3 h and evaporated. The residue was purified by column 
chromatography (silica gel, dichloromethane:methanol = 99:1 as eluent) to furnish 2 (0.17 g, 47%), mp >220 
°C with decomposition (from ethanol). 1H NMR (DMSO-d6): δ 1.53 (s, 3H), 6.49 (s, 1H), 7.16 (d, J = 3.7 Hz, 
2H), 7.22−7.38 (m, 10H), 7.43 (t, J = 7.4 Hz, 2H), 7.72 (s, 1H), 7.96 ppm (d, J = 3.8 Hz, 2H). IR: ν 1616 cm−1. 
Anal. (C27H21N3OS (435.54)): C, 74.46; H, 4.86; N, 9.65; S, 7.36. Found: C, 74.44; H, 4.83; N, 9.69; S, 7.34. 
MS (ESI) calcd for C27H21N3OS: 435.1; found (M + H)+: 436.1. 
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4-([1,1′-Biphenyl]-4-ylmethylene)-3-methyl-1-(4-phenylthiazol-2-yl)-1H-pyrazol-5(4H)-one (3). It was 
synthesized as 2 starting from 17 and [1,1′-biphenyl]-4-carbaldehyde. Yield 61%, mp >270 °C with 
decomposition (from ethanol). 1H NMR (DMSO-d6): δ 2.13 (s, 3H), 7.29−7.38 (m, 4H), 7.40−7.48 (m, 5H), 
7.58−7.68 (m, 4H), 7.72 (s, 1H), 7.98 (d, J = 3.7 Hz, 2H). IR: ν 1625 cm−1. Anal. (C26H19N3OS (421.51)): C, 
74.08; H, 4.54; N, 9.97; S, 7.61. Found: C, 74.04; H, 4.58; N, 9.92; S, 7.59. MS (ESI) calcd for C26H19N3OS: 
421.1; found (M + H)+: 422.3. 
 
 
 
3-Methyl-4-(naphthalen-2-ylmethylene)-1-(4-phenylthiazol-2-yl)-1H-pyrazol-5(4H)-one (4). It was 
synthesized as 2 starting from 17 and 2-naphthaldehyde. Yield 37%, mp >270 °C with decomposition (from 
ethanol). 1H NMR (DMSO-d6): δ 2.07 (s, 3H), 7.29−7.38 (m, 1H), 7.39−7.50 (m, 5H), 7.70 (s, 1H), 7.75 (s, 1H), 
7.80−7.90 (m, 3H), 7.93−8.03 ppm (m, 3H). IR: ν 1615 cm−1. Anal. (C24H17N3OS (395.48)): C, 72.89; H, 
4.33; N, 10.63; S, 8.11. Found: C, 72.86; H, 4.31; N, 10.59; S, 8.09. MS (ESI) calcd for C24H17N3OS:, 395.1; 
found(M + H)+: 396.1. 
 
 
 
4-((1H-Imidazol-2-yl)methylene)-3-methyl-1(4-phenylthiazol-2-yl)-1H-pyrazol-5(4H)-one (5). It was 
synthesized as 2 starting from 17 and 1H-imidazole-2-carbaldehyde. Yield 28%, mp 189−191 °C (from 
ethanol). 1H NMR (DMSO-d6): δ 1.98 (s, 3H), 7.18 (s, 1H), 7.26− 7.48 (m, 5H), 7.62 (d, J = 3.6 Hz, 1H), 7.69 (s, 
1H), 7.92 ppm (d, J = 3.8 Hz, 2H). IR: ν 1615 cm−1. Anal. (C17H13N5OS (335.38)): C,60.88; H, 3.91; N, 20.88; 
S, 9.56. Found: C, 60.87; H, 3.90; N, 20.86;S, 9.54. MS (ESI) calcd for C17H13N5OS: 335.1; found (M + 
H)+:336.2. 
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4-Benzylidene-3-methyl-1-(4-phenylthiazol-2-yl)-1H-pyrazol-5(4H)-one (16). It was synthesized as 2 starting 
from 17 and benzaldehyde. Yield 30%, mp >270 °C with decomposition (from ethanol). 1H NMR (DMSO-d6): 
δ 2.07 (s, 3H), 7.17−7.23 (m, 1H),7.24−7.35 (m, 5H), 7.39−7.46 (m, 3H), 7.70 (s, 1H), 7.97 ppm (d, J= 3.7 Hz, 
2H). IR: ν 1360, 1495, 1622 cm−1. Anal. (C20H15N3OS (345.42)): C, 69.54; H, 4.38; N, 12.17; S, 9.28. Found: 
C, 69.50; H, 4.36; N, 12.17; S, 9.26. MS (ESI) calcd for C20H15N3OS: 345.1; found (M + H)+: 346.2 
 
 
 
4-(2-(2-Ethoxyphenyl)acetyl)-3-methyl-1-(4-phenylthiazol-2-yl)-1H-pyrazol-5(4H)-one (6). A suspension of 
potassium tert-butoxide (0.13 g, 1.2 mmol) in anhydrous tetrahydrofuran (15.0 mL) was cooled at −40 °C, 
and a solution of 17 (0.25 g, 0.97 mmol) in the same solvent (10.0 mL) was added dropwise under Ar 
stream. The reaction mixture was stirred in the same conditions for 1 h, and a solution of 2-(2-
ethoxyphenyl)acetyl chloride (0.31 g, 1.2 mmol) in the same solvent (5.0 mL) was added dropwise. The 
reaction mixture was stirred at 25 °C for 1 h, diluted with water, and extracted with ethyl acetate. Organic 
layer was washed with brine, dried, and filtered. Evaporation of the solvent gave a residue that was purified 
by column chromatography (silica gel, ethyl acetate:n-hexane = 1:1 as eluent) to furnish 6 (0.3 g, 74%), mp 
105−110 °C (from ethanol). 1H NMR (DMSO-d6): δ 1.22 (t, J = 6.9 Hz, 3H), 2.25 (s, 3H), 3.97−4.02 (m,4H), 
6.26 (s, 1H), 6.85 (t, J = 7.3 Hz, 1H), 6.99 (d, J = 8.2 Hz, 1H),7.16 (d, J = 6.4 Hz, 1H), 7.24 (t, J = 8.0 Hz, 1H), 
7.40 (t, J = 7.2 Hz,1H), 7.50 (t, J = 7.8 Hz, 2H), 7.90−7.94 ppm (m, 3H). IR: ν 1780,1784 cm−1. Anal 
(C23H21N3O3S (419.50)): C, 65.85; H, 5.05; N, 10.02; S, 7.64. Found: C, 65.80; H, 5.02; N, 10.06; S, 7.60. MS 
(ESI) calcd for C23H21N3O3S: 419.1; found (M + H)+: 420.0. 2-(2-Ethoxyphenyl)acetyl chloride: A mixture of 
2-(2-hydroxyphenyl)aceticacid (2.0 g, 13 mmol) and 37% hydrochloric acid (1.2 mL) in 96 °ethanol (70.0 mL) 
was heated to reflux for 3 h, cooled, diluted with water, and extracted with ethyl acetate. The organic layer 
was washed with brine, dried, and filtered. Removal of the solvent gave ethyl 2-(2-hydroxyphenyl)acetate 
(2.22 g, 94%), mp 65−67 °C (from petroleum ether), lit. 67−68 °C [154]. A mixture of ethyl 2-(2-
hydroxyphenyl)acetate (2.22 g, 12 mmol), anhydrous potassium carbonate (3.69 g, 26 mmol),and 
iodoethane (4.11 g, 2.1 mL, 26 mmol) in anhydrous N,Ndimethylformamide (10.0 mL) was heated at 50 °C 
for 12 h. After cooling, the reaction mixture was diluted with water and extracted with ethyl acetate. The 
organic layer was washed with brine, dried, and filtered. Removal of the solvent gave a residue that was 
purified by column chromatography (silica gel, ethyl acetate:n-hexane = 3:7 as eluent) to furnish ethyl 2-(2-
ethoxyphenyl)acetate (2.22 g, 86%), oil. 1H NMR (DMSO-d6): δ 1.16 (t, J = 7.1 Hz, 3H), 1.27 (t, J = 6.9 Hz, 
3H), 3.55 (s, 2H), 3.96−4.07 (m, 4H), 6.86 (t, J = 7.4 Hz, 1H), 6.93 (d, J = 8.1 Hz, 1H), 7.15−7.23 ppm (m, 2H). 
IR: ν 1733 cm−1. A mixture of ethyl 2-(2-ethoxyphenyl)acetate (4.86 g, 23 mmol) in 3N sodium 
hydroxide/96° ethanol (1:1, v/v) (180.0 mL) was heated to reflux for 12 h. After cooling, the reaction 
mixture was made acidic with 6N hydrogen chloride and extracted with ethyl acetate. The organic layer was 
washed with brine, dried, and filtered. Removal of the solvent gave 2-(2-ethoxyphenyl)acetic acid (3.50 g, 
83%), mp 99−102 °C (from ethanol), lit 103 °C. [155] 1H NMR (DMSO-d6): δ 1.28 (t, J= 6.7 Hz, 3H), 3.48 (s, 
2H), 3.98 (q, J = 6.8 Hz, 2H), 6.85 (t, J = 6.9Hz, 1H), 6.93 (d, J = 8.0 Hz, 1H), 7.14−7.31 (m, 2H), 12.13 
ppm(broad s, disappeared on treatment with D2O, 1H). IR: ν 1730, 2987 cm−1. To a mixture of 2-(2-
ethoxyphenyl)acetic acid (0.21 g, 1.2 mol) in anhydrous benzene (9.0 mL) was added thionyl chloride (1.45 
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g, 0.9 mL, 12 mmol). The reaction mixture was stirred at 25 °C for 1 h and evaporated to give 2-(2-
ethoxyphenyl)acetyl chloride that was used without further purification. 
 
 
 
1-(2-Ethoxyphenyl)-2-(3-methyl-5-oxo-1-(4-phenylthiazol-2-yl)-4,5-dihydro-1H-pyrazol-4-yl)ethane-1,2-dione 
(7). A mixture of 6 (0.25 g, 0.59 mmol), potassium permanganate (0.38 g, 2.4 mmol), and a catalytic amount 
of 98% sulfuric acid in acetone (10.0 mL) was heated to reflux for 12 h. Removal of the solvent gave a 
residue that was purified by column chromatography (silica gel, ethyl acetate:nhexane = 3:7 as eluent) to 
furnish 7 (0.013 g, 5%), mp 108−110 °C (from ethanol). 1H NMR (DMSO-d6): δ 1.22 (t, J = 6.8 Hz, 3H), 2.29(s, 
3H), 4.06 (d, J = 6.7 Hz, 2H), 6.39 (s, 1H), 7.12−7.28 (m, 5H),7.53 (d, J = 7.4 Hz, 2H), 7.74 (m, 1H), 7.86 (s, 1H), 
8.19 ppm (d, J =6.6 Hz, 1H). IR: ν 1215, 2926 cm−1. Anal. (C23H19N3O4S (433.48)):C, 63.73; H, 4.42; N, 9.69; 
S, 7.40. Found: C, 63.70; H, 4.39; N, 9.72;S, 7.38. MS (ESI) calcd for C23H19N3O4S: 433.1; found (M + 
H)+:434.4. 
 
 
 
General Procedure for the Preparation of Compounds 8, 12,15, and 22−26.  
Example: 1-(4′-(Dimethylamino)-5-hydroxy-[1,1’-biphenyl]-3-yl)-4-(2-(2-ethoxyphenyl)hydrazono)-3-
methyl-1H-pyrazol-5(4H)-one (8) A mixture of 20 (0.07 g, 0.17 mmol), 2 M sodium carbonate (0.3 mL), and 
(4-(dimethylamino)phenyl)boronic acid (0.034 g, 0.21 mmol) in tetrahydrofuran (0.6 mL) was degassed for 
10 min. Dichloro[1,1′-bis(diphenylphosphino)ferrocene]-palladium(II)(0.0082 g, 0.01 mmol; complex with 
dichloromethane (1:1), Pd13%) was added, and the reaction mixture was stirred at reflux temperature for 
90 min under Ar stream, cooled, diluted with water, and extracted with ethyl acetate. Organic layer was 
washed with brine,dried, and filtered. Removal of the solvent gave a residue that was purified by column 
chromatography (silica gel, ethyl acetate:n-hexane= 7:3 as eluent) to furnish 8 (0.010 g, 13%), mp 230−232 
°C (from ethanol). 1H NMR (DMSO-d6): δ 1.42 (t, J = 7.1 Hz, 3H), 2.32−2.49 (m, 6H), 2.94 (s, 3H), 4.23 (q, J = 
7.1 Hz, 2H), 6.78−6.80 (m, 2H), 7.08 (s, 1H), 7.20 (s, 2H), 7.35 (s, 1H), 7.44−7.46 (d, J = 7.8 Hz, 2H), 7.53−7.70 
(m, 3H), 9.71 (broad s, disappeared on treatment with D2O, 1H), 13.60 ppm (broad s, disappeared on 
treatment with D2O,1H). 13C NMR (DMSO-d6): δ 11.97, 15.08, 40.47, 65.12, 103.47, 106.73, 109.75, 113.05, 
113.72, 114.72, 122.08, 126.70, 127.49, 128.04, 129.12, 130.59, 139.66, 142.67, 147.58, 148.34, 157.71, 
158.55. IR: ν 1656, 2854, 2924 cm−1. Anal. (C26H27N5O3 (457.52)): C, 68.25; H, 5.95; N, 15.31. Found: C, 
68.22; H, 5.90; N, 15.29. HRMS (ESI) calcd for C26H27N5O3: 457.2114; found (M − H)−: 456.2021. 
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2-(3′-Amino-5-hydroxy-[1,1′-biphenyl]-3-yl)-4-(2-(2-ethoxyphenyl)hydrazono)-5-methyl-2,4-dihydro-3H-
pyrazol-3-one(12). It was synthesized as 8 starting from 20 and (3-aminophenyl)-boronic acid. Yield 66%, 
mp 180−183 °C (from ethanol). 1H NMR (DMSO-d6): δ 1.42 (t, J = 7.2 Hz, 3H), 2.31 (s, 3H), 4.21 (q, J = 7.1 Hz, 
2H), 5.19 (broad s, disappeared on treatment with D2O, 2H), 6.56 (d, J = 6.9 Hz, 1H), 6.70 (d, J = 7.3 Hz, 1H), 
6.76−6.80 (m, 2H),7.03−7.11 (m, 2H), 7.19 (s, 2H), 7.44 (s, 1H), 7.52 (s, 1H), 7.71 (d, J= 8.3 Hz, 1H), 9.75 
(broad s, disappeared on treatment with D2O,1H), 13.59 ppm (broad s, disappeared on treatment with 
D2O, 1H). IR: ν 1693, 2852, 2922, 3271 cm−1. Anal. (C24H23N5O3 (429.48)): C, 67.12; H, 5.40; N, 16.31. 
Found: C, 67.10; H, 5.38; N, 16.29. MS (ESI) calcd for C23H19N3O4S: 429.2; found (M + H)+: 430.1. 
 
 
 
2-(4′-(Dimethylamino)-5-hydroxy-[1,1′-biphenyl]-3-yl)-5-methyl-4-(2-(naphthalen-2-yl)hydrazono)-2,4-
dihydro-3H-pyrazol-3-one(15). It was synthesized as 8 starting from 21 and (4-(dimethylamino) 
phenyl)boronic acid. Yield 18%, mp 221−226 °C (from ethanol). 1H NMR (DMSO-d6): δ 2.35 (s, 3H), 2.93 (s, 
6H), 3.76−6.81 (m, 3H),7.29 (s, 1H), 7.38−7.49 (m, 3H), 7.54−7.56 (m, 1H), 7.70 (s, 1H),7.85−7.93 (m, 3H), 
8.00−8.07 (m, 2H), 9.67 (broad s, disappeared on treatment with D2O, 1H), 13.59 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR: ν 1655, 1736, 2852, 2922, cm−1. Anal.(C28H25N5O2 (463.20)): C, 
72.55; H, 5.44; N, 15.11. Found: C, 72.53; H, 5.46; N, 15.10. MS (ESI) calcd for C28H25N5O2: 463.2; found (M + 
H)+: 463.3. 
 
 
 
1-(5-Hydroxy-[1,1′-biphenyl]-3-yl)-3-methyl-1H-pyrazol-5(4H)-one (22). It was synthesized as 8 starting 
from 19 and phenylboronic acid. Yield 60%, mp 160−163 °C (from ethanol). 1H NMR (DMSOd6): δ 2.36 (s, 
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3H), 6.88 (s, 1H), 7.35−7.37 (m, 2H), 7.43−7.46 (m,3H), 7.60−7.62 (m, 3H), 9.84 (broad s, disappeared on 
treatment with D2O, 1H), 12.12 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 1599, 1685, 
3063 cm−1. 
 
 
 
1-(3-Hydroxy-5-(thiophen-2-yl)phenyl)-3-methyl-1H-pyrazol- 5(4H)-one (23). It was synthesized as 8 starting 
from 19 and thiophen-2-ylboronic acid. Yield 32%, mp 175−178 °C (from ethanol). 1H NMR (DMSO-d6): δ 
2.10 (s, 3H), 5.37 (s, 1H), 6.87 (s, 1H), 7.12−7.16 (m, 2H), 7.41−7.45 (m, 2H), 7.53 (s, 1H), 9.78 (broad s, 
disappeared on treatment with D2O, 1H), 11.56 ppm (broad s, disappeared on treatment with D2O, 1H). IR: 
ν 1587, 1679, 3091cm−1. 
 
 
 
2-(5-Hydroxy-4′-isopropyl-[1,1′-biphenyl]-3-yl)-5-methyl-2,4-dihydro-3H-pyrazol-3-one (24). It was 
synthesized as 8 starting from 19 and (4-isopropylphenyl)boronic acid and was used without further 
purification.  
 
 
 
3-Nitro-5-(pyridin-4-yl)phenol (25). It was synthesized as 8 starting from 3-bromo-5-nitrophenol [156] and 
pyridin-4-ylboronic acid. Yield14%, mp 200 °C with decomposition (from ethanol). 1H NMR (DMSO-d6): δ 
7.56−7.61 (m, 1H), 7.63−7.64 (m, 1H), 7.74−7.75 (m, 2H), 7.98−8.00 (m, 1H), 8.64−8.67 ppm (m, 2H), 10.76 
ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 2923 cm−1. 
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4′-(Dimethylamino)-5-nitro-[1,1′-biphenyl]-3-ol (26). It was synthesized as 8 starting from 1-bromo-3-
nitrobenzene and (4-(dimethylamino)phenyl)boronic acid. Yield 25%, mp 130−134 °C (from ethanol). 1H 
NMR (DMSO-d6): δ 2.95 8s, 6H), 6.80−6.84 (m, 2H), 7.61−7.68 (m, 3H), 8.04−8.07 (m, 2H), 8.33 ppm (m, 
1H). 
 
 
 
General Procedure for the Preparation of Compounds 9−11, 13, 14, 20, and 21. 
Example: 4-(2-(2-Ethoxyphenyl)-hydrazono)-1-(5-hydroxy-[1,1′-biphenyl]-3-yl)-3-methyl-1H-pyrazol- 5(4H)-
one (9). A mixture of 22 (0.054 g, 0.000203 mol) and sodium acetate (0.028 g, 0.20 mmol) in 96° ethanol 
(1.1 mL) was cooled at 0 °C. 2-Ethoxybenzenediazonium chloride (0.02 mmol) was added, and the reaction 
mixture was stirred at the same temperature for 2 h, diluted with water, and extracted with ethyl acetate. 
The organic layer was washed with brine, dried, and filtered. Removal of the solvent gave a residue that 
was purified by column chromatography (silica gel, ethyl acetate:n-hexane = 7:3 as eluent) to furnish 9 
(0.070 g, 8%), mp 163−166 °C (from ethanol). 1H NMR (DMSO-d6): δ 1.42 (t, J = 6.9 Hz, 3H), 2.32 (s, 3H), 
4.22 (q, J = 7.0 Hz, 2H), 6.86 (s, 1H), 7.06−7.08 (m, 1H), 7.19−7.21 (m, 2H), 7.36−7.38 (m, 1H), 7.47−7.49 (m, 
3H), 7.58−7.60 (m, 3H), 7.69−7.71 ppm (m, 1H),9.84 (broad s, disappeared on treatment with D2O, 1H), 
13.59 ppm(broad s, disappeared on treatment with D2O, 1H). IR: ν 1594, 1663,2924, 3149 cm−1. Anal. 
(C24H22N4O3 (414.46)): C, 69.55; H, 5.35; N,13.52. Found: C, 69.53; H, 5.30; N, 13.54. MS (ESI) calcd for 
C24H22N4O3: 414.2; found (M + H)+: 415.1. 2-Ethoxybenzenediazonium chloride: 1-Ethoxy-2-nitrobenzene 
was synthesized as ethyl 2-(2- ethoxyphenyl)acetate starting from 2-nitrophenol and iodoethane. Yield 
90%, yellow oil [157]. A solution of 1-ethoxy-2-nitrobenzene (0.10 g,0.6 mmol) in methanol (15.0 mL) was 
treated with hydrogen gas (30psi) in the presence of palladium on carbon (0.01 g) at 25 °C for 2 h,filtered, 
and evaporated to give 2-ethoxyaniline that was used without further purification. To a cold solution of 
crude 2-ethoxyaniline (0.05 g, 0.36 mmol) in 37% hydrogen chloride (0.7 mL), a solution of sodium nitrite 
(0.025 g, 0.36 mmol) in water (0.2 mL) was added dropwise. The reaction mixture was stirred at 0 °C for 20 
min to give 2-ethoxybenzenediazonium chloride that was used without further purification. 
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4-(2-(2-Ethoxyphenyl)hydrazono)-1-(3-hydroxy-5-(pyridin-4-yl)-phenyl)-3-methyl-1H-pyrazol-5(4H)-one (10). 
It was synthesized as 9 starting from 29 and 2-ethoxybenzenediazonium chloride. Yield 36%, slurry. 1H NMR 
(DMSO-d6): δ 1.43 (t, J = 7.0 Hz, 3H), 2.33 (s, 3H), 4.24 (q, J = 7.0 Hz, 2H), 7.10−7.12 (m, 2H), 7.20−7.22 (m, 
2H), 7.71−7.78 (m, 3H), 8.00−8.10 (m, 2H), 8.84−8.86 (m, 2H), 10.22 (broad s, disappeared on treatment 
with D2O, 1H), 13.55 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 1732, 2583, 2855, 2896 
cm−1. Anal. (C23H21N5O3 (415.44)): C, 66.49; H, 5.09; N, 16.86. Found: C, 66.47; H, 5.11; N, 16.84. MS (ESI) 
calcd for C23H21N5O3: 415.2; found (M + H)+: 415.9. 
 
 
 
4-(2-(2-Ethoxyphenyl)hydrazono)-1-(3-hydroxy-5-(thiophen-2-yl)phenyl)-3-methyl-1H-pyrazol-5(4H)-one 
(11). It was synthesized as 9 starting from 23 and 2-ethoxybenzenediazonium chloride. Yield 3%, mp 165−
167 °C (from ethanol). 1H NMR (DMSO-d6): δ 1.42 (t, J = 7.0 Hz, 3H), 2.32 (s, 3H), 4.22 (q, J = 7.1 Hz, 2H), 
6.90 (s, 1H), 7.08−7.09 (m, 1H), 7.14−7.15 (m, 1H), 7.20−7.22 (m, 2H), 7.42− 7.44 (m, 2H), 7.55−7.56 (m, 
1H), 7.61−7.63 (m, 1H), 7.69−7.71 (m, 1H), 9.89 (broad s, disappeared on treatment with D2O, 1H), 13.59 
ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 1661, 1730, 2854, 2923, 2956 cm−1. Anal. 
(C22H20N4O3S (420.48)): C, 62.84; H, 4.79; N, 13.32; S, 7.63. Found: C, 62.82; H, 4.78; N, 13.29; S, 7.61. MS 
(ESI) calcd for C22H20N4O3S: 420.1; found (M + H)+: 421.0. 
 
 
 
4-(2-(2-Ethoxyphenyl)hydrazono)-1-(5-hydroxy-4′-isopropyl- [1,1′-biphenyl]-3-yl)-3-methyl-1H-pyrazol-
5(4H)-one (13). It was synthesized as 9 starting from 24 and 2-ethoxybenzenediazonium chloride. Yield 17%, 
slurry. 1H NMR (DMSO-d6): δ 1.22 (s, 3H), 1.24 (s, 3H), 1.42 (t, J = 7.0 Hz, 3H), 1.98 (s, 3H), 2.91−2.94 (m, 1H) 
4.02 (q, J = 6.2 Hz, 2H), 6.84−6.86 (m, 1H), 7.08−7.10 (m, 1H), 7.19−7.21 (m, 2H), 7.33−7.35 (m, 2H), 7.44−
7.46 (m, 1H), 7.50− 7.53 (m, 2H), 7.58−7.60 (m, 1H), 7.70−7.72 (m, 1H), 9.79 (broad s,disappeared on 
treatment with D2O, 1H), 13.59 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 1655, 1728, 
2854, 2924, 2958 cm−1. Anal. (C27H28N4O3 (456.54)): C, 71.03; H, 6.18; N, 12.27. Found: C, 71.00; H, 6.16; N, 
12.29. MS (ESI) calcd for C27H28N4O3: 456.2; found (M + H)+: 456.3. 
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1-(4′-(Dimethylamino)-[1,1′-biphenyl]-3-yl)-4-(2-(2- ethoxyphenyl)hydrazono)-3-methyl-1H-pyrazol-
5(4H)-one (14). It was synthesized as 9 starting from 30 and 2-ethoxybenzenediazonium chloride. Yield 
47%, 230−232 °C (from ethanol). 1H NMR (DMFd7): δ 1.67 (t, J = 7.0 Hz, 3H), 2.56 (s, 3H), 3.18 (s, 6H), 4.47 
(q, J =6.9 Hz, 2H), 7.06 (d, J = 8.8 Hz, 2H), 7.28−7.30 (m, 1H), 7.40−7.43 (m, 2H), 7.67−7.69 (m, 2H), 7.76−
7.78 (d, J = 8.9 Hz, 2H), 7.96 (d, J = 7.5 Hz, 1H), 8.01−8.13 (m, 1H), 8.41 (s, 1H), 13.98 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR: ν 1652, 1713, 2851, 2922 cm−1. Anal. (C26H27N5O2 (441.52)): C, 
70.73; H, 6.16; N, 15.86. Found: C, 70.71; H, 6.14; N, 15.84. MS (ESI) calcd for C26H27N5O2: 441.2; found (M + 
H)+: 441.3. 
 
 
 
1-(3-Bromo-5-hydroxyphenyl)-4-(2-(2-ethoxyphenyl)hydrazono)- 3-methyl-1H-pyrazol-5(4H)-one (20). It was 
synthesized as 9 starting from 19 and 2-ethoxybenzenediazonium chloride. Yield 48%, mp 215−217 °C (from 
ethanol). 1H NMR (DMSO-d6): δ 1.43 (t, J = 7.0 Hz, 3H), 2.29 (s, 3H), 4.22 (q, J = 6.9 Hz, 2H), 6.78 (s, 1H), 7.06
−7.09 (m, 1H), 7.19−7.21 (m, 2H), 7.45 (s, 1H), 7.55 (s, 1H), 7.69−7.70 (m, 1H), 10.15 (broad s, disappeared 
on treatment with D2O,1H), 13.50 ppm (broad s, disappeared on treatment with D2O, 1H).IR: ν 1661, 2934, 
2979, 3121 cm−1. 
 
 
 
1-(3-Bromo-5-hydroxyphenyl)-3-methyl-4-(2-(naphthalen-2-yl)-hydrazono)-1H-pyrazol-5(4H)-one (21). It 
was synthesized as 9 starting from 19 and naphthalene-2-diazonium chloride. Yield 7%, mp233−237 °C 
(from ethanol). 1H NMR (DMSO-d6): δ 1.22 (s, 3H),6.78 (s, 1H), 7.43−7.47 (m, 2H), 7.52−7.55 (m, 1H), 7.64−
7.66 (m,2H), 7.5−7.87 (m, 1H), 7.90−7.92 (m, 2H), 8.01−8.20 (m, 1H), 8.07(broad s, disappeared on 
treatment with D2O, 1H), 10.16 ppm (broads, disappeared on treatment with D2O, 1H). IR: ν 1731, 2853, 
2922 cm−1. 
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General Procedure for the Preparation of Compounds 17,19, 29, and 30.  
Example: 3-Methyl-1-(4-phenylthiazol-2-yl)-1Hpyrazol- 5(4H)-one (17). A solution of 2-hydrazinyl-4-
phenylthiazole(0.50 g, 2.6 mmol) and ethyl acetoacetate (0.26 g, 0.3 mL, 2.6 mmol)in glacial acetic acid (5.0 
mL) was heated to reflux for 3 h. After evaporation of the solvent, the residue was treated with a saturated 
aqueous solution of sodium hydrogen carbonate and extracted with ethyl acetate. The organic layer was 
washed with brine, dried, and filtered. Removal of the solvent gave a residue that was purified by column 
chromatography (silica gel, ethyl acetate:n-hexane = 2:1 as eluent) to furnish 16 (0.42 g, 62%), mp 188−192 
°C (from ethanol), lit. 188−189 °C. [156] . 
 
 
 
2-(3-Bromo-5-hydroxyphenyl)-5-methyl-2,4-dihydro-3H-pyrazol-3-one (19). It was synthesized as 17, starting 
from 18 and ethyl acetoacetate. Yield 13%, mp 170−172 °C (from ethanol). 1H NMR (DMSO-d6): δ 2.06 (s, 
3H), 5.35 (s, 1H), 6.73 (s, 1H), 7.23−7.35 (m, 2H), 10.04 (broad s, disappeared on treatment with D2O, 1H), 
11.72 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 1730, 2952, 3160 cm−1. 
 
 
 
1-(3-Hydroxy-5-(pyridin-4-yl)phenyl)-3-methyl-1H-pyrazol-5(4H)- one (29). It was synthesized as 17, starting 
from 27 and ethyl acetoacetate. Yield 13%, mp 250 °C with decomposition (from ethanol). 1H NMR (DMSO-
d6): δ 2.09 (s, 3H), 5.38 (s, 1H), 6.92− 6.95 (m, 1H), 7.30−7.32 (m, 1H), 7.52−7.59 (m, 3H), 8.60−8.62 (m, 2H), 
9.89 (broad s, disappeared on treatment with D2O, 1H), 11.57 ppm (broad s, disappeared on treatment 
with D2O, 1H). IR: ν 1736, 2854, 2923, 2932 cm−1. 
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1-(4′-(Dimethylamino)-[1,1′-biphenyl]-3-yl)-3-methyl-1H-pyrazol-5(4H)-one (30). It was synthesized as 
17, starting from 28 and ethyl acetoacetate. Yield 12%, slurry. 1H NMR (DMSO-d6): δ 2.12 (s, 3H), 2.94 (s, 
6H), 5.43 (s, 1H), 6.80 (d, J = 8.8 Hz, 2H), 7.39−7.41 (m, 2H), 7.49−7.53 (m, 3H), 7.87 (s, 1H), 11.51 ppm 
(broad s disappeared on treatment with D2O, 1H). IR: ν 1715, 2803, 2852, 2921 cm−1. 
 
 
 
 
General Procedure for the Preparation of Compounds 18,27, and 28.  
Example: 3-Bromo-5-hydrazinylphenol Hydrochloride(18). A mixture of 3-bromo-5-nitrophenol [158] (1.0 g, 
4.6 mmol) and tin(II) chloride dihydrate (5.17 g, 23 mmol) in ethyl acetate (30.0 mL) was heated to reflux 
for 3 h. After cooling, the reaction mixture was made basic with a saturated aqueous solution of sodium 
hydrogen carbonate and the resulting suspension filtered. Layers were separated and the organic one 
washed with brine, dried, and filtered. Removal of the solvent gave 3-amino-5-bromophenol (0.86 g) that 
was used without further purification. To a cold solution of crude 3-amino-5- bromophenol (0.86 g, 4.5 
mmol) in 37% hydrogen chloride (9.4 mL), a solution of sodium nitrite (0.32 g, 4.6 mmol) in water (2.3 mL) 
was added dropwise. The reaction mixture was stirred at 0 °C for 20 min, and a solution of tin(II) chloride 
dihydrate (2.30 g, 10 mmol) in 37% hydrogen chloride was added dropwise. The reaction mixture was 
stirred at the same temperature for additional 20 min and resulting suspension filtered to give 18 (0.93 g) 
that was used without further purification. 
 
 
 
3-Hydrazinyl-5-(pyridin-4-yl)phenol Hydrochloride (27). It was synthesized as 18 starting from 25 and was 
used without further purification. 
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3′-Hydrazinyl-N,N-dimethyl-[1,1′-biphenyl]-4-amine Hydrochloride (28). It was synthesized as 18 starting 
from 26 and was used without further purification. 
 
 
 
Peptide Synthesis. Nα-Fmoc-protected amino acids, Fmoc-Rink Amide-Am resin, O-benzotriazole-N,N,N
′,N′-tetramethyl-uroniumhexafluorophosphate(HBTU), N,N-diisopropylethylamine 
(DIEA),triisopropylsilane (TIS), trifluoroacetic acid (TFA), and piperidine were purchased from IRIS Biotech, 
N-hydroxybenzotriazole (HOBt),N,N-dimethylformamide (DMF), dichloromethane (DCM), andfluorescein-5-
isothiocyanate (FITC) from Organics (Morris Plains).For Nα-Fmoc-protected amino acids, the following side 
chain protecting groups were used: Arg(Pbf), Asn(Trt), Asp(OtBu), Gln(Trt), Trp(Nin-Boc), and Tyr(tBu). 
Solvents and reagents were reagent grade and used without further purification unless otherwise noted. 
Peptides were analyzed by analytical HPLC (Shimadzu Prominance HPLC system) equipped with a C18-
bounded analytical reverse-phase HPLC column (Phenomenex Luna, 4.6 mm × 250 mm 5 μM) using a 
gradient elution (10−90% acetonitrile in water (0.1% TFA) over 20 min; flow rate = 1.0 mL/min; diode array 
UV detector). Peptides were purified by preparative HPLC (Shimadzu HPLC system) equipped with a C18-
bounded preparative reverse-phase HPLC column (Phenomenex Kinetex 21.2 mm × 150 mm 5 μm). 
Molecular weights of compounds were confirmed by ESI-mass spectrometry using an Agilent 6110 
quadrupole LC/MS system.Peptide syntheses were performed manually by a stepwise solidphase 
procedure using 0.1 mmol Rink Amide aminomethylpolystyrene resin (0.48 mmol/g). The linear sequence 
was synthesized by introducing each amino acid with the following protocols: (1) deprotection of Nα-Fmoc 
protecting group by the treatment with piperidine (20% in DMF; 1 × 5 min and 1 × 25 min), and (2) coupling 
reaction using Fmoc-AA (4 equiv) in the presence of HBTU (152 mg, 4 equiv), HOBt (54 mg, 4 equiv), and 
DIEA (140 μL, 8 equiv) in DMF (2 mL) for 2 h at room temperature. The coupling efficiency for each amino 
acid was determined by the quantitative ninhydrin test and TNBS test. Next, for the peptide BIM-RIF, the 
Nα- Fmoc of the last amino acid was removed and the free amino group was acetylated with acetic 
anhydride (96 μL, 8 equiv) and DIPEA (174 μL, 4 equiv) in DCM (4 mL) for 30 min. For FITC-BIM, once amino 
hexanoic acid (Ahx) was introduced as spacer, the peptide was fluorescently labeled by mixing the resin 
with of fluorescein-5- isothiocyanate (FITC) (238 mg, 6 equiv) and DIEA (210 μL, 12 equiv) in minimal DMF 
for 12 h in the dark. Finally, both the peptides were cleaved from the resin by the treatment with 
TFA/TIS/water (10mL, 90:5:5) for 3 h at room temperature. Then, the resin was filtered and the TFA 
solution and the peptide was precipitated by adding cold diethyl ether (40 mL) and centrifuged. Crude 
peptide extracts were then analyzed by analytical reverse-phase HPLC. Analytical separations were 
conducted in 0.1% TFA with an acetonitrile gradient (10−90%) acetonitrile in water over 20 min, flow rate 
of 1.0 mL/min) on a Phenomenex C18 column (0.46 mm × 150 mm 5 μm). After analytical analysis, the 
crude peptide was purified by preparative chromatography in 0.1% TFA with an acetonitrile gradient (10−
90% acetonitrile in water over 15 min, flow rate of 15 mL/min) on a Phenomenex Kinetex C18 column (21.2 
mm × 150 mm 5 μm). 
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Acetylated-BIM (Ac-BIM) (Ac-DMRPEIWIAQELRRIGDEFNAYYARRNH2). Purity >95%, tR 16.2 min (analytical 
HPLC, 10−90% acetonitrile in water (0.1% TFA) over 20 min, flow rate of 1.0 mL/min); molecular formula, 
C147H225N45O41S; calculated mass, 3308.7; found, 1104.4 (M + 3H)/3, 828.4 (M + 4)/4. 
FITC-BIM (FITC-Ahx-EIWIAQELRRIGDEFNAYYARR-NH2). Purity >95%, tR 12.3 min (analytical HPLC, 10−90% 
acetonitrile in water (0.1% TFA) over 20 min, flow rate of 1.0 mL/min); molecular formula, C152H212N40O40S; 
calculated mass, 3269.6; found, 1090.8 (M + 3H)/3. 
Molecular Modeling. Molecular docking of 1 and 8 into the solution structure of BAX (PDB code: 2K7W) 
was carried out using the Glide 5.5 program [159].Maestro 9.0.211 [160] was employed as the graphical 
user interface, and Figure 11 was rendered by the Chimera software package [161].The inhibitor structures 
were first generated through the Maestro sketcher and prepared through the LigPrep module. The target 
protein was prepared through the Protein Preparation Wizard of the graphical user interface Maestro and 
the OPLS-2001 force field. Water molecules were removed, hydrogen atoms were added, and minimization 
was performed until the RMSD of all heavy atoms was within 0.3 Å of the crystallographically determined 
positions. The binding pocket was identified by placing a 20 Å cube centered on the BIM helix. Molecular 
docking calculations were performed with the aid of Glide 5.5 in extra-precision (XP) mode, using 
Glidescore for ligand ranking. For multiple ligand docking experiments, an output maximum of 5000 ligand 
poses per docking run with a limit of 100 poses for each ligand was adopted. 
Biology. Reagents. Salt and organic solvents were from Fluka, Sigma-Aldrich (USA), Applichem (Germany), 
and Carlo Erba (Italy). FITC, Texas Red, and HRP conjugated monoclonal and polyclonal secondary 
antibodies were from Sigma-Aldrich (USA). The caspase inhibitor peptide NAc-Asp-Glu-Val-Asp-al (Ac-DEVD-
CHO) was from Sigma. Escherichia coli produced recombinant N-terminal GSTtagged human BAX 
(SRP5166), Bcl-2 (SRP0186), and Bcl-XL (SRP0187) were from Sigma.  
Cell Cultures. HuH7 [81] cells were cultured in DMEM supplemented with 10% FBS. SHSY-5Y [162]were 
cultured in DMEM/F12 medium supplemented with 10% FBS and nonessential amminoacids. NB4 [70] and 
Jurkat [163] cells were cultured in RPMI medium supplemented with 10% FBS. Lewis lung carcinoma cells 
(LLC1), [72] kindly gifted from Prof. Aldo Pinto (Department of Pharmaceutical and Biomedical Sciences, 
University of Salerno, Italy), were cultured in DMEM containing 10% FBS, penicillin (100 U/mL), and 
streptomycin (100 μg/mL). MEF cells wild-type (MEF wt), MEF BCL-2 knockout (MEF Bcl2−/−), MEF BAD 
knockout (MEF Bad−/−), MEF BAX knockout (MEF BAX−/−), MEF BID knockout (MEF Bid−/−), MEF BAK 
knockout (MEF Bak−/−), and MEF BAX/BAK double knockout (MEF BAX−/−BAK−/−) were purchased from 
ATCC (TCP-2110) and grown in IMDM supplemented with 10% FBS supplemented with nonessential 
amminoacids and cultivated according manufacturer procedures. All cultures were grown in an atmosphere 
of 5% CO2 at 37 °C. 
Primary Antibodies. Polyclonal AntiBax N20 (Santa Cruz), monoclonal AntiBax 6A7 (Santa Cruz), polyclonal 
Anti active Casp- 3 (Abgene), and polyclonal anti Cyt-C (Santa Cruz). 
Buffers. Buffer B: 20 mM Tris HCl pH 7.4, NaCl 150 mM, protease inhibitors. Buffer D: 100 mM potassium 
phosphate pH 6.7, 7.5 mM MgCl2, 250 mM sucrose, digitonin 40 μg/mL. Buffer E: 20 mM Hepes KOH pH 
7.4, 150 mM NaCl. Buffer F: 3.7% formaldehyde in PBS pH 7.4. Buffer G: 0.1 M glycine in PBS. Buffer H: 20 
mM Hepes KOH pH 7.4, 120 mM sucrose. Buffer S: 1% SDS in Buffer B. Buffer L: 1% Tryton X-100 in Buffer B. 
Buffer T: 0.1% Triton in PBS pH 7.4. 
Fluorescence Polarization Binding Assay. FITC-BIM direct binding curves to GST-BAX, BCL-2, and BCL-XL 
were generated by incubation of the fluorescent peptide (50 nM) with the indicated dilution of 
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recombinant purified proteins in buffer E. Fluorescent polarization was measured before and after the 
addition of Acetylated- BIM (50 μM). FITC-BIM specific binding was calculated subtracting nonspecific 
binding (measured in the presence of Acetylated-BIM) from total binding (measured in the absence of 
acetylated-BIM). EC50 was calculated by fitting direct total binding data by nonlinear regression analysis of 
dose−response curve using Prism software (GraphPad). Ki was calculated by fitting direct specific binding 
data by nonlinear regression analysis of competitive binding curves. Fluorescent polarization was measured 
with an Envision station (PerkinElmer) using the following setting (excitation filter, FITC-FP- 480 (code: 104) 
(X480; CWL = 480 nm; BW = 30 nm; Tmin = 70%); emission filter (P), FITC FP P-pol 535 (code: 209) (M535p; 
CWL = 535 nm; BW = 40 nm; Tmin = 80%); emission filter (S) FITC FP S-pol 535 (code: 208) (M535s; CWL = 
535 nm; BW = 40 nm; Tmin = 80%) and the mirror modules FP 431 used by top. For competition assays, 
serial dilution of the candidate compounds were obtained by dilution in buffer E supplemented with 50 nM 
FITC-BIM. After 5 min, recombinant proteins were added to the mixture at 1 μM concentration. 
Fluorescence polarization was measured after 30 min of incubation. Measurements were done in 
triplicates, and pKi were calculated fitting the values by nonlinear regression analysis of competitive binding 
curves using Prism software (GraphPad). All the best-fit values reported in Table 1 had SE <10% (the curve 
fitting for competitive binding of compound 3 to BAX has SE <15%, the one of compound 15 for Bcl-2 has SE 
<16%). 
Assessment of Apoptosis Rate. Mother stocks of compounds dissolved in DMSO (30 mM) were diluted in 
complete culture medium. Cells were treated with the diluted compounds for the indicated time. After 
treatment, cells were fixed in buffer F and apoptosis rate was measured by evaluation of nuclear 
fragmentation (visualized by DAPI staining), positivity to antiactive caspase 3 antibody, and blebbing of cell 
membrane. Percent of cells in apoptosis was calculated by counting cells from 20 random fields. 
Measurements were done in triplicate, and EC50 were calculated fitting the values by nonlinear regression 
analysis of competitive binding curves using Prism software (GraphPad). All the best-fit values reported in 
Table 1 had SE <10%. 
Immunofluorescence. HuH7 cells growing on glass coverslips were fixed in buffer F for 30 min. 
Formaldehyde was quenched by incubating the coverslips for 30 min in buffer G. Cells were permeabilized 
in buffer T for 10 min at 25 °C to then be incubated with primary and secondary antibody diluted in PBS for 
1 h and 30 min, respectively. The following dilutions were used: polyclonal anti- Bax 1:50, antiactive Casp-3 
1:500, DAPI 1:400, and anti Cyt-C 1:200. Immunofluorescence images were taken by a Leica DFC320 video 
camera (Leica, Milan, Italy) connected to a Leica DMRB microscope equipped with a 100× objective, and the 
ImageJ Software (National Institutes of Health, Bethesda, MD) was used for analysis. 
MitoTracker Staining and Measurement. Cells were incubated for 30 min at 37 °C in complete medium 
supplemented with MitoTracker Red CMXRos (Invitrogen) at the final concentration of 200 nM. After the 
incubation, cells were washed twice in fresh medium and then lysed in absolute DMSO. The absorbance of 
the probe was read at 570 nM in a spectrophotometer. For microscope visualization of stained cells, cells 
were fixed in buffer F and processed as described above. 
Mice. Female C57BL/6J mice (6 wks) were purchased from Harlan Laboratories (Milan, Italy) and housed at 
the Department of Pharmacy, University of Naples, Italy. Before the experiments, the mice were acclimated 
for 1 week and were fed with standard chow diet and water ad libitum. All animal experiments were 
performed under protocols that followed the Italian and European Community Council for Animal Care (DL 
no. 116/92). 
Animal Experiments. Subconfluent LLC1 cells were harvested and passed through a 40 μm cell strainer, 
washed 3 times in PBS, resuspended in PBS, and inoculated at 3 × 105 cells in 7 week old mice through the 
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tail vein (day 0). After 14 days, mice were randomly divided into two groups: control and 8 1 mg/kg (n = 6 
and n = 8, respectively). For the treatment, 8 was first dissolved in DMSO and then suspended in sterile 
water (1% DMSO final concentration). 8 (1 mg/kg) was administered once a day by ip injection from day 14 
to 17. The control group received 1% DMSO (2 μL) daily. At day 18, mice were euthanized, the thorax was 
opened, and the lungs were perfused with phosphate-buffered saline (PBS), pH 7.4, via the pulmonary 
artery to remove blood. The entire tumor-bearing lung was used and examined as described below. Drug 
toxicity indexes such as weight loss, ruffled fur, behavior change, and feeding patterns were continuously 
observed during the whole treatment. 
Splenocyte Preparation. C57BL/6J mice were euthanized as already described. After excision, spleen was 
sliced into pieces and passed through a strainer using the plunger end of a syringe. Cell suspension was 
centrifuged for 5 min at 1600 rpm and cell pellet resuspended in prewarmed complete culture medium 
with the treatment with compounds starting immediately. 
Organic Extraction of Tissue. First, 100 μg of protein lysates were supplemented with 9 volumes of cold 
acetone and incubated for 2 h at −20 °C. Proteins were then pelleted by centrifuging the samples at 14000 
rpm at 4 °C. The absorbance spectrum of the organic extracts (1 mL in volume using quartz cuvettes) was 
recorded in the wavelength range between 220 and 800 nM and compared with the absorbance spectra of 
8 10 μM in water, acetone, or extraction buffer (acetone:water = 9:1) as indicated. 
Histological Analysis. Right lung lobes were fixed in 10% buffered formalin for 24−48 h. The fixed lobes 
were cut in two transverse portions, paraffin-embedded, and sectioned at 7 μm. Haematoxylin and eosin 
staining was performed and used to measure the tumor burden. Tumor lesions and lung area were 
analyzed by using 20 serial sections per lobe. The results were expressed as the ratio of the tumor lesions 
area compared with the total lung area. Images were taken by a Leica DFC320 video camera (Leica, Milan, 
Italy) connected to a Leica DMRB microscope, and the ImageJ Software (National Institutes of Health, 
Bethesda, MD) was used for analysis. 
Mitochondria Isolation. Cells or lung tissue were incubated in buffer D for 30 min. After lysis, cell debris and 
permeabilized cells were spun down for 30 min at 3000g (4 °C). Mitochondrial fractions were obtained 
centrifuging the supernatant for 30 min at 14000g. Mitochondrial pellet was lysed in B-buffer 1% Triton for 
1 h at 4 °C. 
Processing of the Tissues. Lung tissues were disrupted in buffer H in a Teflon Douce. The tissue homogenate 
was supplemented with 1% Triton and incubated for 1 h on ice. Cell debris and unbroken cells were 
sedimented by spinning down the homogenate for 1 h at 14000g. The supernatant containing the protein 
extracts was quantitated by Biorad (Pierce) using BSA as standard. Equal amounts of protein were 
processed further and stored at −80 °C after having been snap frozen in liquid nitrogen. 
Immunoprecipitation. Lysates were immunoprecipitated with 6A7 anti-BAX mouse monoclonal antibody 
overnight at 4 °C (25 μL of antibody per mL of lysate) and with protein-A sepharose for 45 min followed by 
fur washes in buffer L. After the last wash, beads were resuspended in 20 μL of buffer L before Western 
blot processing. 
Western Blotting. Samples were diluted in 20 mM Tris HCl (pH 6.8), 50 mM DTT, 1% SDS, 5% glycerol, and 
bromophenol blue to then be boiled for 10 min at 95 °C. Samples were loaded on a 12.5% SDS PAGE gel. 
Run was performed at 100 V at 25 °C. After the run, proteins were transferred on nitrocellulose filter 
(Schleicher-Schuel) at 80 V for 1 h at 4 °C. Filters were blocked for 2 h at 25 °C in PBS supplemented with 3% 
nonfat dry milk (Biorad) for 2 h at 25 °C and incubated with primary and secondary antibody diluted in PBS 
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supplemented with 0.3% nonfat dry milk in PBS. ECL reaction was performed using the Lumi Light ECL kit 
(Roche) according manufacturer procedures. 
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4.4 Part IV: Synthesis of Sirt6 Inhibitors 
Chemistry: Commercially available solvents and reagents were used without further purification. Organic 
solutions were dried over anhydrous sodium sulfate. Evaporation of the solvents was carried out on Büchi 
Rotavapor R-210 equipped with Büchi V-855 vacuum controller and Büchi V-700 (~ 5 mbar). Column 
chromatography was performed on glass columns packed with silica gel from Fluka and from Aldrich 
(70−230 mesh). Silica gel thin layer chromatography (TLC) cards from Fluka and Macherey-Nagel (silica gel 
precoated aluminum cards with fluorescent indicator visualizable at 254 nm were used for TLC. Developed 
plates were visualized by a Spectroline ENF 260C/FE UV apparatus. Melting points (mp) were determined 
on a Stuart Scientific SMP1 apparatus and on a Stuart Scientific SMP30 apparatus and are uncorrected.. 
Mass spectral (MS) and high resolution mass spectral (HRMS) analyses were recorded on AB Sciex API-2000 
(MS) and Thermo Fisher Scientific Inc. Orbitrap Exactive (HRMS) spectrometers equipped with an ESI 
source. Proton (1H, 400.13 MHz) and carbon (13C, 100.6 MHz) nuclear magnetic resonance spectra were 
recorded on a Bruker Avance 400 and a Varian Inova 400 spectrometers in the indicated solvent and 
corresponding fid files processed by MestreLab Research SL MestreReNova 6.2.1− 769 and Bruker Topspin 
3.2 software. Chemical shifts are expressed in δ units (ppm) from tetramethylsilane. Elemental analyses of 
the compounds were found within ±0.4% of the theoretical values.  
Methyl- 4-oxo-3,4-dihydrothieno[3,2-d]pyrimidine-6-carboxylate : A mixture of dimethyl-3-aminothiophene-
2,5-dicarboxylate(1 equiv) , formamidine acetate salt (4 equiv) and 2-mehoxyethanol dry ( 0,6M ) under N2 
was stirred at reflux 130°C for 60 min. The addition of formamidine acetate salt (4 equiv) was repeated  and 
then the mixture was heated for overnight. Then the reaction was cooled to room temperature , was 
diluted with water and NaHCO3 solution and extracted with EtOAc . Organic phase was washed with water, 
brine and dried. To obtain the methyl-3H thieno[3,2-d]pirimidin-4-one-6-carboxylate as a yellow solid in 
without purification Yield 73% . NMR (DMSO-d6) δ 8.24 (s, 1H), 8.01 (s, 1H), 3.92 (s, 3H). MS (ESI) calcd for 
C8H6N2O3S :, 210.0; found (M + H)+: 211.0. 
 
4-oxo-3,4-dihydrothieno[3,2-d]pyrimidine-6-carboxylic acid : A suspension of methyl- 4-oxo-3,4-
dihydrothieno[3,2-d]pyrimidine-6-carboxylate , LiOH.H2O (5 equiv) in 2-propanol (0,25 M) and water (0,40 
M) was stirred at 75°C for 1h. Then the reaction was cooled and diluted with water and EtOAc. The two 
phases were separated and the aqueous phase was acidified with HCl 1M at pH 1 and the precipitate was 
filtered and washed with water to obtain a white solid. Yield  75%. . NMR (DMSO-d6) δ 12.80 ( br s, 1H), 
9.16 (s, 1H), 8.27 (s, 1H). MS (ESI) calcd for C7H4N2O3S :, 196.1 ; found (M + H)+: 197.1 
 
4-chlorothieno[3,2-d]pyrimidine-6-carboxamide: A solution of 4-oxo-3,4-dihydrothieno[3,2-d]pyrimidine-6-
carboxylic acid in SO2Cl (0,17 M) and DMF (33 M) was stirred at 80°C for 2h. Then the reaction was 
concentrated to dryness. The crude acid chloride was dissolved in a solution of NH4OH 28-30% basis (1 M) 
in EtOAC (0,35 M) was added to chloride in ice bath and then the reaction was stirred at room temperature 
for 2h under N2.The mixture was diluted with water and extracted with EtOAc . Organic phase was dried 
and concentrated to give the 4-chlorothieno[3,2-d]pyrimidine-6-carboxamide as a yellow solid without 
purification. Yield 75%. 1H NMR (DMSO-d6) δ 9.11 (s, 1H), 8.62 (br s, 1H), 8.35 (s, 1H), 8.15 (br s, 1H). 13C 
NMR (DMSO-d6) δ 161.53, 161.21, 154.75 (CH), 154.13, 150.77, 131.47, 124.80 (CH). MS (ESI) calcd for 
C7H4ClN3OS:, 213.6 ; found (M + H)+: 214.0 
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tert-Butyl (2-(1-(6-Carbamoylthieno[3,2-d]pyrimidin-4-yl)-piperidin-4-yl)ethyl)carbamate: A solution of 4-
chlorothieno[3,2-d]pyrimidine-6-carboxamide, tert-butyl(2-(piperidin-4-yl)ethyl)carbamate (1 equiv) and 
DIEA (1 equiv) in CH3CN (0,076 M) was heated at reflux for 2h.The reaction mixture was cooled at room 
temperature and concentrated to dryness. The residue was suspended  in MeOH (0,608 M) and water (0,06 
M) was added. The mixture was sonicated and the precipitate was filtered, washed with water and dried 
under vacuum to obtain tert-butyl(2-(1-(6-carbamoylthieno[3,2-d]pyrimidin4-yl)piperidin-4-
yl)ethyl)carbamate as white solid. Yield 80%. NMR (DMSO-d6) δ 8.48 (s, 1H), 8.40 (br s, 1H), 8.03 (s, 1H), 
7.87 (br s, 1H), 6.81 (t, 1H), 4.69 (d, 2H), 3.16 (t, 2H), 2.976 (q, 2H), 1.83 (d, 2H), 1.66 (br, 1H), 1.37 (s, 9H), 
1.34 (m, 2H), 1.16 (m, 2H). MS (ESI) calcd for C19H27N5O3S, 405.5; found, 406.5. 
 
 
 
4-(4-(2-Aminoethyl)piperidin-1-yl)thieno[3,2-d]pyrimidine-6-carboxamide: To a solution of tert-butyl(2-(1-
(6-carbamoylthieno[3,2-d]pyrimidin4-yl)piperidin-4-yl)ethyl)carbamate in CH2Cl2 (0,05 M) was added 
trifluoroacetic acid (0,207 M). The reaction was stirred at room temperature for overnight , concentrated to 
dryness and chased with CH2Cl2.  To obtain 4-(4-(2-Aminoethyl)piperidin-1-yl)thieno[3,2-d]pyrimidine-6-
carboxamide as the trifluoroacetic salt, white solid .Yield 100%. 1H NMR (DMSO-d6) δ 8.72 (s, 1H), 8.62 (br 
s, 1H), 8.08 (s, 1H), 8.03 (br s, 1H), 7.75 (br s, 3H), 4.80 (d, J=4.79 Hz, 2H), 3.37 (t, J=3.36 Hz, 2H), 2.89 (m, , 
2H), 1.93 (d, J=1.92 Hz, 2H), 1.81 (s, 1H), 1.51 (m, 2H), 1.28 (m, 2H). MS (ESI) calcd for C14H19N5OS , 305.1; 
found, 306.1. 
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Methyl 5-(Ethylcarbamoyl)thiophene-2-carboxylate: To a solution of 5-(methoxycarbonyl)thiophene-2-
carboxylic acid , EDCI.HCl (1,1 equiv ), HOBT (1,1 equiv ) in DMF (0,268 M ) was added DIEA (2,5 equiv ). The 
reaction was stirred for 15 min at room temperature, and then ethylamine hydrochloride (1 equiv) was 
added as a solid. The reaction was stirred at room temperature for overnight. The reaction was diluted with 
water and extracted with EtOAc.  Organic phase was washed with brine, dried and concentrated.  The crude 
was purified by colonm  (7Pe\3 EtOAc) to give 5-(ethylcarbamoyl)thiophene-2-carboxylate as a yellow solid. 
Yield 63%. 1H NMR (DMSO-d6) δ 8.76 (t,  1H), 7.76 (d, J=7.74 Hz, 1H), 7.48 (d, J=7.46 Hz, 1H), 3.93 (s, 3H), 
3.51 (m,2H), 1.30 (t, J=1.28 Hz, 3H). MS (ESI) calcd for C9H11NO3S, 213.1; found, 214.1. 
 
 
 
5-(Ethylcarbamoyl)thiophene-2-carboxylic Acid :To a solution of methyl 5-(ethylcarbamoyl)thiophene-2-
carboxylate in THF (0,25M) was added a solution of LiOH.H2O (2 equiv) in water (0,5 M). The reaction was 
stirred at room temperature for 48h, concentrated to dryness. The residue was diluted with water and 
EtOAc. The two phases were separated and the aqueous phase was acidified with HCl 1M at pH 1 and 
extracted with EtOAc. Organic phase was washed with brine, dried and concentrated. To obtain 5 
(ethylcarbamoyl)thiophene-2-carboxylic acid as a white solid. Yield 80%. 1H NMR (DMSO-d6) δ 13.40 (s, 
1H), 8.71 (t, J=8.69 Hz, 1H) ,7.71 (d, J=7.70 Hz, 1H), 7.68 (d, J=7.67 Hz, 1H), 3.26 (m, 2H), 1.12 (t, J=1.10 Hz, 
3H). MS (ESI) calcd for C8H9NO3S, 199.0; found, 200.0. 
 
 
 
N2-(2-(1-(6-Carbamoylthieno[3,2-d]pyrimidin-4-yl)piperidin-4-yl)-ethyl)-N5-ethylthiophene-2,5 
dicarboxamide: To a solution of 5-(ethylcarbamoyl)thiophene-2-carboxylic acid ,HATU (1,2 equiv ) and DIEA 
(4 equiv) in DMF (0,2 M) was stirred at room temperature for 10 min . Then 4-(4-(2-aminoethyl)piperidin-1-
yl)-thieno[3,2-d]pyrimidine-6-carboxamide (0,80 equiv ) was added and the reaction was stirred overnight. 
The mixture was diluted with water and extracted with EtOAc. Organic phase was washed with NaHCO3 sol, 
brine , dried and concentrated. The crude was purified by column (93 DCM\0,7 MeOH) to give the N2-(2-(1-
(6-carbamoylthieno[3,2-d]pyrimidin-4-yl)piperidin-4-yl)-ethyl)-N5-ethylthiophene-2,5-dicarboxamide as a 
white solid. Yield 50 %. 1H NMR (DMSO-d6) δ 8.67 (s, 1H), 8.56−8.62 (m, 3H), 8.06 (s, 1H), 8.00 (br, 1H), 7.68 
(m, 2H), 4.76 (m, 2H), 3.21−3.37 (m, 6H), 1.95 (m, 2H), 1.76 (m, 1H), 1.49 (m, 2H), 1.25 (m, 2H), 1.11 (t, 
J=1.09 Hz, 3H). MS (ESI) calcd for C22H27N6O3S2, 486.1; found, 487.1. 
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2-tert-butyl 5-methyl thiophene-2,5-dicarboxylate : A solution of 5-(methoxycarbonyl)thiophene-2-
carboxylic acid , (Boc)2O (2,20 equiv), DMAP (0,200 equiv ) in THF (0,54 M) was stirred for overnight at 
room temperature. The reaction was concentrated , was diluted with NaHCO3 sol and extracted with EtOAc. 
Organic phase was dried and concentrated.  The crude was purified by column  (99Pe\0,1 EtOAc) to give 2-
tert-butyl 5-methyl thiophene-2,5-dicarboxylate as a white solid. Yield  72%.1H NMR (DMSO-d6) δ 7.74 (d, 
J=7.73 Hz, 1H), 7.68 (d, J=7.67 Hz, 1H), 3.94 (d, J=3.93 Hz, 3H), 1.60 (s, 9H).  MS (ESI) calcd for C11H14O4S,  
242.0; found 243.0  
 
 
 
5-(tert-butoxycarbonyl)thiophene-2-carboxylic acid: To a solution of 2-tert-butyl 5-methyl thiophene-2,5-
dicarboxylate in THF(0,25M) was added a solution of LiOH.H2O(2 eq) in water(0,5M). The reaction was 
stirred at room temperature for 48h, concentrated to dryness. The residue was diluted with water and 
EtOAc. The two phases were separated and the aqueous phase was acidified with HCl 1M at pH 1 and 
extracted with EtOAc. Organic phase was washed with brine, dried and concentrated. To give the  5-(tert-
butoxycarbonyl)thiophene-2-carboxylic acid as a white solid 80%.1H NMR (DMSO-d6) δ 13.20 (s, 1H), 7.74 
(d, J=7.73 Hz, 1H), 7.69 (d, J=7.68 Hz, 1H), 1.60 (s, 9H). MS (ESI) calcd for C10H12O4S, 228.0; found , 229.0 
 
 
 
To a solution of 5-(tert-butoxycarbonyl)thiophene-2-carboxylic acid, HATU (1,2eq) and DIEA(5eq) in 
DMF(0,2M) was stirred at rt for 10 min . Then 4-(4-(2-aminoethyl)piperidin-1-yl)-thieno[3,2-d]pyrimidine-6-
carboxamide tfa salt(1eq) was added and the reaction was stirred overnight. The mixture was diluted with 
water and extracted with EtOAc(x3). Organic phase was washed with NaHCO3 sol, brine(x6) , dried and 
concentrated. The crude was purified by colonm(97 DCM\0,3MeOH) to give the 5-ter-butyl((2-(1-(6-
carbamoyl)thieno[3,2-d]pyrimidin-4-yl)piperidin-4-yl))ethyl)carbamoyl)thiophene-2-carboxylate as a white 
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solid. Yield 30%. %. 1H NMR (DMSO-d6) δ 8.46 (s, 1H), 7.90 (s, 1H), 7.68 (d, J=7.67 Hz, 1H), 7.64 (d, J=7.63 
Hz, 1H), 3.48 (t, J=3.47 Hz, 2H), 3.27 (t, J=3.25 Hz, 2H), 1.99 (m, 2H), 1.83 (m, 1H), 1.64 (m, 2H), 1.60 (s, 9H), 
1.35 (m, 2H). MS (ESI) calcd for C24H29N5O4S2 , 515.1; found , 516.1 
 
 
 
5-((2-(1-(6-carbamoylthieno[3,2-d]pyrimidin-4-yl)piperidin-4- yl)ethyl)carbamoyl)thiophene-2-carboxylic 
acid : A solution of 5-ter-butyl((2-(1-(6-carbamoyl)thieno[3,2-d]pyrimidin-4-yl)piperidin-4-
yl))ethyl)carbamoyl)thiophene-2-carboxylate in 1:1 TFA\DCM (2,5ml) was stirred overnight. The mixture 
was concentrated and azeotrope with DCM, triturated with the mixture of diethyl ether/ pentane for 20 
min and dried. To obtain a solid orange. Yield 70%. 1H NMR (DMSO-d6) δ 8.72 (m, 1H), 8.66 (s, 1H), 8.55 (br, 
1H), 8.05 (s, 1H), 7.99 (br, 1H) ,7.74 (d, J=7.73 Hz, 1H), 7.70 (d, J=7.69 Hz, 1H), 4.76 (m, 2H), 3.28-3.42 (m, 
4H), 1.95 (m, 2H), 1.75 (m, 1H), 1.50 (m, 2H), 1.20 (m, 3H). MS (ESI) calcd for C20H22N5O4S2, 459.1; found, 
460.1 
 
 
 
4-(4-(2-(methylsulfonamido)ethyl)piperidin-1-yl)thieno[3,2-d]pyrimidine-6-carboxamide: To a mixture of 4-
(4-(2-aminoethyl)piperidin-1-yl)-thieno[3,2-d]pyrimidine-6-carboxamide and trimethylamine (0,506 M) in 
pyridine (0,050 M) was added methansulfonyl chloride (1,10 equiv) at 0°C under N2. The mixture was 
stirred at room temperature overnight, quenched with ammonia hydroxide 5N and concentrated in vacuo. 
The residue  was neutralized to pH-7 using Na2CO3 sol and extracted with DCM. Organic phase was washed 
with brine, dried and concentrated. The crude was  purified by column (93DCM\0,7MeOH)  to give the 4-(4-
(2-(methylsulfonamido)ethyl)piperidin-1-yl)thieno[3,2-d]pyrimidine-6-carboxamide as  orange solid. Yield 
30%. 1H NMR (DMSO-d6) δ 8.49 (s, 1H), 8.40 (br, 1H), 8.03 (s, 1H), 7.87 (br, 1H), 6.95 (t, 1H), 4.70 (m, 2H), 
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3.18 (m, 2H), 2.99 (q, 2H), 2.89 (s, 3H), 1.7-1.9 (m, 3H), 1.42 (q, 2H), 1.18 (m,2H). MS (ESI) calcd for 
C15H21N5O3S2, 383.1; found, 384.1 
 
 
 
 
tert-Butyl ((1-(6-Carbamoylthieno[3,2-d]pyrimidin-4-yl)-piperidin-4-yl)methyl)carbamate: A solution of 4-
chlorothieno[3,2-d]pyrimidine-6-carboxamide, tert-butyl (piperidin-4-ylmethyl)carbamate (1 equiv) and 
DIEA (1 equiv) in CH3CN (0,076 M) was heated at reflux for 2h.The reaction mixture was cooled at room 
temperature and concentrated to dryness. The residue was suspended  in MeOH (0,608 M) and water (0,06 
M) was added. The mixture was sonicated and the precipitate was filtered, washed with water and dried 
under vacuum to obtain tert-butyl(2-(1-(6-carbamoylthieno[3,2-d]pyrimidin4-yl)piperidin-4-
yl)ethyl)carbamate as white solid. Yield 80%. NMR (DMSO-d6) δ 8.49 (s, 1H), 8.41 (br s, 1H), 8.04 (s, 1H), 
7.88 (br s, 1H), 6.92 (t, 1H), 4.67 (d, 2H), 3.18 (t, 2H), 2.85 (q, 2H), 1.77 (d, 2H), 1.66 (br, 1H), 1.38 (s, 9H),  
1.15 (m, 2H). MS (ESI) calcd for C19H27N5O3S, 405.5; found, 406.5. 
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4-(4-(Aminomethyl)piperidin-1-yl)thieno[3,2-d]pyrimidine-6-carboxamide: To a solution of tert-butyl ((1-(6-
carbamoylthieno[3,2-d]pyrimidin4-yl)piperidin-4-yl)methyl)carbamate in CH2Cl2 (0,05 M) was added 
trifluoroacetic acid (0,207 M). The reaction was stirred at room temperature for overnight , concentrated to 
dryness and chased with CH2Cl2.  To obtain 4-(4-(2-Aminoethyl)piperidin-1-yl)thieno[3,2-d]pyrimidine-6-
carboxamide as the trifluoroacetic salt, white solid .Yield 100%. 1H NMR (DMSO-d6) δ 8.72 (s, 1H), 8.62 (br 
s, 1H), 8.08 (s, 1H), 8.03 (br s, 1H), 7.75 (br s, 3H), 4.80 (d, J=4.79 Hz, 2H), 3.37 (t, J=3.36 Hz, 2H), 2.89 (m, , 
2H),  1.81 (s, 1H), 1.51 (m, 2H), 1.28 (m, 2H). MS (ESI) calcd for C14H19N5OS , 305.1; found, 306.1. 
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Chapter 5 – Conclusions 
In summary , new anticancer drugs have been designed and developed by application of new synthetic 
strategies.  
 
In the first chapter, the idenfication of novel electrophilic partners have helped develop the new isocyanide 
mediated MCRs. Specifically, new methodology to prepare structurally diverse aryl α-ketoamide amides has 
been demonstrated. It is important to highlight that the entire sequence of reactions is realized under mild 
reaction conditions avoiding the use of expensive coupling agents and using simple and easily available 
starting materials ((Z)-arylchlorooximes and α-isocyanoacetamides). This method is complementary to 
those previously reported for the synthesis of alkyl α-ketoamide amides [164]. This new protocol can find 
application in the synthesis of tailored aryl α-ketoamide amides given their importance in both organic and 
medicinal chemistry. As a continuous of this study, a solution phase parallel synthesis method have been 
reported to obtain stable α-aryloxyiminoamide derivates. It is an application of Passerini-Smiles reaction 
which is realized under basic condition using  (Z)-chlorooximes, isocyanides and electron-deficient phenols. 
This parallel synthesis method allows to produce easily and rapidly α-aryloxyiminoamides and they can be 
applied in organic and medicinal chemistry. 
 
In the second chapter, a structure-based lead optimization and biological evaluation of BAX direct 
activators have been reported. Optimization of BAX direct activators has been already shown to be 
challenging [63]. In this work it was showed that 1 optimization can successfully lead to new hits with 
improved affinity for BAX. However, minimal changes in the chemical structure of the hits can drastically 
change their selectivity, affecting their affinity for other BCL-2 family members. In MEF cells, whatever the 
main target is, the event of binding leads always to apoptosis. However, in tumor cells, a severe 
unbalancing between proapopototic and antiapopototic proteins exists, with the latter being 
overexpressed in almost every tumor. Thus, ligands with low selectivity can be sequestered by 
antiapoptotic proteins that, ultimately, buffer them, inhibiting the activation of proapoptotic proteins. As a 
result of this first round of 1 optimization, it was here presented 8. In vitro affinity of 8 for BAX is only 
slightly higher than 1. On the contrary, it shows lower affinity for BCL-2 and BCL-XL than 1. Its selectivity 
manifests in MEF BAX−/− knockout cells that, differently from many other tested MEF knockout clones, are 
insensitive to 8 treatments. In cultured tumor cells, it induces MOMP with an EC50 of 700 nM, 1 order of 
magnitude lower than the one measured for 1. As such, it is the most active, low molecular weight, direct 
activator of BAX reported in the published literature. SAR data here developed clearly suggest that the 
phenyl-thiazol moiety can be replaceable by other aromatic groups and that the activity is increased by a 
terminal positive charged group that, according to a theoretical binding mode, would interact with 
negatively charged BAX residues. 8 is able to induce BAX activation and translocation to mitochondria, 
MOMP, and consequent release of cyt-c in all the tumor cell line tested. Moreover, 8 seems to be rather 
selective for cancer cells (HuH7, NB4, SHSY-5Y, and LLC1) and immortalized cells (MEF), leaving 
unperturbed apoptosis rate in healthy resting cells (healthy splenocytes). The in vivo efficiency of 8 in 
tumor mass reduction together with the absence of gross toxicity, although just 4 days of treatment was 
applied, would suggest that BAX direct activators may really represent a novel promising class of anticancer 
agents rather than venoms.  
 
Moreover, it was attempted a molecular screening campaign toward pharmacological chaperones rescuing 
Fz4-FEVR folding with the ultimate goal to identify small organic wild-type (WT) Fz4 (Fz4-WT) modulators. It 
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is reported molecules able to work as folding chaperones by measuring their potency in restoring Fz4-FEVR 
folding and localization at the PM. In this context it was identified three pharmacological chaperones of 
Fz4-FEVR that are indeed Fz4-WT ligands and act as Wnt–β-catenin inhibitors, proving the validity of the 
new screening strategy. One of these hits, namely FzM1, exerts its modulatory activity by inducing con-
formational changes in Fz4-WT that ultimately allow it to inhibit β-catenin nuclear transport and antagonize 
the Wnt pathway. The Fz4 modulators here described represent what are to our knowledge the first 
organic molecules addressing this still-undruggable receptor. Here, the novelty of the screening approach, 
the step of the Wnt–β-catenin cascade targeted by our new compounds together with their mechanism of 
action suggest new avenues for development of inhibitors of the Wnt-β-catenin pathway and for drug 
discovery. 
 
In the third chapter, the ability of small molecules to bind and inhibit SIRT6 has been explored and 
experimented for the first time in the literature. According to in vitro tests, this work has identified N2-(2-(1-
(6-Carbamoylthieno[3,2-d]pyrimidin-4-yl)piperidin-4-yl)-ethyl)-N5-ethylthiophene-2,5 dicarboxamide (the 
so called compound 1) which shows a perceivable SIRT6 inhibition activity. Compound 1, which finds 
applications in cancer treatment, may represent the starting point for further structure lead optimization 
and structure-acitivity relationship studies.  
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